[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fuXXJ3FsO0eq-tH2beoPZXhJ1suQwHce11AEE1XUxNTU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":89,"rows":96},"University of Florida",[4],1263,false,254,26,381620,84,879,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Healthy",48,{"name":18,"count":19},"Coronary Artery Disease",34,{"name":21,"count":22},"Aging",33,{"name":24,"count":25},"Obesity",27,{"name":27,"count":28},"Hypertension",23,{"name":30,"count":31},"Parkinson Disease",21,{"name":33,"count":34},"Pain",20,{"name":36,"count":37},"Breast Cancer",19,[39,44,49,54,59,64,69,74,79,84],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03405792","Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)","2022-11-26","Temozolomide",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT03483038","A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma","2023-09-16","Liposomal Irinotecan",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04220021","Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS\u002FFTD","2024-08-26","Metformin",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT04917042","Tazemetostat in Malignant Peripheral Nerve Sheath Tumors","2025-02-14","Tazemetostat",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05195775","Tadalafil as Adjuvant Therapy for DMD","2025-09-05","Tadalafil",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05892770","Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia","2025-12","Zinc gluconate supplement",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06672666","Use of CBD in the Treatment of Anxiety","2025-12-01","Hemp Derived Cannabidiol Extract",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT04331704","ANCHORS Alcohol & Sexual Health Study: UH3 Project","2025-12-31","PrEP acronym",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT03970655","Functional Endoscopic Sinus Surgery Study","2026-01-23","Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1",{"nctId":85,"briefTitle":86,"date":87,"intervention":88},"NCT05377424","Adenosine 2A Receptor Antagonism and AIH in ALS","2026-01-26","Consume 20mg of istradefylline",[90,91,92,93,94,95],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[97,213,248,326,382,404,439,478,496,514,539,566,584,602,625,643,667,694,786,821,849,867,885,912,973,1014,1064,1097,1128,1162,1190,1222,1244,1281,1302,1320,1338,1363,1388,1413,1435,1453,1479,1504,1522,1558,1580,1598,1622,1642,1664,1691,1714,1736,1760,1778,1796,1821,1845,1871,1889,1909,1932,2005,2030,2073,2138,2168,2198,2235,2261,2287,2310,2328,2357,2375,2398,2416,2442,2474,2496,2518,2543,2577,2606,2641,2683,2723,2754,2788,2815,2849,2879,2914,2951,2973,3007,3033,3066,3096,3125,3151,3177,3203,3227,3245,3274,3298,3322,3340,3364,3382,3408,3426,3451,3469,3493,3511,3540,3558,3576,3594,3619,3637,3655,3680,3704,3727,3752,3770,3795,3813,3837,3862,3888,3909,3934,3952,3976,3999,4017,4042,4067,4085,4110,4136,4154,4178,4201,4219,4244,4262,4289,4307,4325,4347,4365,4391,4409,4432,4457,4475,4493,4511,4533,4551,4569,4587,4605,4631,4654,4672,4696,4714,4739,4757,4784,4802,4820,4846,4864,4882,4907,4925,4962,4996,5026,5044,5062,5080,5098,5125,5143,5171,5189,5215,5233,5258,5276,5302,5320,5344,5368,5394,5412,5430,5454,5498,5539,5572,5605,5641,5674,5706,5740,5771,5800,5823,5848,5866,5884,5908,5926,5944,5962,5980,6003,6021,6039,6064,6086,6109,6136,6154,6172,6190,6208,6231,6256,6280,6302,6320,6342,6365,6391,6415,6433,6455,6480,6498,6522,6540,6563,6589,6630,6648,6666,6690,6714,6732,6760,6784,6802,6824,6846,6869,6887,6905,6923,6941,6959,6977,7002,7024,7048,7071,7094,7116,7141,7163,7181,7205,7223,7246,7264,7286,7308,7339,7357,7380,7405,7433,7456,7474,7492,7510,7534,7552,7570,7588,7611,7635,7664,7682,7700,7718,7736,7761,7785,7817,7844,7862,7886,7908,7930,7953,7971,7989,8013,8031,8055,8073,8100,8118,8142,8166,8189,8212,8230,8248,8272,8290,8313,8331,8354,8383,8405,8423,8441,8459,8477,8501,8527,8552,8577,8595,8629,8651,8669,8692,8713,8736,8759,8781,8803,8827,8850,8873,8891,8913,8931,8955,8977,9001,9024,9047,9072,9090,9108,9126,9154,9172,9196,9214,9238,9256,9274,9297,9318,9339,9360,9378,9396,9418,9441,9465,9483,9507,9531,9557,9581,9605,9631,9654,9678,9696,9755,9810,9864,9897,9936,9962,9993,10015,10045,10076,10098,10124,10156,10181,10208,10240,10263,10288,10306,10328,10351,10373,10400,10424,10449,10467,10491,10509,10535,10553,10579,10597,10615,10633,10651,10674,10698,10721,10746,10764,10782,10805,10823,10846,10864,10887,10910,10933,10951,10974,10996,11018,11041,11065,11083,11101,11122,11140,11158,11176,11194,11216,11238,11260,11285,11303,11321,11342,11365,11387,11405,11429,11447,11465,11486,11509],{"intervention":98,"totalTrials":99,"cells":100},"Clopidogrel",8,{"EARLY_PHASE1":101,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":110,"NA":211},{"trials":102,"activeCount":103},[],0,{"trials":105,"activeCount":103},[],{"trials":107,"activeCount":103},[],{"trials":109,"activeCount":103},[],{"trials":111,"activeCount":210,"soonestReadout":177},[112,123,138,152,163,173,183,196],{"nctId":113,"briefTitle":114,"status":115,"phases":116,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":121},"NCT04483583","Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI","COMPLETED",[94],"2025-01-07","2020-12-08",81,[18],[122,98],"Ticagrelor 60mg",{"nctId":124,"briefTitle":125,"status":115,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":135},"NCT02548650","Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus",[94],"2018-12","2019-02-14","2016-03-25",66,[132,133,134],"Myocardial Infarction","Diabetes Mellitus","Peripheral Arterial Disease",[136,98,137],"Vorapaxar","Aspirin",{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":150},"NCT07025148","Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)","RECRUITING",[94],"2027-08-01","2027-11-01","2025-10-01",40,[148,149],"Coronary Arterial Disease (CAD)","Percutaneous Coronary Intervention (PCI)",[151,98],"Prasugrel",{"nctId":153,"briefTitle":154,"status":115,"phases":155,"primaryCompletion":156,"completion":157,"start":158,"enrollment":146,"conditions":159,"interventions":161},"NCT03437044","Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI",[94],"2019-06-27","2020-06-27","2018-03-14",[160,18],"Diabetes Mellitus, Type 2",[162,98],"Ticagrelor",{"nctId":164,"briefTitle":165,"status":115,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":172},"NCT02287909","Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease",[94],"2017-10","2018-03","2014-12",87,[18],[98,162],{"nctId":174,"briefTitle":175,"status":141,"phases":176,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":182},"NCT06228456","Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention",[94],"2026-12-31","2027-04-30","2024-04-01",50,[18],[122,98],{"nctId":184,"briefTitle":185,"status":115,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":192},"NCT04006288","Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease",[94],"2022-01-31","2022-05-16","2019-09-06",90,[18],[98,151,193,194,195],"ticagrelor","aspirin","rivaroxaban",{"nctId":197,"briefTitle":198,"status":115,"phases":199,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":204,"interventions":208},"NCT03774394","Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus",[94],"2022-05-23","2022-05-31","2019-08-22",61,[205,206,207],"Chronic Kidney Disease (CKD)","Type 2 Diabetes Mellitus (T2DM)","Coronary Artery Disease (CAD)",[98,209],"Clopidogrel active metabolite",2,{"trials":212,"activeCount":103},[],{"intervention":214,"totalTrials":210,"cells":215},"aspirin plus clopidogrel",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":246},{"trials":217,"activeCount":103},[],{"trials":219,"activeCount":103},[],{"trials":221,"activeCount":103},[],{"trials":223,"activeCount":103},[],{"trials":225,"activeCount":210,"soonestReadout":239},[226,235],{"nctId":227,"briefTitle":228,"status":141,"phases":229,"primaryCompletion":177,"completion":230,"start":231,"enrollment":190,"conditions":232,"interventions":233},"NCT05681702","Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI",[94],"2027-03-31","2023-02-15",[18],[214,234],"prasugrel or ticagrelor",{"nctId":236,"briefTitle":237,"status":141,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":190,"conditions":242,"interventions":243},"NCT06588595","The Switching Antiplatelet-9 (SWAP-9) Study",[94],"2026-08-30","2027-02-28","2024-11-01",[148],[244,245],"Prasugrel\u002FTicagrelor monotherapy or aspirin plus clopidogrel","Aspirin plus clopidogrel",{"trials":247,"activeCount":103},[],{"intervention":249,"totalTrials":250,"cells":251},"Ropivacaine",5,{"EARLY_PHASE1":252,"PHASE1":268,"PHASE2":270,"PHASE3":283,"PHASE4":285,"NA":324},{"trials":253,"activeCount":103},[254],{"nctId":255,"briefTitle":256,"status":257,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":103,"conditions":261,"interventions":267},"NCT03906838","Regional Anesthesia Block in Fibula Free Flap Reconstruction","WITHDRAWN",[90],"2020-11-30","2020-01-01",[262,263,264,265,266],"Anesthesia, Local","Surgery","Opioid Use","Pain, Postoperative","Head and Neck Neoplasms",[249],{"trials":269,"activeCount":103},[],{"trials":271,"activeCount":103},[272],{"nctId":273,"briefTitle":274,"status":115,"phases":275,"primaryCompletion":276,"completion":277,"start":278,"enrollment":130,"conditions":279,"interventions":281},"NCT02722746","The Prevention of Hypotension After Epidural Analgesia After Major Surgery",[91,92],"2017-10-04","2018-09-14","2016-11-15",[280,33],"Hypotension",[249,282],"Epinephrine",{"trials":284,"activeCount":103},[],{"trials":286,"activeCount":323,"soonestReadout":315},[287,297,310],{"nctId":288,"briefTitle":289,"status":115,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":180,"conditions":293,"interventions":295},"NCT05667324","Septorhinoplasty Post-operative Pain Control With SPG Nerve Block",[94],"2025-02-28","2023-04-12",[294],"Deviated Nasal Septum",[249,296],"Dexamethasone",{"nctId":298,"briefTitle":299,"status":257,"phases":300,"primaryCompletion":301,"completion":301,"start":302,"enrollment":103,"conditions":303,"interventions":307},"NCT03385967","Duration of Analgesia With Dexmedetomidine and Ropivacaine in Brachial Plexus Block",[94],"2019-12","2019-04",[304,305,306],"Analgesia","Pain, Acute","Peripheral Nerve Block",[308,309],"Dexmedetomidine","ropivacaine",{"nctId":311,"briefTitle":312,"status":313,"phases":314,"primaryCompletion":315,"completion":316,"start":317,"enrollment":146,"conditions":318,"interventions":322},"NCT03632044","Evaluation of Trigeminal Nerve Blockade","ACTIVE_NOT_RECRUITING",[94],"2026-05-31","2027-10-30","2018-11-20",[319,320,321],"Mouth Abnormalities","Cleft Palate","Birth Defect",[249],1,{"trials":325,"activeCount":103},[],{"intervention":327,"totalTrials":328,"cells":329},"Cangrelor",4,{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":380},{"trials":331,"activeCount":103},[],{"trials":333,"activeCount":103},[],{"trials":335,"activeCount":103},[],{"trials":337,"activeCount":103},[],{"trials":339,"activeCount":323,"soonestReadout":344},[340,349,359,370],{"nctId":341,"briefTitle":342,"status":141,"phases":343,"primaryCompletion":344,"completion":345,"start":346,"enrollment":180,"conditions":347,"interventions":348},"NCT07225842","The Bridging Antiplatelet Therapy With Cangrelor 2 Study",[94],"2027-09","2027-11","2026-02-18",[148],[327],{"nctId":350,"briefTitle":351,"status":115,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":358},"NCT04634162","PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment",[94],"2021-08-16","2021-11-30","2021-02-09",22,[18],[327],{"nctId":360,"briefTitle":361,"status":115,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT04668144","Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI",[94],"2023-02-02","2023-05-11","2021-02-18",359,[18,368],"Acute Coronary Syndrome",[327,151],{"nctId":371,"briefTitle":372,"status":115,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":180,"conditions":376,"interventions":379},"NCT03247738","Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI",[94],"2018-12-13","2017-11-20",[377,378],"ST Segment Elevation Myocardial Infarction","Percutaneous Coronary Intervention",[327],{"trials":381,"activeCount":103},[],{"intervention":122,"totalTrials":210,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":402},{"trials":385,"activeCount":103},[],{"trials":387,"activeCount":103},[],{"trials":389,"activeCount":103},[],{"trials":391,"activeCount":103},[],{"trials":393,"activeCount":323,"soonestReadout":177},[394,398],{"nctId":113,"briefTitle":114,"status":115,"phases":395,"primaryCompletion":117,"completion":117,"start":118,"enrollment":119,"conditions":396,"interventions":397},[94],[18],[122,98],{"nctId":174,"briefTitle":175,"status":141,"phases":399,"primaryCompletion":177,"completion":178,"start":179,"enrollment":180,"conditions":400,"interventions":401},[94],[18],[122,98],{"trials":403,"activeCount":103},[],{"intervention":405,"totalTrials":210,"cells":406},"Fluoxetine",{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":424,"PHASE4":426,"NA":437},{"trials":408,"activeCount":103},[],{"trials":410,"activeCount":103},[],{"trials":412,"activeCount":103},[413],{"nctId":414,"briefTitle":415,"status":115,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":422},"NCT04850222","Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma",[92],"2025-02-17","2021-09-01",55,[421],"Musculoskeletal Injury",[405,423],"Calcium",{"trials":425,"activeCount":103},[],{"trials":427,"activeCount":323,"soonestReadout":432},[428],{"nctId":429,"briefTitle":430,"status":141,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":434,"conditions":435,"interventions":436},"NCT06046859","Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?",[94],"2027-03-17","2024-03-01",200,[421],[405],{"trials":438,"activeCount":103},[],{"intervention":440,"totalTrials":210,"cells":441},"clopidogrel 75 mg",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":476},{"trials":443,"activeCount":103},[],{"trials":445,"activeCount":103},[],{"trials":447,"activeCount":103},[],{"trials":449,"activeCount":103},[],{"trials":451,"activeCount":323,"soonestReadout":456},[452,463],{"nctId":453,"briefTitle":454,"status":141,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},"NCT06821191","Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study",[94],"2026-11-01","2027-01-07","2025-03-10",78,[18],[440,462],"Prasugrel 5 mg",{"nctId":464,"briefTitle":465,"status":115,"phases":466,"primaryCompletion":167,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":471},"NCT02567461","Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel",[94],"2018-03-15","2016-03",80,[18],[472,473,474,475],"Edoxaban 60 mg","Edoxaban 30 mg","Clopidogrel 75 mg","Aspirin 81 mg",{"trials":477,"activeCount":103},[],{"intervention":234,"totalTrials":323,"cells":479},{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":494},{"trials":481,"activeCount":103},[],{"trials":483,"activeCount":103},[],{"trials":485,"activeCount":103},[],{"trials":487,"activeCount":103},[],{"trials":489,"activeCount":323,"soonestReadout":177},[490],{"nctId":227,"briefTitle":228,"status":141,"phases":491,"primaryCompletion":177,"completion":230,"start":231,"enrollment":190,"conditions":492,"interventions":493},[94],[18],[214,234],{"trials":495,"activeCount":103},[],{"intervention":244,"totalTrials":323,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":504,"PHASE4":506,"NA":512},{"trials":499,"activeCount":103},[],{"trials":501,"activeCount":103},[],{"trials":503,"activeCount":103},[],{"trials":505,"activeCount":103},[],{"trials":507,"activeCount":323,"soonestReadout":239},[508],{"nctId":236,"briefTitle":237,"status":141,"phases":509,"primaryCompletion":239,"completion":240,"start":241,"enrollment":190,"conditions":510,"interventions":511},[94],[148],[244,245],{"trials":513,"activeCount":103},[],{"intervention":515,"totalTrials":323,"cells":516},"Minocycline Hydrochloride",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":537},{"trials":518,"activeCount":103},[],{"trials":520,"activeCount":103},[],{"trials":522,"activeCount":103},[],{"trials":524,"activeCount":103},[],{"trials":526,"activeCount":323,"soonestReadout":531},[527],{"nctId":528,"briefTitle":529,"status":141,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT06246396","Antihypertensive Mechanisms of Minocycline in Resistant Hypertension",[94],"2028-07","2025-01-08",120,[535],"Hypertension, Resistant to Conventional Therapy",[515],{"trials":538,"activeCount":103},[],{"intervention":540,"totalTrials":323,"cells":541},"TIVA",{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":550,"NA":564},{"trials":543,"activeCount":103},[],{"trials":545,"activeCount":103},[],{"trials":547,"activeCount":103},[],{"trials":549,"activeCount":103},[],{"trials":551,"activeCount":323,"soonestReadout":556},[552],{"nctId":553,"briefTitle":554,"status":141,"phases":555,"primaryCompletion":556,"completion":557,"start":558,"enrollment":146,"conditions":559,"interventions":562},"NCT04281017","Effect of Position and Anesthetic Choice in Intraocular Pressure in Robotic GYN (Gynecologic) Oncology Patients",[94],"2026-06-18","2027-06-18","2020-11-10",[560,561],"Intraocular Pressure","Oncology",[540,563],"Balanced anesthesia",{"trials":565,"activeCount":103},[],{"intervention":563,"totalTrials":323,"cells":567},{"EARLY_PHASE1":568,"PHASE1":570,"PHASE2":572,"PHASE3":574,"PHASE4":576,"NA":582},{"trials":569,"activeCount":103},[],{"trials":571,"activeCount":103},[],{"trials":573,"activeCount":103},[],{"trials":575,"activeCount":103},[],{"trials":577,"activeCount":323,"soonestReadout":556},[578],{"nctId":553,"briefTitle":554,"status":141,"phases":579,"primaryCompletion":556,"completion":557,"start":558,"enrollment":146,"conditions":580,"interventions":581},[94],[560,561],[540,563],{"trials":583,"activeCount":103},[],{"intervention":462,"totalTrials":323,"cells":585},{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":594,"NA":600},{"trials":587,"activeCount":103},[],{"trials":589,"activeCount":103},[],{"trials":591,"activeCount":103},[],{"trials":593,"activeCount":103},[],{"trials":595,"activeCount":323,"soonestReadout":456},[596],{"nctId":453,"briefTitle":454,"status":141,"phases":597,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":598,"interventions":599},[94],[18],[440,462],{"trials":601,"activeCount":103},[],{"intervention":603,"totalTrials":323,"cells":604},"Ticagrelor 90 mg",{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":623},{"trials":606,"activeCount":103},[],{"trials":608,"activeCount":103},[],{"trials":610,"activeCount":103},[],{"trials":612,"activeCount":103},[],{"trials":614,"activeCount":323,"soonestReadout":619},[615],{"nctId":616,"briefTitle":617,"status":141,"phases":618,"primaryCompletion":619,"completion":177,"start":532,"enrollment":16,"conditions":620,"interventions":621},"NCT06691191","Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors",[94],"2026-08-31",[18],[603,622],"Prasugrel 10 mg",{"trials":624,"activeCount":103},[],{"intervention":622,"totalTrials":323,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":641},{"trials":628,"activeCount":103},[],{"trials":630,"activeCount":103},[],{"trials":632,"activeCount":103},[],{"trials":634,"activeCount":103},[],{"trials":636,"activeCount":323,"soonestReadout":619},[637],{"nctId":616,"briefTitle":617,"status":141,"phases":638,"primaryCompletion":619,"completion":177,"start":532,"enrollment":16,"conditions":639,"interventions":640},[94],[18],[603,622],{"trials":642,"activeCount":103},[],{"intervention":78,"totalTrials":323,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":665},{"trials":646,"activeCount":103},[],{"trials":648,"activeCount":103},[],{"trials":650,"activeCount":103},[],{"trials":652,"activeCount":103},[],{"trials":654,"activeCount":323,"soonestReadout":77},[655],{"nctId":75,"briefTitle":76,"status":141,"phases":656,"primaryCompletion":77,"completion":657,"start":658,"enrollment":659,"conditions":660,"interventions":664},[94],"2026-06-30","2021-01-12",88,[661,662,663],"Alcohol Use, Unspecified","Substance Use","Sex Behavior",[78],{"trials":666,"activeCount":103},[],{"intervention":668,"totalTrials":323,"cells":669},"Lasix ONYU",{"EARLY_PHASE1":670,"PHASE1":672,"PHASE2":674,"PHASE3":676,"PHASE4":678,"NA":692},{"trials":671,"activeCount":103},[],{"trials":673,"activeCount":103},[],{"trials":675,"activeCount":103},[],{"trials":677,"activeCount":103},[],{"trials":679,"activeCount":323,"soonestReadout":684},[680],{"nctId":681,"briefTitle":682,"status":141,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":691},"NCT06979726","Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure",[94],"2026-03-31","2026-05-01","2025-11-20",100,[689,690],"Heart Failure","Volume Overload",[668],{"trials":693,"activeCount":103},[],{"intervention":151,"totalTrials":695,"cells":696},10,{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":766},{"trials":698,"activeCount":103},[],{"trials":700,"activeCount":103},[],{"trials":702,"activeCount":103},[],{"trials":704,"activeCount":103},[],{"trials":706,"activeCount":323,"soonestReadout":143},[707,716,725,729,739,749,753,762],{"nctId":708,"briefTitle":709,"status":115,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":714,"interventions":715},"NCT02065479","A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:",[94],"2019-04-22","2014-03",65,[18],[151,162],{"nctId":717,"briefTitle":718,"status":115,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":713,"conditions":723,"interventions":724},"NCT01201772","Prasugrel Re-load Strategies",[94],"2011-05","2011-09","2010-08",[18],[151],{"nctId":139,"briefTitle":140,"status":141,"phases":726,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":727,"interventions":728},[94],[148,149],[151,98],{"nctId":730,"briefTitle":731,"status":115,"phases":732,"primaryCompletion":733,"completion":733,"start":734,"enrollment":735,"conditions":736,"interventions":737},"NCT02212028","Pharmacological Effects of Crushing Prasugrel in STEMI Patients",[94],"2015-08","2014-10",52,[18],[738],"prasugrel",{"nctId":740,"briefTitle":741,"status":115,"phases":742,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT02545933","Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor",[94],"2019-05","2020-01","2016-02",130,[132],[151,136,137,162],{"nctId":360,"briefTitle":361,"status":115,"phases":750,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":751,"interventions":752},[94],[18,368],[327,151],{"nctId":754,"briefTitle":755,"status":115,"phases":756,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":761},"NCT03489863","Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study",[94],"2019-03-20","2018-05-30",14,[18],[151,162],{"nctId":184,"briefTitle":185,"status":115,"phases":763,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":764,"interventions":765},[94],[18],[98,151,193,194,195],{"trials":767,"activeCount":103},[768,776],{"nctId":769,"briefTitle":770,"status":115,"phases":771,"primaryCompletion":772,"completion":733,"start":773,"enrollment":180,"conditions":774,"interventions":775},"NCT01852214","Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes",[95],"2015-07","2013-02",[133,18],[151,162],{"nctId":777,"briefTitle":778,"status":115,"phases":779,"primaryCompletion":780,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT01852175","Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease",[95],"2014-06","2014-07","2012-01",110,[18],[151,162],{"intervention":63,"totalTrials":210,"cells":787},{"EARLY_PHASE1":788,"PHASE1":790,"PHASE2":792,"PHASE3":809,"PHASE4":817,"NA":819},{"trials":789,"activeCount":103},[],{"trials":791,"activeCount":103},[],{"trials":793,"activeCount":323,"soonestReadout":798},[794],{"nctId":795,"briefTitle":796,"status":141,"phases":797,"primaryCompletion":798,"completion":798,"start":799,"enrollment":180,"conditions":800,"interventions":808},"NCT06290713","Vasodilator and Exercise Study for DMD (VASO-REx)",[92],"2026-11","2024-06-05",[801,802,803,804,805,806,807],"Duchenne Muscular Dystrophy","Duchenne Disease","Muscular Dystrophy","Muscular Dystrophy in Children","Vasodilation","Exercise","DMD",[63],{"trials":810,"activeCount":323,"soonestReadout":62},[811],{"nctId":60,"briefTitle":61,"status":313,"phases":812,"primaryCompletion":62,"completion":62,"start":813,"enrollment":814,"conditions":815,"interventions":816},[92,93],"2021-12-14",25,[801],[63,63],{"trials":818,"activeCount":103},[],{"trials":820,"activeCount":103},[],{"intervention":822,"totalTrials":323,"cells":823},"Ticagrelor + Aspirin",{"EARLY_PHASE1":824,"PHASE1":826,"PHASE2":828,"PHASE3":830,"PHASE4":845,"NA":847},{"trials":825,"activeCount":103},[],{"trials":827,"activeCount":103},[],{"trials":829,"activeCount":103},[],{"trials":831,"activeCount":323,"soonestReadout":836},[832],{"nctId":833,"briefTitle":834,"status":313,"phases":835,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":842},"NCT05047172","Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis",[93],"2027-01-31","2022-08-02",1683,[840,841],"Intracranial Arteriosclerosis","Stroke",[822,843,844],"Rivaroxaban + Aspirin","Clopidogrel + Aspirin",{"trials":846,"activeCount":103},[],{"trials":848,"activeCount":103},[],{"intervention":843,"totalTrials":323,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":863,"NA":865},{"trials":852,"activeCount":103},[],{"trials":854,"activeCount":103},[],{"trials":856,"activeCount":103},[],{"trials":858,"activeCount":323,"soonestReadout":836},[859],{"nctId":833,"briefTitle":834,"status":313,"phases":860,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":861,"interventions":862},[93],[840,841],[822,843,844],{"trials":864,"activeCount":103},[],{"trials":866,"activeCount":103},[],{"intervention":844,"totalTrials":323,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":881,"NA":883},{"trials":870,"activeCount":103},[],{"trials":872,"activeCount":103},[],{"trials":874,"activeCount":103},[],{"trials":876,"activeCount":323,"soonestReadout":836},[877],{"nctId":833,"briefTitle":834,"status":313,"phases":878,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":879,"interventions":880},[93],[840,841],[822,843,844],{"trials":882,"activeCount":103},[],{"trials":884,"activeCount":103},[],{"intervention":886,"totalTrials":323,"cells":887},"Pfizer-BioNTech mRNA COVID-19 vaccine",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":908,"NA":910},{"trials":889,"activeCount":103},[],{"trials":891,"activeCount":103},[],{"trials":893,"activeCount":103},[],{"trials":895,"activeCount":323,"soonestReadout":901},[896],{"nctId":897,"briefTitle":898,"status":899,"phases":900,"primaryCompletion":901,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":907},"NCT07597070","Universal Immunization to Fortify Immunotherapy Efficacy and Response","NOT_YET_RECRUITING",[92,93],"2035-03","2026-09",1200,[905,906],"Stage 4 NSCLC","Melanoma (Skin) Stage IV",[886],{"trials":909,"activeCount":103},[],{"trials":911,"activeCount":103},[],{"intervention":913,"totalTrials":328,"cells":914},"Pembrolizumab",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":935,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":916,"activeCount":103},[],{"trials":918,"activeCount":323,"soonestReadout":923},[919],{"nctId":920,"briefTitle":921,"status":313,"phases":922,"primaryCompletion":923,"completion":924,"start":925,"enrollment":926,"conditions":927,"interventions":930},"NCT06514898","Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma",[91],"2027-09-01","2028-12-01","2025-05-05",12,[928,929],"Recurrent Group 3 Medulloblastoma","Recurrent Group 4 (Non-SHH\u002FNon-WNT) Medulloblastoma",[931,932,933,934,913],"TTRNA-DC vaccines with GM-CSF","TTRNA-xALT","Td vaccine","autologous HSCs",{"trials":936,"activeCount":210,"soonestReadout":42},[937,950,959],{"nctId":938,"briefTitle":939,"status":940,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":948},"NCT05669352","A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases","SUSPENDED",[91,92],"2026-08","2027-08","2025-04",29,[947],"Melanoma Metastatic in the Brain",[949,913],"CA-4948",{"nctId":951,"briefTitle":952,"status":141,"phases":953,"primaryCompletion":954,"completion":954,"start":955,"enrollment":34,"conditions":956,"interventions":958},"NCT06558214","OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial",[92],"2029-10","2024-12-10",[957],"Recurrent Glioblastoma",[913],{"nctId":40,"briefTitle":41,"status":313,"phases":960,"primaryCompletion":42,"completion":961,"start":962,"enrollment":146,"conditions":963,"interventions":966},[92],"2027-12","2018-02-23",[964,965],"Glioblastoma","Glioblastoma, WHO Grade IV",[43,913],{"trials":968,"activeCount":103},[],{"trials":970,"activeCount":103},[],{"trials":972,"activeCount":103},[],{"intervention":974,"totalTrials":210,"cells":975},"AB-free kava",{"EARLY_PHASE1":976,"PHASE1":994,"PHASE2":996,"PHASE3":1008,"PHASE4":1010,"NA":1012},{"trials":977,"activeCount":323,"soonestReadout":982},[978],{"nctId":979,"briefTitle":980,"status":899,"phases":981,"primaryCompletion":982,"completion":983,"start":984,"enrollment":146,"conditions":985,"interventions":993},"NCT07219186","Kava Aging and Mobility Study",[90],"2027-03","2027-05","2026-04",[986,987,988,989,990,991,992],"Old Adults","Sleep Quality","Kava","Mobility Impairment","Physical Activity and Stress","Physical Impairment","Sedentary Lifestyle in Patients Over 70",[974],{"trials":995,"activeCount":103},[],{"trials":997,"activeCount":323,"soonestReadout":836},[998],{"nctId":999,"briefTitle":1000,"status":141,"phases":1001,"primaryCompletion":836,"completion":1002,"start":1003,"enrollment":1004,"conditions":1005,"interventions":1007},"NCT05814055","The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence",[92],"2027-10-31","2024-06-06",76,[1006],"Smoking",[974],{"trials":1009,"activeCount":103},[],{"trials":1011,"activeCount":103},[],{"trials":1013,"activeCount":103},[],{"intervention":1015,"totalTrials":1016,"cells":1017},"Cisplatin",3,{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1048,"PHASE4":1060,"NA":1062},{"trials":1019,"activeCount":103},[],{"trials":1021,"activeCount":103},[],{"trials":1023,"activeCount":323,"soonestReadout":1042},[1024,1038],{"nctId":1025,"briefTitle":1026,"status":1027,"phases":1028,"start":1029,"enrollment":34,"conditions":1030,"interventions":1034},"NCT00003583","Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer","UNKNOWN",[92],"1997-06",[1031,1032,1033],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Lung Cancer","Radiation Toxicity",[1035,1036,1037],"amifostine trihydrate","cisplatin","etoposide",{"nctId":1039,"briefTitle":1040,"status":141,"phases":1041,"primaryCompletion":1042,"completion":1043,"start":188,"enrollment":1044,"conditions":1045,"interventions":1047},"NCT05268614","Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma",[92],"2029-06","2032-06",250,[1046],"Oropharyngeal Squamous Cell Carcinoma",[1015],{"trials":1049,"activeCount":103},[1050],{"nctId":1051,"briefTitle":1052,"status":1053,"phases":1054,"primaryCompletion":1055,"completion":1055,"start":1056,"enrollment":328,"conditions":1057,"interventions":1059},"NCT01487499","Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)","TERMINATED",[93],"2015-03","2011-12",[1058],"Small Cell Lung Cancer",[1015],{"trials":1061,"activeCount":103},[],{"trials":1063,"activeCount":103},[],{"intervention":1065,"totalTrials":210,"cells":1066},"Gemcitabine",{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1091,"PHASE4":1093,"NA":1095},{"trials":1068,"activeCount":103},[],{"trials":1070,"activeCount":103},[],{"trials":1072,"activeCount":323,"soonestReadout":943},[1073,1082],{"nctId":1074,"briefTitle":1075,"status":141,"phases":1076,"primaryCompletion":943,"completion":943,"start":1077,"enrollment":19,"conditions":1078,"interventions":1080},"NCT06488222","Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer",[92],"2024-11-05",[1079],"Bladder Cancer",[1081,1065],"Docetaxel",{"nctId":1083,"briefTitle":1084,"status":115,"phases":1085,"primaryCompletion":1086,"completion":1086,"start":1087,"enrollment":210,"conditions":1088,"interventions":1090},"NCT01553019","Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer",[92],"2017-08-31","2011-10",[1089],"Pancreatic Cancer",[1065],{"trials":1092,"activeCount":103},[],{"trials":1094,"activeCount":103},[],{"trials":1096,"activeCount":103},[],{"intervention":988,"totalTrials":210,"cells":1098},{"EARLY_PHASE1":1099,"PHASE1":1101,"PHASE2":1112,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1100,"activeCount":103},[],{"trials":1102,"activeCount":103},[1103],{"nctId":1104,"briefTitle":1105,"status":257,"phases":1106,"primaryCompletion":1107,"completion":1108,"start":744,"enrollment":103,"conditions":1109,"interventions":1111},"NCT03606655","Exploring the Impact of Two-week Kava on the Metabolism of Nicotine and NNK",[91],"2020-10","2021-01",[1110],"Kava on the Metabolism of Nicotine and NNK",[988],{"trials":1113,"activeCount":323,"soonestReadout":1118},[1114],{"nctId":1115,"briefTitle":1116,"status":313,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":1119,"enrollment":34,"conditions":1120,"interventions":1121},"NCT05081882","Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava",[92],"2026-12","2022-06-09",[1006],[988],{"trials":1123,"activeCount":103},[],{"trials":1125,"activeCount":103},[],{"trials":1127,"activeCount":103},[],{"intervention":1129,"totalTrials":210,"cells":1130},"Methylphenidate Pill",{"EARLY_PHASE1":1131,"PHASE1":1144,"PHASE2":1146,"PHASE3":1156,"PHASE4":1158,"NA":1160},{"trials":1132,"activeCount":103},[1133],{"nctId":1134,"briefTitle":1135,"status":115,"phases":1136,"primaryCompletion":1137,"completion":1137,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1143},"NCT06063200","Methylphenidate and Response to Alcohol Cues Pilot Study",[90],"2025-07-01","2024-03-20",31,[1141,1142],"Alcohol Use Disorder","Attention Deficit Hyperactivity Disorder",[1129],{"trials":1145,"activeCount":103},[],{"trials":1147,"activeCount":323,"soonestReadout":1152},[1148],{"nctId":1149,"briefTitle":1150,"status":899,"phases":1151,"primaryCompletion":1152,"completion":1152,"start":1153,"enrollment":180,"conditions":1154,"interventions":1155},"NCT07306078","Methylphenidate and Response to Alcohol Cues",[92],"2028-04","2026-05",[1141],[1129],{"trials":1157,"activeCount":103},[],{"trials":1159,"activeCount":103},[],{"trials":1161,"activeCount":103},[],{"intervention":43,"totalTrials":210,"cells":1163},{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1184,"PHASE4":1186,"NA":1188},{"trials":1165,"activeCount":103},[],{"trials":1167,"activeCount":103},[],{"trials":1169,"activeCount":323,"soonestReadout":42},[1170,1180],{"nctId":1171,"briefTitle":1172,"status":1053,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1016,"conditions":1177,"interventions":1179},"NCT00717275","Study of Temozolomide to Treat Newly Diagnosed Brain Metastases",[92],"2011-01","2011-06","2008-09",[1178],"Brain Metastases",[43],{"nctId":40,"briefTitle":41,"status":313,"phases":1181,"primaryCompletion":42,"completion":961,"start":962,"enrollment":146,"conditions":1182,"interventions":1183},[92],[964,965],[43,913],{"trials":1185,"activeCount":103},[],{"trials":1187,"activeCount":103},[],{"trials":1189,"activeCount":103},[],{"intervention":1191,"totalTrials":210,"cells":1192},"Epidiferphane",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1194,"activeCount":103},[],{"trials":1196,"activeCount":103},[],{"trials":1198,"activeCount":323,"soonestReadout":1118},[1199,1208],{"nctId":1200,"briefTitle":1201,"status":141,"phases":1202,"primaryCompletion":1118,"completion":1118,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1206},"NCT05074290","Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients",[91,92],"2023-03-30",74,[36],[1191,1207],"Taxane Chemotherapy",{"nctId":1209,"briefTitle":1210,"status":257,"phases":1211,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":103,"conditions":1214,"interventions":1215},"NCT03611985","Phase I\u002FIIa Study of Pharmacokinetics and Safety of Epidiferphane™ and Taxanes in Breast Cancer Patients",[91,92],"2023-03","2020-03",[36],[1191,1207],{"trials":1217,"activeCount":103},[],{"trials":1219,"activeCount":103},[],{"trials":1221,"activeCount":103},[],{"intervention":1207,"totalTrials":210,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1238,"PHASE4":1240,"NA":1242},{"trials":1225,"activeCount":103},[],{"trials":1227,"activeCount":103},[],{"trials":1229,"activeCount":323,"soonestReadout":1118},[1230,1234],{"nctId":1200,"briefTitle":1201,"status":141,"phases":1231,"primaryCompletion":1118,"completion":1118,"start":1203,"enrollment":1204,"conditions":1232,"interventions":1233},[91,92],[36],[1191,1207],{"nctId":1209,"briefTitle":1210,"status":257,"phases":1235,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":103,"conditions":1236,"interventions":1237},[91,92],[36],[1191,1207],{"trials":1239,"activeCount":103},[],{"trials":1241,"activeCount":103},[],{"trials":1243,"activeCount":103},[],{"intervention":1245,"totalTrials":210,"cells":1246},"Indocyanine green",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1275,"PHASE4":1277,"NA":1279},{"trials":1248,"activeCount":103},[],{"trials":1250,"activeCount":103},[],{"trials":1252,"activeCount":323,"soonestReadout":1270},[1253,1266],{"nctId":1254,"briefTitle":1255,"status":115,"phases":1256,"primaryCompletion":1257,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1265},"NCT04942665","Low Dose ICG for Biliary Tract and Tumor Imaging",[92],"2022-09-15","2023-04-01","2021-09-15",60,[1262,1263,1264],"Cholecystitis","Hepatocellular Carcinoma","Liver Metastases",[1245],{"nctId":1267,"briefTitle":1268,"status":141,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT06327490","A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer",[92],"2028-06","2024-10-15",30,[36],[1245],{"trials":1276,"activeCount":103},[],{"trials":1278,"activeCount":103},[],{"trials":1280,"activeCount":103},[],{"intervention":48,"totalTrials":323,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1296,"PHASE4":1298,"NA":1300},{"trials":1284,"activeCount":103},[],{"trials":1286,"activeCount":103},[],{"trials":1288,"activeCount":323,"soonestReadout":47},[1289],{"nctId":45,"briefTitle":46,"status":313,"phases":1290,"primaryCompletion":47,"completion":1118,"start":374,"enrollment":1291,"conditions":1292,"interventions":1294},[92],45,[1293],"Pancreatic Adenocarcinoma",[48,1295],"FOLFOX regimen",{"trials":1297,"activeCount":103},[],{"trials":1299,"activeCount":103},[],{"trials":1301,"activeCount":103},[],{"intervention":1295,"totalTrials":323,"cells":1303},{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1314,"PHASE4":1316,"NA":1318},{"trials":1305,"activeCount":103},[],{"trials":1307,"activeCount":103},[],{"trials":1309,"activeCount":323,"soonestReadout":47},[1310],{"nctId":45,"briefTitle":46,"status":313,"phases":1311,"primaryCompletion":47,"completion":1118,"start":374,"enrollment":1291,"conditions":1312,"interventions":1313},[92],[1293],[48,1295],{"trials":1315,"activeCount":103},[],{"trials":1317,"activeCount":103},[],{"trials":1319,"activeCount":103},[],{"intervention":1081,"totalTrials":323,"cells":1321},{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1332,"PHASE4":1334,"NA":1336},{"trials":1323,"activeCount":103},[],{"trials":1325,"activeCount":103},[],{"trials":1327,"activeCount":323,"soonestReadout":943},[1328],{"nctId":1074,"briefTitle":1075,"status":141,"phases":1329,"primaryCompletion":943,"completion":943,"start":1077,"enrollment":19,"conditions":1330,"interventions":1331},[92],[1079],[1081,1065],{"trials":1333,"activeCount":103},[],{"trials":1335,"activeCount":103},[],{"trials":1337,"activeCount":103},[],{"intervention":1339,"totalTrials":323,"cells":1340},"Flotufolastat F 18",{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1357,"PHASE4":1359,"NA":1361},{"trials":1342,"activeCount":103},[],{"trials":1344,"activeCount":103},[],{"trials":1346,"activeCount":323,"soonestReadout":1351},[1347],{"nctId":1348,"briefTitle":1349,"status":141,"phases":1350,"primaryCompletion":1351,"completion":1352,"start":1353,"enrollment":1272,"conditions":1354,"interventions":1356},"NCT07220720","POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2\u002F3 Lesions",[92],"2030-07-15","2032-11-15","2025-11-04",[1355],"Prostate",[1339],{"trials":1358,"activeCount":103},[],{"trials":1360,"activeCount":103},[],{"trials":1362,"activeCount":103},[],{"intervention":1364,"totalTrials":323,"cells":1365},"Glucagon-like peptide 1 receptor agonist",{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1367,"activeCount":103},[],{"trials":1369,"activeCount":103},[],{"trials":1371,"activeCount":323,"soonestReadout":1376},[1372],{"nctId":1373,"briefTitle":1374,"status":141,"phases":1375,"primaryCompletion":1376,"completion":1377,"start":1378,"enrollment":34,"conditions":1379,"interventions":1381},"NCT07107334","A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia",[92],"2028-11","2029-11","2026-04-07",[1380],"Endometrioid Endometrial Adenocarcinoma",[1364],{"trials":1383,"activeCount":103},[],{"trials":1385,"activeCount":103},[],{"trials":1387,"activeCount":103},[],{"intervention":1389,"totalTrials":323,"cells":1390},"Pioglitazone",{"EARLY_PHASE1":1391,"PHASE1":1393,"PHASE2":1395,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1392,"activeCount":103},[],{"trials":1394,"activeCount":103},[],{"trials":1396,"activeCount":323,"soonestReadout":1401},[1397],{"nctId":1398,"briefTitle":1399,"status":141,"phases":1400,"primaryCompletion":1401,"completion":1401,"start":1402,"enrollment":1403,"conditions":1404,"interventions":1406},"NCT04501406","Low-Dose Pioglitazone in Patients With NASH (AIM 2)",[92],"2027-08-31","2020-12-15",166,[206,1405],"Nonalcoholic Steatohepatitis",[1389],{"trials":1408,"activeCount":103},[],{"trials":1410,"activeCount":103},[],{"trials":1412,"activeCount":103},[],{"intervention":68,"totalTrials":323,"cells":1414},{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1416,"activeCount":103},[],{"trials":1418,"activeCount":103},[],{"trials":1420,"activeCount":323,"soonestReadout":67},[1421],{"nctId":65,"briefTitle":66,"status":313,"phases":1422,"primaryCompletion":67,"completion":67,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1427},[91,92],"2023-08-01",36,[1426],"Spasmodic Dysphonia",[68,1428],"Botulinum toxin type A",{"trials":1430,"activeCount":103},[],{"trials":1432,"activeCount":103},[],{"trials":1434,"activeCount":103},[],{"intervention":1428,"totalTrials":323,"cells":1436},{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1438,"activeCount":103},[],{"trials":1440,"activeCount":103},[],{"trials":1442,"activeCount":323,"soonestReadout":67},[1443],{"nctId":65,"briefTitle":66,"status":313,"phases":1444,"primaryCompletion":67,"completion":67,"start":1423,"enrollment":1424,"conditions":1445,"interventions":1446},[91,92],[1426],[68,1428],{"trials":1448,"activeCount":103},[],{"trials":1450,"activeCount":103},[],{"trials":1452,"activeCount":103},[],{"intervention":1454,"totalTrials":323,"cells":1455},"Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1457,"activeCount":103},[],{"trials":1459,"activeCount":103},[],{"trials":1461,"activeCount":323,"soonestReadout":1466},[1462],{"nctId":1463,"briefTitle":1464,"status":141,"phases":1465,"primaryCompletion":1466,"completion":240,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1472},"NCT06008795","BLOCK-SAH - PPF-Block for Post-SAH Headache",[92],"2027-01-15","2023-12-17",195,[1470,1471],"Subarachnoid Hemorrhage, Aneurysmal","Headache",[1454],{"trials":1474,"activeCount":103},[],{"trials":1476,"activeCount":103},[],{"trials":1478,"activeCount":103},[],{"intervention":1480,"totalTrials":323,"cells":1481},"Anti-thymocyte globulin",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1483,"activeCount":103},[],{"trials":1485,"activeCount":103},[],{"trials":1487,"activeCount":323,"soonestReadout":1376},[1488],{"nctId":1489,"briefTitle":1490,"status":141,"phases":1491,"primaryCompletion":1376,"completion":1492,"start":1493,"enrollment":1260,"conditions":1494,"interventions":1496},"NCT06455319","Precision Administration of Anti-thymocyte Globulin With or Without Verapamil",[92],"2030-08","2025-11-12",[1495],"Type 1 Diabetes",[1480,1497],"verapamil extended release",{"trials":1499,"activeCount":103},[],{"trials":1501,"activeCount":103},[],{"trials":1503,"activeCount":103},[],{"intervention":1497,"totalTrials":323,"cells":1505},{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1507,"activeCount":103},[],{"trials":1509,"activeCount":103},[],{"trials":1511,"activeCount":323,"soonestReadout":1376},[1512],{"nctId":1489,"briefTitle":1490,"status":141,"phases":1513,"primaryCompletion":1376,"completion":1492,"start":1493,"enrollment":1260,"conditions":1514,"interventions":1515},[92],[1495],[1480,1497],{"trials":1517,"activeCount":103},[],{"trials":1519,"activeCount":103},[],{"trials":1521,"activeCount":103},[],{"intervention":1523,"totalTrials":323,"cells":1524},"Zoledronic acid",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1526,"activeCount":103},[],{"trials":1528,"activeCount":103},[],{"trials":1530,"activeCount":323,"soonestReadout":1535},[1531],{"nctId":1532,"briefTitle":1533,"status":141,"phases":1534,"primaryCompletion":1535,"completion":1535,"start":1536,"enrollment":25,"conditions":1537,"interventions":1551},"NCT06625190","Alpha\u002FBeta T and B Cell Depletion With Zoledronic Acid for Solid Tumors",[91,92],"2030-02","2026-02-11",[1538,1539,1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550],"Neuroblastoma","Rhabdomyosarcoma","Synovial Sarcoma","Peripheral Nerve Sheath Tumors","Clear Cell Sarcoma","Alveolar Soft Part Sarcoma","Desmoplastic Small Round Cell Tumor","Chordoma","Rhabdoid Tumor","Epithelioid Sarcoma","Myoepithelial Tumor","Osteosarcoma","Ewing Sarcoma",[1523],{"trials":1553,"activeCount":103},[],{"trials":1555,"activeCount":103},[],{"trials":1557,"activeCount":103},[],{"intervention":83,"totalTrials":323,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1561,"activeCount":103},[],{"trials":1563,"activeCount":103},[],{"trials":1565,"activeCount":323,"soonestReadout":82},[1566],{"nctId":80,"briefTitle":81,"status":313,"phases":1567,"primaryCompletion":82,"completion":1568,"start":1569,"enrollment":469,"conditions":1570,"interventions":1572},[91,92],"2027-01-23","2019-09-25",[1571],"Chronic Rhinosinusitis (Diagnosis)",[83,1573],"Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2",{"trials":1575,"activeCount":103},[],{"trials":1577,"activeCount":103},[],{"trials":1579,"activeCount":103},[],{"intervention":1573,"totalTrials":323,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1583,"activeCount":103},[],{"trials":1585,"activeCount":103},[],{"trials":1587,"activeCount":323,"soonestReadout":82},[1588],{"nctId":80,"briefTitle":81,"status":313,"phases":1589,"primaryCompletion":82,"completion":1568,"start":1569,"enrollment":469,"conditions":1590,"interventions":1591},[91,92],[1571],[83,1573],{"trials":1593,"activeCount":103},[],{"trials":1595,"activeCount":103},[],{"trials":1597,"activeCount":103},[],{"intervention":1599,"totalTrials":323,"cells":1600},"Zinc citrate",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1616,"PHASE4":1618,"NA":1620},{"trials":1602,"activeCount":103},[],{"trials":1604,"activeCount":103},[],{"trials":1606,"activeCount":323,"soonestReadout":1611},[1607],{"nctId":1608,"briefTitle":1609,"status":141,"phases":1610,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":814,"conditions":1613,"interventions":1615},"NCT07140874","Zinc as an Adjunctive Therapy for Cervical Dystonia",[92],"2027-05-31","2026-06-01",[1614],"Cervical Dystonia",[1599],{"trials":1617,"activeCount":103},[],{"trials":1619,"activeCount":103},[],{"trials":1621,"activeCount":103},[],{"intervention":58,"totalTrials":323,"cells":1623},{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1636,"PHASE4":1638,"NA":1640},{"trials":1625,"activeCount":103},[],{"trials":1627,"activeCount":103},[],{"trials":1629,"activeCount":323,"soonestReadout":57},[1630],{"nctId":55,"briefTitle":56,"status":313,"phases":1631,"primaryCompletion":57,"completion":984,"start":1632,"enrollment":695,"conditions":1633,"interventions":1635},[92],"2021-08-25",[1634],"Peripheral Nerve Sheath Tumor",[58],{"trials":1637,"activeCount":103},[],{"trials":1639,"activeCount":103},[],{"trials":1641,"activeCount":103},[],{"intervention":1643,"totalTrials":323,"cells":1644},"Magtrace",{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1658,"PHASE4":1660,"NA":1662},{"trials":1646,"activeCount":103},[],{"trials":1648,"activeCount":103},[],{"trials":1650,"activeCount":323,"soonestReadout":1042},[1651],{"nctId":1652,"briefTitle":1653,"status":141,"phases":1654,"primaryCompletion":1042,"completion":1042,"start":984,"enrollment":1272,"conditions":1655,"interventions":1657},"NCT06868238","Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)",[92],[1656],"Ductal Carcinoma in Situ",[1643],{"trials":1659,"activeCount":103},[],{"trials":1661,"activeCount":103},[],{"trials":1663,"activeCount":103},[],{"intervention":1665,"totalTrials":323,"cells":1666},"pp65 RNA LP",{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1685,"PHASE4":1687,"NA":1689},{"trials":1668,"activeCount":103},[],{"trials":1670,"activeCount":103},[],{"trials":1672,"activeCount":323,"soonestReadout":1677},[1673],{"nctId":1674,"briefTitle":1675,"status":313,"phases":1676,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":1424,"conditions":1680,"interventions":1683},"NCT05660408","RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors",[91,92],"2033-10","2035-10","2025-03-12",[1681,1682],"Recurrent Pulmonary Osteosarcoma","Recurrent High-grade Glioma",[1665,1684],"pp65\u002Ftumor mRNA RNA-LP",{"trials":1686,"activeCount":103},[],{"trials":1688,"activeCount":103},[],{"trials":1690,"activeCount":103},[],{"intervention":1692,"totalTrials":323,"cells":1693},"Cannabidiol (CBD) Extract",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1695,"activeCount":103},[],{"trials":1697,"activeCount":103},[],{"trials":1699,"activeCount":323,"soonestReadout":177},[1700],{"nctId":1701,"briefTitle":1702,"status":141,"phases":1703,"primaryCompletion":177,"completion":177,"start":1704,"enrollment":1272,"conditions":1705,"interventions":1707},"NCT06414473","CBD for Knee Osteoarthritis",[91,92],"2024-06-14",[1706],"Osteoarthritis, Knee",[1692],{"trials":1709,"activeCount":103},[],{"trials":1711,"activeCount":103},[],{"trials":1713,"activeCount":103},[],{"intervention":53,"totalTrials":323,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1717,"activeCount":103},[],{"trials":1719,"activeCount":103},[],{"trials":1721,"activeCount":323,"soonestReadout":52},[1722],{"nctId":50,"briefTitle":51,"status":313,"phases":1723,"primaryCompletion":52,"completion":657,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1729},[92],"2020-01-10",41,[1727,1728],"C9orf72 Amyotrophic Lateral Sclerosis (ALS)","Frontotemporal Dementia",[53],{"trials":1731,"activeCount":103},[],{"trials":1733,"activeCount":103},[],{"trials":1735,"activeCount":103},[],{"intervention":1737,"totalTrials":323,"cells":1738},"Irinotecan",{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1743,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1740,"activeCount":103},[],{"trials":1742,"activeCount":103},[],{"trials":1744,"activeCount":323,"soonestReadout":984},[1745],{"nctId":1746,"briefTitle":1747,"status":141,"phases":1748,"primaryCompletion":984,"completion":984,"start":1749,"enrollment":926,"conditions":1750,"interventions":1751},"NCT05669339","AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma",[92],"2024-12-02",[1263],[1737,1752,1753],"Sonidegib","Sorafenib",{"trials":1755,"activeCount":103},[],{"trials":1757,"activeCount":103},[],{"trials":1759,"activeCount":103},[],{"intervention":1752,"totalTrials":323,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1763,"activeCount":103},[],{"trials":1765,"activeCount":103},[],{"trials":1767,"activeCount":323,"soonestReadout":984},[1768],{"nctId":1746,"briefTitle":1747,"status":141,"phases":1769,"primaryCompletion":984,"completion":984,"start":1749,"enrollment":926,"conditions":1770,"interventions":1771},[92],[1263],[1737,1752,1753],{"trials":1773,"activeCount":103},[],{"trials":1775,"activeCount":103},[],{"trials":1777,"activeCount":103},[],{"intervention":1753,"totalTrials":323,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":103},[],{"trials":1783,"activeCount":103},[],{"trials":1785,"activeCount":323,"soonestReadout":984},[1786],{"nctId":1746,"briefTitle":1747,"status":141,"phases":1787,"primaryCompletion":984,"completion":984,"start":1749,"enrollment":926,"conditions":1788,"interventions":1789},[92],[1263],[1737,1752,1753],{"trials":1791,"activeCount":103},[],{"trials":1793,"activeCount":103},[],{"trials":1795,"activeCount":103},[],{"intervention":1797,"totalTrials":323,"cells":1798},"Genotype",{"EARLY_PHASE1":1799,"PHASE1":1801,"PHASE2":1803,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1800,"activeCount":103},[],{"trials":1802,"activeCount":103},[],{"trials":1804,"activeCount":323,"soonestReadout":1809},[1805],{"nctId":1806,"briefTitle":1807,"status":313,"phases":1808,"primaryCompletion":1809,"completion":619,"start":1810,"enrollment":146,"conditions":1811,"interventions":1813},"NCT05120284","Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)",[92],"2026-07-01","2022-07-01",[1812],"Glioblastoma Multiforme",[1814,1797],"Dichloroacetate",{"trials":1816,"activeCount":103},[],{"trials":1818,"activeCount":103},[],{"trials":1820,"activeCount":103},[],{"intervention":1822,"totalTrials":323,"cells":1823},"Use of Linaclotide as a single agent Colonoscopy prep",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1825,"activeCount":103},[],{"trials":1827,"activeCount":103},[],{"trials":1829,"activeCount":323,"soonestReadout":1834},[1830],{"nctId":1831,"briefTitle":1832,"status":141,"phases":1833,"primaryCompletion":1834,"completion":1835,"start":72,"enrollment":695,"conditions":1836,"interventions":1838},"NCT06692673","Linaclotide for Colonoscopy Bowel Prep",[91,92],"2026-04-30","2026-07-28",[1837],"Patients Scheduled for Colonoscopy",[1822],{"trials":1840,"activeCount":103},[],{"trials":1842,"activeCount":103},[],{"trials":1844,"activeCount":103},[],{"intervention":1846,"totalTrials":323,"cells":1847},"Intermediate-dose ivermectin",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1849,"activeCount":103},[],{"trials":1851,"activeCount":103},[],{"trials":1853,"activeCount":323,"soonestReadout":1858},[1854],{"nctId":1855,"briefTitle":1856,"status":899,"phases":1857,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":469,"conditions":1861,"interventions":1863},"NCT07487805","Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC)",[92],"2027-07","2027-10","2026-07",[1862],"Solid Tumor, Adult",[1846,1864],"High-dose ivermectin",{"trials":1866,"activeCount":103},[],{"trials":1868,"activeCount":103},[],{"trials":1870,"activeCount":103},[],{"intervention":1864,"totalTrials":323,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":103},[],{"trials":1876,"activeCount":103},[],{"trials":1878,"activeCount":323,"soonestReadout":1858},[1879],{"nctId":1855,"briefTitle":1856,"status":899,"phases":1880,"primaryCompletion":1858,"completion":1859,"start":1860,"enrollment":469,"conditions":1881,"interventions":1882},[92],[1862],[1846,1864],{"trials":1884,"activeCount":103},[],{"trials":1886,"activeCount":103},[],{"trials":1888,"activeCount":103},[],{"intervention":88,"totalTrials":323,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1892,"activeCount":103},[],{"trials":1894,"activeCount":103},[],{"trials":1896,"activeCount":323,"soonestReadout":87},[1897],{"nctId":85,"briefTitle":86,"status":313,"phases":1898,"primaryCompletion":87,"completion":619,"start":1899,"enrollment":146,"conditions":1900,"interventions":1902},[91,92],"2022-06-21",[1901],"ALS",[88],{"trials":1904,"activeCount":103},[],{"trials":1906,"activeCount":103},[],{"trials":1908,"activeCount":103},[],{"intervention":73,"totalTrials":323,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1926,"PHASE4":1928,"NA":1930},{"trials":1912,"activeCount":103},[],{"trials":1914,"activeCount":103},[],{"trials":1916,"activeCount":323,"soonestReadout":72},[1917],{"nctId":70,"briefTitle":71,"status":141,"phases":1918,"primaryCompletion":72,"completion":1919,"start":1920,"enrollment":1272,"conditions":1921,"interventions":1925},[92],"2026-12-01","2025-01-06",[1922,1923,1924],"Anxiety","Generalized Anxiety Disorder","Sleep Problems",[73],{"trials":1927,"activeCount":103},[],{"trials":1929,"activeCount":103},[],{"trials":1931,"activeCount":103},[],{"intervention":1814,"totalTrials":1933,"cells":1934},7,{"EARLY_PHASE1":1935,"PHASE1":1937,"PHASE2":1957,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1936,"activeCount":103},[],{"trials":1938,"activeCount":103},[1939,1948],{"nctId":1940,"briefTitle":1941,"status":115,"phases":1942,"primaryCompletion":1943,"completion":1944,"start":1945,"enrollment":1291,"conditions":1946,"interventions":1947},"NCT02690285","A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers",[91],"2017-05-30","2017-11-01","2016-03-01",[15],[1814],{"nctId":1949,"briefTitle":1950,"status":115,"phases":1951,"primaryCompletion":712,"completion":712,"start":1952,"enrollment":1953,"conditions":1954,"interventions":1956},"NCT01111097","Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors",[91],"2010-04",15,[1955,964],"Brain Tumor",[1814],{"trials":1958,"activeCount":323,"soonestReadout":1809},[1959],{"nctId":1806,"briefTitle":1807,"status":313,"phases":1960,"primaryCompletion":1809,"completion":619,"start":1810,"enrollment":146,"conditions":1961,"interventions":1962},[92],[1812],[1814,1797],{"trials":1964,"activeCount":103},[],{"trials":1966,"activeCount":103},[],{"trials":1968,"activeCount":103},[1969,1977,1987,1998],{"nctId":1970,"briefTitle":1971,"status":1972,"phases":1973,"conditions":1974,"interventions":1976},"NCT01797276","Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access","NO_LONGER_AVAILABLE",[],[1975],"Mitochondrial Enzyme Deficiencies",[1814],{"nctId":1978,"briefTitle":1979,"status":115,"phases":1980,"primaryCompletion":1981,"completion":1981,"start":1982,"enrollment":31,"conditions":1983,"interventions":1985},"NCT00874276","Pharmacotoxicology of Trichloroethylene Metabolites",[95],"2012-11","2009-08",[1984],"Congenital Lactic Acidosis",[1814,1986],"Genetic Marker on Chromosome 14q24.3",{"nctId":1988,"briefTitle":1989,"status":115,"phases":1990,"completion":1991,"start":1992,"enrollment":1272,"conditions":1993,"interventions":1996},"NCT00031161","Prevention of Dichloroacetate Toxicity",[95],"2005-09","2001-09",[1994,1995],"Acidosis, Lactic","Chronic Disease",[1997,1814],"Nitisinone",{"nctId":1999,"briefTitle":1979,"status":1053,"phases":2000,"primaryCompletion":782,"completion":782,"start":2001,"enrollment":210,"conditions":2002,"interventions":2003},"NCT00865514",[95],"2011-08",[15],[1814,2004],"Genotyping",{"intervention":1684,"totalTrials":210,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":2008,"activeCount":103},[],{"trials":2010,"activeCount":103},[],{"trials":2012,"activeCount":323,"soonestReadout":1677},[2013],{"nctId":1674,"briefTitle":1675,"status":313,"phases":2014,"primaryCompletion":1677,"completion":1678,"start":1679,"enrollment":1424,"conditions":2015,"interventions":2016},[91,92],[1681,1682],[1665,1684],{"trials":2018,"activeCount":103},[],{"trials":2020,"activeCount":103},[],{"trials":2022,"activeCount":103},[2023],{"nctId":2024,"briefTitle":2025,"status":1972,"phases":2026,"conditions":2027,"interventions":2029},"NCT07560709","Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma",[],[2028],"Recurrent Osteosarcoma",[1684],{"intervention":2031,"totalTrials":1016,"cells":2032},"Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells",{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2065,"PHASE3":2067,"PHASE4":2069,"NA":2071},{"trials":2034,"activeCount":103},[],{"trials":2036,"activeCount":1016,"soonestReadout":961},[2037,2048,2057],{"nctId":2038,"briefTitle":2039,"status":899,"phases":2040,"primaryCompletion":2041,"completion":2042,"start":1860,"enrollment":2043,"conditions":2044,"interventions":2047},"NCT06946680","IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)",[91],"2030-12","2045-12",24,[2045,2046],"High-grade Glioma","Diffuse Intrinsic Pontine Glioma",[2031],{"nctId":2049,"briefTitle":2050,"status":141,"phases":2051,"primaryCompletion":961,"completion":2052,"start":2053,"enrollment":2054,"conditions":2055,"interventions":2056},"NCT05353530","IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma",[91],"2042-12","2023-07-25",39,[1812,964],[2031],{"nctId":2058,"briefTitle":2059,"status":899,"phases":2060,"primaryCompletion":2061,"completion":2062,"start":1860,"enrollment":926,"conditions":2063,"interventions":2064},"NCT07569263","IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases",[91],"2029-12","2044-12",[1178],[2031],{"trials":2066,"activeCount":103},[],{"trials":2068,"activeCount":103},[],{"trials":2070,"activeCount":103},[],{"trials":2072,"activeCount":103},[],{"intervention":932,"totalTrials":250,"cells":2074},{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2118,"PHASE3":2132,"PHASE4":2134,"NA":2136},{"trials":2076,"activeCount":103},[],{"trials":2078,"activeCount":210,"soonestReadout":923},[2079,2089,2093,2107],{"nctId":2080,"briefTitle":2081,"status":141,"phases":2082,"primaryCompletion":961,"completion":1270,"start":2083,"enrollment":926,"conditions":2084,"interventions":2087},"NCT06254326","ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients",[91],"2024-09-19",[2085,2086],"Recurrent Oligodendroglioma","Progressive Oligodendroglioma",[931,2088,932,933],"Autologous Hematopoietic Stem cells",{"nctId":920,"briefTitle":921,"status":313,"phases":2090,"primaryCompletion":923,"completion":924,"start":925,"enrollment":926,"conditions":2091,"interventions":2092},[91],[928,929],[931,932,933,934,913],{"nctId":2094,"briefTitle":2095,"status":1053,"phases":2096,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2100,"interventions":2103},"NCT03396575","Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)",[91],"2025-03-20","2018-07-17",11,[2101,2102],"Diffuse Intrinsic Pontine Glioma (DIPG)","Brain Stem Glioma",[931,932,2104,2105,933,2106],"Cyclophosphamide + Fludarabine Lymphodepletive Conditioning","Dose-Intensified TMZ","Autologous Hematopoietic Stem Cells",{"nctId":2108,"briefTitle":2109,"status":1053,"phases":2110,"primaryCompletion":2097,"completion":2097,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2116},"NCT03334305","Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas",[91],"2018-08-27",18,[2114,2115],"Malignant Glioma","High Grade Glioma",[931,2117,2088,932,933],"Dose-intensified TMZ",{"trials":2119,"activeCount":103},[2120],{"nctId":2121,"briefTitle":2122,"status":115,"phases":2123,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":9,"conditions":2127,"interventions":2130},"NCT01326104","Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor",[92],"2020-03-28","2025-03-28","2010-09-07",[2128,2129],"Medulloblastoma","Neuroectodermal Tumor",[932,2131],"TTRNA-DCs",{"trials":2133,"activeCount":103},[],{"trials":2135,"activeCount":103},[],{"trials":2137,"activeCount":103},[],{"intervention":931,"totalTrials":328,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2160,"PHASE3":2162,"PHASE4":2164,"NA":2166},{"trials":2141,"activeCount":103},[],{"trials":2143,"activeCount":210,"soonestReadout":923},[2144,2148,2152,2156],{"nctId":2080,"briefTitle":2081,"status":141,"phases":2145,"primaryCompletion":961,"completion":1270,"start":2083,"enrollment":926,"conditions":2146,"interventions":2147},[91],[2085,2086],[931,2088,932,933],{"nctId":920,"briefTitle":921,"status":313,"phases":2149,"primaryCompletion":923,"completion":924,"start":925,"enrollment":926,"conditions":2150,"interventions":2151},[91],[928,929],[931,932,933,934,913],{"nctId":2094,"briefTitle":2095,"status":1053,"phases":2153,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2154,"interventions":2155},[91],[2101,2102],[931,932,2104,2105,933,2106],{"nctId":2108,"briefTitle":2109,"status":1053,"phases":2157,"primaryCompletion":2097,"completion":2097,"start":2111,"enrollment":2112,"conditions":2158,"interventions":2159},[91],[2114,2115],[931,2117,2088,932,933],{"trials":2161,"activeCount":103},[],{"trials":2163,"activeCount":103},[],{"trials":2165,"activeCount":103},[],{"trials":2167,"activeCount":103},[],{"intervention":933,"totalTrials":328,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2190,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2171,"activeCount":103},[],{"trials":2173,"activeCount":210,"soonestReadout":923},[2174,2178,2182,2186],{"nctId":2080,"briefTitle":2081,"status":141,"phases":2175,"primaryCompletion":961,"completion":1270,"start":2083,"enrollment":926,"conditions":2176,"interventions":2177},[91],[2085,2086],[931,2088,932,933],{"nctId":920,"briefTitle":921,"status":313,"phases":2179,"primaryCompletion":923,"completion":924,"start":925,"enrollment":926,"conditions":2180,"interventions":2181},[91],[928,929],[931,932,933,934,913],{"nctId":2094,"briefTitle":2095,"status":1053,"phases":2183,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2184,"interventions":2185},[91],[2101,2102],[931,932,2104,2105,933,2106],{"nctId":2108,"briefTitle":2109,"status":1053,"phases":2187,"primaryCompletion":2097,"completion":2097,"start":2111,"enrollment":2112,"conditions":2188,"interventions":2189},[91],[2114,2115],[931,2117,2088,932,933],{"trials":2191,"activeCount":103},[],{"trials":2193,"activeCount":103},[],{"trials":2195,"activeCount":103},[],{"trials":2197,"activeCount":103},[],{"intervention":2199,"totalTrials":210,"cells":2200},"Autologous total tumor mRNA and pp65 full length",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2202,"activeCount":103},[],{"trials":2204,"activeCount":210,"soonestReadout":2209},[2205,2217],{"nctId":2206,"briefTitle":2207,"status":141,"phases":2208,"primaryCompletion":2209,"completion":2210,"start":2211,"enrollment":2212,"conditions":2213,"interventions":2216},"NCT04573140","A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)",[91],"2027-07-01","2029-07-01","2021-12-13",28,[2214,2115,2215],"Adult Glioblastoma","WHO Grade III or IV Malignant Glioma",[2199],{"nctId":2218,"briefTitle":2219,"status":141,"phases":2220,"primaryCompletion":2221,"completion":2222,"start":2223,"enrollment":2043,"conditions":2224,"interventions":2226},"NCT07492316","RNA-lipid Particle (RNA-LP) Vaccines for Recurrent\u002FProgressive Medulloblastoma (MB)",[91],"2030-09-01","2031-03-31","2026-05-15",[2225],"Recurrent Medulloblastoma",[2199],{"trials":2228,"activeCount":103},[],{"trials":2230,"activeCount":103},[],{"trials":2232,"activeCount":103},[],{"trials":2234,"activeCount":103},[],{"intervention":2088,"totalTrials":1016,"cells":2236},{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2253,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2238,"activeCount":103},[],{"trials":2240,"activeCount":323,"soonestReadout":961},[2241,2245,2249],{"nctId":2080,"briefTitle":2081,"status":141,"phases":2242,"primaryCompletion":961,"completion":1270,"start":2083,"enrollment":926,"conditions":2243,"interventions":2244},[91],[2085,2086],[931,2088,932,933],{"nctId":2094,"briefTitle":2095,"status":1053,"phases":2246,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2247,"interventions":2248},[91],[2101,2102],[931,932,2104,2105,933,2106],{"nctId":2108,"briefTitle":2109,"status":1053,"phases":2250,"primaryCompletion":2097,"completion":2097,"start":2111,"enrollment":2112,"conditions":2251,"interventions":2252},[91],[2114,2115],[931,2117,2088,932,933],{"trials":2254,"activeCount":103},[],{"trials":2256,"activeCount":103},[],{"trials":2258,"activeCount":103},[],{"trials":2260,"activeCount":103},[],{"intervention":2262,"totalTrials":323,"cells":2263},"tocilizumab-aazg",{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2279,"PHASE3":2281,"PHASE4":2283,"NA":2285},{"trials":2265,"activeCount":103},[],{"trials":2267,"activeCount":323,"soonestReadout":2272},[2268],{"nctId":2269,"briefTitle":2270,"status":141,"phases":2271,"primaryCompletion":2272,"completion":2273,"start":2274,"enrollment":1272,"conditions":2275,"interventions":2278},"NCT06863480","Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events",[91],"2028-07-30","2028-10-30","2026-03-02",[2276,2277],"Aneurysmal Subarachnoid Hemorrhage","Delayed Cerebral Ischemia",[2262],{"trials":2280,"activeCount":103},[],{"trials":2282,"activeCount":103},[],{"trials":2284,"activeCount":103},[],{"trials":2286,"activeCount":103},[],{"intervention":2288,"totalTrials":323,"cells":2289},"pp65 RNA loaded lipid particles, pp65 RNA-LPs",{"EARLY_PHASE1":2290,"PHASE1":2292,"PHASE2":2302,"PHASE3":2304,"PHASE4":2306,"NA":2308},{"trials":2291,"activeCount":103},[],{"trials":2293,"activeCount":323,"soonestReadout":1919},[2294],{"nctId":2295,"briefTitle":2296,"status":141,"phases":2297,"primaryCompletion":1919,"completion":2298,"start":1749,"enrollment":2043,"conditions":2299,"interventions":2300},"NCT06389591","RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)",[91],"2027-12-01",[957],[2288,2301],"RNA loaded lipid particles, RNA-LPs",{"trials":2303,"activeCount":103},[],{"trials":2305,"activeCount":103},[],{"trials":2307,"activeCount":103},[],{"trials":2309,"activeCount":103},[],{"intervention":2301,"totalTrials":323,"cells":2311},{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2320,"PHASE3":2322,"PHASE4":2324,"NA":2326},{"trials":2313,"activeCount":103},[],{"trials":2315,"activeCount":323,"soonestReadout":1919},[2316],{"nctId":2295,"briefTitle":2296,"status":141,"phases":2317,"primaryCompletion":1919,"completion":2298,"start":1749,"enrollment":2043,"conditions":2318,"interventions":2319},[91],[957],[2288,2301],{"trials":2321,"activeCount":103},[],{"trials":2323,"activeCount":103},[],{"trials":2325,"activeCount":103},[],{"trials":2327,"activeCount":103},[],{"intervention":2329,"totalTrials":323,"cells":2330},"exHSC",{"EARLY_PHASE1":2331,"PHASE1":2333,"PHASE2":2349,"PHASE3":2351,"PHASE4":2353,"NA":2355},{"trials":2332,"activeCount":103},[],{"trials":2334,"activeCount":323,"soonestReadout":2041},[2335],{"nctId":2336,"briefTitle":2337,"status":313,"phases":2338,"primaryCompletion":2041,"completion":2339,"start":2340,"enrollment":926,"conditions":2341,"interventions":2347},"NCT07031765","Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma",[91],"2032-12","2025-07-25",[1682,2342,2343,2344,2345,2346],"Grade III Astrocytoma","Oligodendroglioma","Oligoastrocytoma","Ependymoma","Grade IV Astrocytoma",[2329,2348],"Nivolumab",{"trials":2350,"activeCount":103},[],{"trials":2352,"activeCount":103},[],{"trials":2354,"activeCount":103},[],{"trials":2356,"activeCount":103},[],{"intervention":2348,"totalTrials":323,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":103},[],{"trials":2362,"activeCount":323,"soonestReadout":2041},[2363],{"nctId":2336,"briefTitle":2337,"status":313,"phases":2364,"primaryCompletion":2041,"completion":2339,"start":2340,"enrollment":926,"conditions":2365,"interventions":2366},[91],[1682,2342,2343,2344,2345,2346],[2329,2348],{"trials":2368,"activeCount":103},[],{"trials":2370,"activeCount":103},[],{"trials":2372,"activeCount":103},[],{"trials":2374,"activeCount":103},[],{"intervention":2376,"totalTrials":323,"cells":2377},"Tumor-specific ex vivo expanded autologous lymphocyte transfer",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2390,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2379,"activeCount":103},[],{"trials":2381,"activeCount":323,"soonestReadout":344},[2382],{"nctId":2383,"briefTitle":2384,"status":313,"phases":2385,"primaryCompletion":344,"completion":2386,"start":2387,"enrollment":2043,"conditions":2388,"interventions":2389},"NCT04837547","PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy",[91],"2032-09","2021-09-20",[1538,2046],[2376],{"trials":2391,"activeCount":103},[],{"trials":2393,"activeCount":103},[],{"trials":2395,"activeCount":103},[],{"trials":2397,"activeCount":103},[],{"intervention":934,"totalTrials":323,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2408,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2401,"activeCount":103},[],{"trials":2403,"activeCount":323,"soonestReadout":923},[2404],{"nctId":920,"briefTitle":921,"status":313,"phases":2405,"primaryCompletion":923,"completion":924,"start":925,"enrollment":926,"conditions":2406,"interventions":2407},[91],[928,929],[931,932,933,934,913],{"trials":2409,"activeCount":103},[],{"trials":2411,"activeCount":103},[],{"trials":2413,"activeCount":103},[],{"trials":2415,"activeCount":103},[],{"intervention":2417,"totalTrials":323,"cells":2418},"PremierMaxCB®-Platinum (CFL001);",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2434,"PHASE3":2436,"PHASE4":2438,"NA":2440},{"trials":2420,"activeCount":103},[],{"trials":2422,"activeCount":323,"soonestReadout":1466},[2423],{"nctId":2424,"briefTitle":2425,"status":313,"phases":2426,"primaryCompletion":1466,"completion":2427,"start":2428,"enrollment":2429,"conditions":2430,"interventions":2433},"NCT06415461","A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)",[91],"2028-03-06","2024-05-10",9,[2431,2432],"Sacroiliac; Backache","Pain, Back",[2417],{"trials":2435,"activeCount":103},[],{"trials":2437,"activeCount":103},[],{"trials":2439,"activeCount":103},[],{"trials":2441,"activeCount":103},[],{"intervention":2443,"totalTrials":210,"cells":2444},"OxyCODONE 5 mg Oral",{"EARLY_PHASE1":2445,"PHASE1":2464,"PHASE2":2466,"PHASE3":2468,"PHASE4":2470,"NA":2472},{"trials":2446,"activeCount":210,"soonestReadout":1118},[2447,2456],{"nctId":2448,"briefTitle":2449,"status":141,"phases":2450,"primaryCompletion":177,"completion":177,"start":2451,"enrollment":1291,"conditions":2452,"interventions":2453},"NCT04218409","Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination",[90],"2021-09-02",[33],[2443,2454,2455],"Oxytocin nasal spray","OxyCODONE 2.5 mg Oral",{"nctId":2457,"briefTitle":2458,"status":141,"phases":2459,"primaryCompletion":1118,"completion":1858,"start":2460,"enrollment":1291,"conditions":2461,"interventions":2462},"NCT05761860","The Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults",[90],"2023-09-12",[33],[2443,2455,2463],"Oxytocin Nasal Spray",{"trials":2465,"activeCount":103},[],{"trials":2467,"activeCount":103},[],{"trials":2469,"activeCount":103},[],{"trials":2471,"activeCount":103},[],{"trials":2473,"activeCount":103},[],{"intervention":2454,"totalTrials":210,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2486,"PHASE2":2488,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2477,"activeCount":210,"soonestReadout":1118},[2478,2482],{"nctId":2448,"briefTitle":2449,"status":141,"phases":2479,"primaryCompletion":177,"completion":177,"start":2451,"enrollment":1291,"conditions":2480,"interventions":2481},[90],[33],[2443,2454,2455],{"nctId":2457,"briefTitle":2458,"status":141,"phases":2483,"primaryCompletion":1118,"completion":1858,"start":2460,"enrollment":1291,"conditions":2484,"interventions":2485},[90],[33],[2443,2455,2463],{"trials":2487,"activeCount":103},[],{"trials":2489,"activeCount":103},[],{"trials":2491,"activeCount":103},[],{"trials":2493,"activeCount":103},[],{"trials":2495,"activeCount":103},[],{"intervention":2455,"totalTrials":210,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2508,"PHASE2":2510,"PHASE3":2512,"PHASE4":2514,"NA":2516},{"trials":2499,"activeCount":210,"soonestReadout":1118},[2500,2504],{"nctId":2448,"briefTitle":2449,"status":141,"phases":2501,"primaryCompletion":177,"completion":177,"start":2451,"enrollment":1291,"conditions":2502,"interventions":2503},[90],[33],[2443,2454,2455],{"nctId":2457,"briefTitle":2458,"status":141,"phases":2505,"primaryCompletion":1118,"completion":1858,"start":2460,"enrollment":1291,"conditions":2506,"interventions":2507},[90],[33],[2443,2455,2463],{"trials":2509,"activeCount":103},[],{"trials":2511,"activeCount":103},[],{"trials":2513,"activeCount":103},[],{"trials":2515,"activeCount":103},[],{"trials":2517,"activeCount":103},[],{"intervention":2519,"totalTrials":323,"cells":2520},"Melatonin",{"EARLY_PHASE1":2521,"PHASE1":2533,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2522,"activeCount":323,"soonestReadout":2527},[2523],{"nctId":2524,"briefTitle":2525,"status":141,"phases":2526,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":2530,"interventions":2532},"NCT02621944","Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia",[90],"2026-03","2016-11",70,[2531],"Hypoxic Ischemic Encephalopathy",[2519],{"trials":2534,"activeCount":103},[],{"trials":2536,"activeCount":103},[],{"trials":2538,"activeCount":103},[],{"trials":2540,"activeCount":103},[],{"trials":2542,"activeCount":103},[],{"intervention":2544,"totalTrials":210,"cells":2545},"Nicotine Replacement Therapy",{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2554,"NA":2565},{"trials":2547,"activeCount":103},[],{"trials":2549,"activeCount":103},[],{"trials":2551,"activeCount":103},[],{"trials":2553,"activeCount":103},[],{"trials":2555,"activeCount":103},[2556],{"nctId":2557,"briefTitle":2558,"status":115,"phases":2559,"primaryCompletion":2560,"completion":2560,"start":2561,"enrollment":190,"conditions":2562,"interventions":2564},"NCT03482583","Tobacco Use Treatment in Cancer Patients",[94],"2019-12-31","2018-05-14",[2563],"Smoking, Cigarette",[2544],{"trials":2566,"activeCount":323,"soonestReadout":2571},[2567],{"nctId":2568,"briefTitle":2569,"status":141,"phases":2570,"primaryCompletion":2571,"completion":1401,"start":2572,"enrollment":2573,"conditions":2574,"interventions":2576},"NCT05628389","Phone Enabled Implementation of Cessation Support",[95],"2027-08-30","2024-03-06",1500,[2575],"Smoking Cessation",[2544],{"intervention":2578,"totalTrials":323,"cells":2579},"Albuterol inhaler.",{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2581,"activeCount":103},[],{"trials":2583,"activeCount":103},[],{"trials":2585,"activeCount":103},[],{"trials":2587,"activeCount":103},[],{"trials":2589,"activeCount":103},[],{"trials":2591,"activeCount":323,"soonestReadout":2596},[2592],{"nctId":2593,"briefTitle":2594,"status":141,"phases":2595,"primaryCompletion":2596,"completion":2597,"start":2598,"enrollment":2599,"conditions":2600,"interventions":2605},"NCT01851642","Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs",[],"2032-07-20","2033-07-20","2007-08-09",220,[2601,2602,2603,2604],"Alpha-1 Antitrypsin Deficiency","AAT Deficiency","AATD","Cystic Fibrosis (CF)",[2578],{"intervention":137,"totalTrials":328,"cells":2607},{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2614,"PHASE4":2616,"NA":2639},{"trials":2609,"activeCount":103},[],{"trials":2611,"activeCount":103},[],{"trials":2613,"activeCount":103},[],{"trials":2615,"activeCount":103},[],{"trials":2617,"activeCount":103},[2618,2622,2626,2635],{"nctId":124,"briefTitle":125,"status":115,"phases":2619,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":2620,"interventions":2621},[94],[132,133,134],[136,98,137],{"nctId":740,"briefTitle":741,"status":115,"phases":2623,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":2624,"interventions":2625},[94],[132],[151,136,137,162],{"nctId":2627,"briefTitle":2628,"status":115,"phases":2629,"primaryCompletion":2630,"completion":2630,"start":2631,"enrollment":34,"conditions":2632,"interventions":2634},"NCT01201785","Aspirin Dosing in Diabetic Patients",[94],"2010-09","2009-01",[2633,18],"Type 2 Diabetes Mellitus",[137],{"nctId":184,"briefTitle":185,"status":115,"phases":2636,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":2637,"interventions":2638},[94],[18],[98,151,193,194,195],{"trials":2640,"activeCount":103},[],{"intervention":2642,"totalTrials":1016,"cells":2643},"Chemotherapy",{"EARLY_PHASE1":2644,"PHASE1":2646,"PHASE2":2648,"PHASE3":2668,"PHASE4":2670,"NA":2681},{"trials":2645,"activeCount":103},[],{"trials":2647,"activeCount":103},[],{"trials":2649,"activeCount":103},[2650,2659],{"nctId":2651,"briefTitle":2652,"status":115,"phases":2653,"primaryCompletion":2654,"completion":2655,"start":1087,"enrollment":695,"conditions":2656,"interventions":2657},"NCT01470417","Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma",[92],"2014-01","2019-10",[1089],[2642,2658],"Chemotherapy + ChemoRadiotherapy",{"nctId":2660,"briefTitle":2661,"status":257,"phases":2662,"primaryCompletion":2663,"completion":2663,"start":2664,"enrollment":103,"conditions":2665,"interventions":2667},"NCT03234842","Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer",[92],"2018-12-11","2017-10-30",[2666],"Esophageal Cancer",[2642],{"trials":2669,"activeCount":103},[],{"trials":2671,"activeCount":103},[2672],{"nctId":2673,"briefTitle":2674,"status":257,"phases":2675,"primaryCompletion":2676,"completion":2676,"start":2677,"enrollment":103,"conditions":2678,"interventions":2680},"NCT03388931","Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx",[94],"2019-05-06","2019-02-04",[2679],"Advanced Squamous Cell Carcinoma",[2642],{"trials":2682,"activeCount":103},[],{"intervention":296,"totalTrials":1016,"cells":2684},{"EARLY_PHASE1":2685,"PHASE1":2687,"PHASE2":2698,"PHASE3":2700,"PHASE4":2702,"NA":2721},{"trials":2686,"activeCount":103},[],{"trials":2688,"activeCount":103},[2689],{"nctId":2690,"briefTitle":2691,"status":257,"phases":2692,"primaryCompletion":773,"completion":773,"start":773,"enrollment":103,"conditions":2693,"interventions":2695},"NCT01680796","Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed\u002FRefractory Multiple Myeloma",[91],[2694],"Multiple Myeloma",[2696,2697,296],"Dovitinib","Bortezomib",{"trials":2699,"activeCount":103},[],{"trials":2701,"activeCount":103},[],{"trials":2703,"activeCount":103},[2704,2708],{"nctId":288,"briefTitle":289,"status":115,"phases":2705,"primaryCompletion":291,"completion":291,"start":292,"enrollment":180,"conditions":2706,"interventions":2707},[94],[294],[249,296],{"nctId":2709,"briefTitle":2710,"status":1053,"phases":2711,"primaryCompletion":2712,"completion":2712,"start":2713,"enrollment":2714,"conditions":2715,"interventions":2719},"NCT02780479","Steroids in Children Hospitalized With Asthma",[94],"2017-08-29","2017-03-20",6,[2716,2717,2718],"Asthma","Status Asthmaticus","Wheezes",[296,2720],"Prednisone",{"trials":2722,"activeCount":103},[],{"intervention":2724,"totalTrials":210,"cells":2725},"HFA FP MDI",{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2732,"PHASE4":2734,"NA":2752},{"trials":2727,"activeCount":103},[],{"trials":2729,"activeCount":103},[],{"trials":2731,"activeCount":103},[],{"trials":2733,"activeCount":103},[],{"trials":2735,"activeCount":103},[2736,2744],{"nctId":2737,"briefTitle":2738,"status":115,"phases":2739,"completion":2740,"start":2741,"enrollment":1260,"conditions":2742,"interventions":2743},"NCT00308932","Effect of Age and Device on Delivery of Fluticasone",[94],"2004-04","2003-02",[2716],[2724],{"nctId":2745,"briefTitle":2746,"status":115,"phases":2747,"completion":2748,"start":2749,"enrollment":926,"conditions":2750,"interventions":2751},"NCT00307970","Impact of Anti-static Chamber\u002FMask",[94],"2003-09","2003-04",[2716],[2724],{"trials":2753,"activeCount":103},[],{"intervention":2755,"totalTrials":210,"cells":2756},"Nebivolol",{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2765,"NA":2786},{"trials":2758,"activeCount":103},[],{"trials":2760,"activeCount":103},[],{"trials":2762,"activeCount":103},[],{"trials":2764,"activeCount":103},[],{"trials":2766,"activeCount":103},[2767,2776],{"nctId":2768,"briefTitle":2769,"status":115,"phases":2770,"primaryCompletion":781,"completion":781,"start":2771,"enrollment":2772,"conditions":2773,"interventions":2774},"NCT01157234","Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients",[94],"2010-07",32,[27],[2755,2775],"Metoprolol",{"nctId":2777,"briefTitle":2778,"status":1053,"phases":2779,"primaryCompletion":2780,"completion":2780,"start":2654,"enrollment":2099,"conditions":2781,"interventions":2785},"NCT02053246","Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure",[94],"2021-03",[2782,2783,2784],"Pulmonary Hypertension","Diastolic Heart Failure","Heart Failure With Preserved Ejection Fraction",[2755],{"trials":2787,"activeCount":103},[],{"intervention":2775,"totalTrials":210,"cells":2789},{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2796,"PHASE4":2798,"NA":2813},{"trials":2791,"activeCount":103},[],{"trials":2793,"activeCount":103},[],{"trials":2795,"activeCount":103},[],{"trials":2797,"activeCount":103},[],{"trials":2799,"activeCount":103},[2800,2804],{"nctId":2768,"briefTitle":2769,"status":115,"phases":2801,"primaryCompletion":781,"completion":781,"start":2771,"enrollment":2772,"conditions":2802,"interventions":2803},[94],[27],[2755,2775],{"nctId":2805,"briefTitle":2806,"status":115,"phases":2807,"primaryCompletion":2808,"completion":2808,"start":722,"enrollment":2809,"conditions":2810,"interventions":2811},"NCT01203852","Pharmacogenomic Evaluation of Antihypertensive Responses 2",[94],"2014-04",839,[27],[2775,2812],"Chlorthalidone",{"trials":2814,"activeCount":103},[],{"intervention":2816,"totalTrials":210,"cells":2817},"Hydrochlorothiazide",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2822,"PHASE3":2824,"PHASE4":2826,"NA":2847},{"trials":2819,"activeCount":103},[],{"trials":2821,"activeCount":103},[],{"trials":2823,"activeCount":103},[],{"trials":2825,"activeCount":103},[],{"trials":2827,"activeCount":103},[2828,2837],{"nctId":2829,"briefTitle":2830,"status":115,"phases":2831,"primaryCompletion":2832,"completion":2832,"start":2833,"enrollment":2043,"conditions":2834,"interventions":2835},"NCT00887510","Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)",[94],"2009-11","2007-05",[27],[2816,2836],"Trandolapril",{"nctId":2838,"briefTitle":2839,"status":115,"phases":2840,"primaryCompletion":2841,"completion":2841,"start":2842,"enrollment":2843,"conditions":2844,"interventions":2845},"NCT00246519","Pharmacogenomic Evaluation of Antihypertensive Responses",[94],"2010-12","2005-10",1701,[27],[2816,2846],"Atenolol",{"trials":2848,"activeCount":103},[],{"intervention":2812,"totalTrials":210,"cells":2850},{"EARLY_PHASE1":2851,"PHASE1":2853,"PHASE2":2855,"PHASE3":2857,"PHASE4":2871,"NA":2877},{"trials":2852,"activeCount":103},[],{"trials":2854,"activeCount":103},[],{"trials":2856,"activeCount":103},[],{"trials":2858,"activeCount":103},[2859],{"nctId":2860,"briefTitle":2861,"status":115,"phases":2862,"primaryCompletion":720,"completion":720,"start":2863,"enrollment":2864,"conditions":2865,"interventions":2868},"NCT00241839","Uric Acid and Hypertension in African Americans",[93],"2005-08",150,[2866,2867,27],"Cardiovascular Diseases","Heart Diseases",[2869,2812,2870],"Allopurinol","Potassium chloride",{"trials":2872,"activeCount":103},[2873],{"nctId":2805,"briefTitle":2806,"status":115,"phases":2874,"primaryCompletion":2808,"completion":2808,"start":722,"enrollment":2809,"conditions":2875,"interventions":2876},[94],[27],[2775,2812],{"trials":2878,"activeCount":103},[],{"intervention":2880,"totalTrials":210,"cells":2881},"misoprostol",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2899,"PHASE4":2901,"NA":2912},{"trials":2883,"activeCount":103},[],{"trials":2885,"activeCount":103},[],{"trials":2887,"activeCount":103},[2888],{"nctId":2889,"briefTitle":2890,"status":115,"phases":2891,"completion":2892,"start":2893,"enrollment":746,"conditions":2894,"interventions":2897},"NCT00325026","Randomized Trial Comparing Misoprostol and Foley Bulb for Labor Induction in the Preterm Gestation",[92],"2007-04","2005-04",[2895,2896],"Premature Birth","Cervical Ripening",[2898],"Misoprostol",{"trials":2900,"activeCount":103},[],{"trials":2902,"activeCount":103},[2903],{"nctId":2904,"briefTitle":2905,"status":115,"phases":2906,"primaryCompletion":2892,"completion":2892,"start":2907,"enrollment":1272,"conditions":2908,"interventions":2911},"NCT00324519","Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester",[94],"2005-02",[2909,2910],"Pregnancy Trimester, Second","Induced Abortion",[2880],{"trials":2913,"activeCount":103},[],{"intervention":2915,"totalTrials":210,"cells":2916},"Tacrolimus",{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2935,"PHASE4":2937,"NA":2949},{"trials":2918,"activeCount":103},[],{"trials":2920,"activeCount":103},[],{"trials":2922,"activeCount":103},[2923],{"nctId":2924,"briefTitle":2925,"status":115,"phases":2926,"primaryCompletion":2927,"completion":2928,"start":2929,"enrollment":2930,"conditions":2931,"interventions":2934},"NCT03527238","Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine",[92],"2020-06-02","2021-08-31","2018-09-21",62,[2932,2933],"Liver Transplant","Kidney Transplant",[2915],{"trials":2936,"activeCount":103},[],{"trials":2938,"activeCount":103},[2939],{"nctId":2940,"briefTitle":2941,"status":115,"phases":2942,"primaryCompletion":2943,"completion":2943,"start":2944,"enrollment":2054,"conditions":2945,"interventions":2947},"NCT00821587","Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation",[94],"2008-05","2004-06",[2946],"Hepatitis C",[2948,2915],"Cyclosporine",{"trials":2950,"activeCount":103},[],{"intervention":136,"totalTrials":210,"cells":2952},{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2957,"PHASE3":2959,"PHASE4":2961,"NA":2971},{"trials":2954,"activeCount":103},[],{"trials":2956,"activeCount":103},[],{"trials":2958,"activeCount":103},[],{"trials":2960,"activeCount":103},[],{"trials":2962,"activeCount":103},[2963,2967],{"nctId":124,"briefTitle":125,"status":115,"phases":2964,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":2965,"interventions":2966},[94],[132,133,134],[136,98,137],{"nctId":740,"briefTitle":741,"status":115,"phases":2968,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":2969,"interventions":2970},[94],[132],[151,136,137,162],{"trials":2972,"activeCount":103},[],{"intervention":2974,"totalTrials":210,"cells":2975},"Exenatide",{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2989,"PHASE3":2991,"PHASE4":2993,"NA":3005},{"trials":2977,"activeCount":103},[],{"trials":2979,"activeCount":103},[2980],{"nctId":2981,"briefTitle":2982,"status":115,"phases":2983,"primaryCompletion":2984,"completion":1632,"start":2985,"enrollment":250,"conditions":2986,"interventions":2988},"NCT03456687","Effects of Exenatide on Motor Function and the Brain",[91],"2020-10-16","2018-06-05",[2987],"Parkinson's Disease",[2974],{"trials":2990,"activeCount":103},[],{"trials":2992,"activeCount":103},[],{"trials":2994,"activeCount":103},[2995],{"nctId":2996,"briefTitle":2997,"status":115,"phases":2998,"primaryCompletion":2999,"completion":3000,"start":3001,"enrollment":2043,"conditions":3002,"interventions":3004},"NCT01006889","Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease",[94],"2009-12","2010-02","2008-01",[3003,2633],"Nonalcoholic Fatty Liver Disease",[2974],{"trials":3006,"activeCount":103},[],{"intervention":2846,"totalTrials":210,"cells":3008},{"EARLY_PHASE1":3009,"PHASE1":3011,"PHASE2":3013,"PHASE3":3015,"PHASE4":3017,"NA":3031},{"trials":3010,"activeCount":103},[],{"trials":3012,"activeCount":103},[],{"trials":3014,"activeCount":103},[],{"trials":3016,"activeCount":103},[],{"trials":3018,"activeCount":103},[3019,3023],{"nctId":2838,"briefTitle":2839,"status":115,"phases":3020,"primaryCompletion":2841,"completion":2841,"start":2842,"enrollment":2843,"conditions":3021,"interventions":3022},[94],[27],[2816,2846],{"nctId":3024,"briefTitle":3025,"status":115,"phases":3026,"primaryCompletion":2771,"completion":2771,"start":3027,"enrollment":1725,"conditions":3028,"interventions":3029},"NCT00669279","Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure",[94],"2008-04",[27],[3030,2846],"Carvedilol CR",{"trials":3032,"activeCount":103},[],{"intervention":3034,"totalTrials":210,"cells":3035},"Atorvastatin",{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3064},{"trials":3037,"activeCount":103},[],{"trials":3039,"activeCount":103},[3040],{"nctId":3041,"briefTitle":3042,"status":115,"phases":3043,"primaryCompletion":3044,"completion":3044,"start":780,"enrollment":22,"conditions":3045,"interventions":3047},"NCT02097589","The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23",[91],"2014-09",[3046],"Healthy Controls",[3034,3048],"Pneumovax 23",{"trials":3050,"activeCount":103},[],{"trials":3052,"activeCount":103},[],{"trials":3054,"activeCount":103},[3055],{"nctId":3056,"briefTitle":3057,"status":115,"phases":3058,"primaryCompletion":3059,"completion":2631,"start":2944,"enrollment":3060,"conditions":3061,"interventions":3063},"NCT00361283","Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis",[94],"2008-12",108,[3062],"Inflammation",[3034],{"trials":3065,"activeCount":103},[],{"intervention":3067,"totalTrials":210,"cells":3068},"Rasagiline",{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3083,"PHASE4":3085,"NA":3094},{"trials":3070,"activeCount":103},[],{"trials":3072,"activeCount":103},[],{"trials":3074,"activeCount":103},[3075],{"nctId":3076,"briefTitle":3077,"status":115,"phases":3078,"primaryCompletion":364,"completion":364,"start":3079,"enrollment":3080,"conditions":3081,"interventions":3082},"NCT02789020","Image Parkinson's Disease Progression Study",[92],"2016-12",96,[2987],[3067],{"trials":3084,"activeCount":103},[],{"trials":3086,"activeCount":103},[3087],{"nctId":3088,"briefTitle":3089,"status":115,"phases":3090,"primaryCompletion":3091,"completion":3091,"start":2999,"enrollment":1272,"conditions":3092,"interventions":3093},"NCT01168596","Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease",[94],"2012-05",[2987],[3067],{"trials":3095,"activeCount":103},[],{"intervention":2720,"totalTrials":210,"cells":3097},{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3115,"PHASE4":3117,"NA":3123},{"trials":3099,"activeCount":103},[],{"trials":3101,"activeCount":103},[],{"trials":3103,"activeCount":103},[3104],{"nctId":3105,"briefTitle":3106,"status":115,"phases":3107,"primaryCompletion":3108,"completion":3109,"start":3110,"enrollment":31,"conditions":3111,"interventions":3113},"NCT04322357","Twice Weekly Steroids and Exercise as Therapy for DMD",[92],"2024-12-04","2025-09-04","2020-07-30",[3112],"Duchenne Muscular Dystrophy (DMD)",[2720,3114],"Exercise training on twice-weekly steroids",{"trials":3116,"activeCount":103},[],{"trials":3118,"activeCount":103},[3119],{"nctId":2709,"briefTitle":2710,"status":1053,"phases":3120,"primaryCompletion":2712,"completion":2712,"start":2713,"enrollment":2714,"conditions":3121,"interventions":3122},[94],[2716,2717,2718],[296,2720],{"trials":3124,"activeCount":103},[],{"intervention":3126,"totalTrials":323,"cells":3127},"Rivaroxaban 2.5 mg",{"EARLY_PHASE1":3128,"PHASE1":3130,"PHASE2":3132,"PHASE3":3134,"PHASE4":3136,"NA":3149},{"trials":3129,"activeCount":103},[],{"trials":3131,"activeCount":103},[],{"trials":3133,"activeCount":103},[],{"trials":3135,"activeCount":103},[],{"trials":3137,"activeCount":103},[3138],{"nctId":3139,"briefTitle":3140,"status":115,"phases":3141,"primaryCompletion":3142,"completion":3143,"start":3144,"enrollment":3145,"conditions":3146,"interventions":3148},"NCT03718429","Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies",[94],"2020-02-13","2020-08-30","2019-01-14",86,[18,134,3147],"Atrial Fibrillation",[3126],{"trials":3150,"activeCount":103},[],{"intervention":3152,"totalTrials":323,"cells":3153},"Intravenous Sedatives",{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3160,"PHASE4":3162,"NA":3175},{"trials":3155,"activeCount":103},[],{"trials":3157,"activeCount":103},[],{"trials":3159,"activeCount":103},[],{"trials":3161,"activeCount":103},[],{"trials":3163,"activeCount":103},[3164],{"nctId":3165,"briefTitle":3166,"status":115,"phases":3167,"primaryCompletion":3168,"completion":3168,"start":3169,"enrollment":1272,"conditions":3170,"interventions":3174},"NCT03404180","Peripheral Nerve Blocks for Above-the-knee Amputations",[94],"2024-12-18","2018-02-09",[3171,3172,27,18,3173],"Peripheral Vascular Diseases","Hyperglycaemia (Diabetic)","Pulmonary Disease, Chronic Obstructive",[3152],{"trials":3176,"activeCount":103},[],{"intervention":3178,"totalTrials":323,"cells":3179},"Promethazine",{"EARLY_PHASE1":3180,"PHASE1":3182,"PHASE2":3184,"PHASE3":3186,"PHASE4":3188,"NA":3201},{"trials":3181,"activeCount":103},[],{"trials":3183,"activeCount":103},[],{"trials":3185,"activeCount":103},[],{"trials":3187,"activeCount":103},[],{"trials":3189,"activeCount":103},[3190],{"nctId":3191,"briefTitle":3192,"status":115,"phases":3193,"primaryCompletion":3194,"completion":3194,"start":3195,"enrollment":3196,"conditions":3197,"interventions":3200},"NCT04805073","Treatment of Pruritus With Intramuscular Promethazine",[94],"2024-05-30","2021-08-09",72,[3198,3199],"Pruritus","Pregnancy Related",[3178],{"trials":3202,"activeCount":103},[],{"intervention":3204,"totalTrials":323,"cells":3205},"Verapamil SR\u002FTrandolapril\u002FHydrochlorothiazide",{"EARLY_PHASE1":3206,"PHASE1":3208,"PHASE2":3210,"PHASE3":3212,"PHASE4":3214,"NA":3225},{"trials":3207,"activeCount":103},[],{"trials":3209,"activeCount":103},[],{"trials":3211,"activeCount":103},[],{"trials":3213,"activeCount":103},[],{"trials":3215,"activeCount":103},[3216],{"nctId":3217,"briefTitle":3218,"status":115,"phases":3219,"completion":2741,"start":3220,"enrollment":3221,"conditions":3222,"interventions":3223},"NCT00133692","INVEST: INternational VErapamil SR Trandolapril STudy",[94],"1997-09",22000,[27,18],[3204,3224],"Atenolol\u002FHCTZ\u002FTrandolapril",{"trials":3226,"activeCount":103},[],{"intervention":3224,"totalTrials":323,"cells":3228},{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3235,"PHASE4":3237,"NA":3243},{"trials":3230,"activeCount":103},[],{"trials":3232,"activeCount":103},[],{"trials":3234,"activeCount":103},[],{"trials":3236,"activeCount":103},[],{"trials":3238,"activeCount":103},[3239],{"nctId":3217,"briefTitle":3218,"status":115,"phases":3240,"completion":2741,"start":3220,"enrollment":3221,"conditions":3241,"interventions":3242},[94],[27,18],[3204,3224],{"trials":3244,"activeCount":103},[],{"intervention":3246,"totalTrials":323,"cells":3247},"Levetiracetam",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3252,"PHASE3":3254,"PHASE4":3256,"NA":3272},{"trials":3249,"activeCount":103},[],{"trials":3251,"activeCount":103},[],{"trials":3253,"activeCount":103},[],{"trials":3255,"activeCount":103},[],{"trials":3257,"activeCount":103},[3258],{"nctId":3259,"briefTitle":3260,"status":115,"phases":3261,"primaryCompletion":3262,"completion":3262,"start":3263,"enrollment":119,"conditions":3264,"interventions":3271},"NCT02334722","1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients",[94],"2020-10-07","2015-08-05",[3265,3266,3267,3268,3269,3270],"Brain Neoplasms","Brain Cancer","Brain Tumors","Cancer of the Brain","Cancer of Brain","Seizure",[3246],{"trials":3273,"activeCount":103},[],{"intervention":3275,"totalTrials":323,"cells":3276},"Quinapril",{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3281,"PHASE3":3283,"PHASE4":3285,"NA":3296},{"trials":3278,"activeCount":103},[],{"trials":3280,"activeCount":103},[],{"trials":3282,"activeCount":103},[],{"trials":3284,"activeCount":103},[],{"trials":3286,"activeCount":103},[3287],{"nctId":3288,"briefTitle":3289,"status":115,"phases":3290,"primaryCompletion":3291,"completion":3291,"start":3292,"enrollment":459,"conditions":3293,"interventions":3295},"NCT00150826","QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia",[94],"2004-12","2000-05",[3294],"Ischemic Heart Disease",[3275],{"trials":3297,"activeCount":103},[],{"intervention":3299,"totalTrials":323,"cells":3300},"CBD oil",{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3320},{"trials":3302,"activeCount":103},[],{"trials":3304,"activeCount":103},[],{"trials":3306,"activeCount":103},[],{"trials":3308,"activeCount":103},[],{"trials":3310,"activeCount":103},[3311],{"nctId":3312,"briefTitle":3313,"status":115,"phases":3314,"primaryCompletion":3315,"completion":3315,"start":3316,"enrollment":328,"conditions":3317,"interventions":3319},"NCT05209867","Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV",[94],"2022-12-12","2022-05-01",[3318],"Chronic Inflammation",[3299],{"trials":3321,"activeCount":103},[],{"intervention":2836,"totalTrials":323,"cells":3323},{"EARLY_PHASE1":3324,"PHASE1":3326,"PHASE2":3328,"PHASE3":3330,"PHASE4":3332,"NA":3338},{"trials":3325,"activeCount":103},[],{"trials":3327,"activeCount":103},[],{"trials":3329,"activeCount":103},[],{"trials":3331,"activeCount":103},[],{"trials":3333,"activeCount":103},[3334],{"nctId":2829,"briefTitle":2830,"status":115,"phases":3335,"primaryCompletion":2832,"completion":2832,"start":2833,"enrollment":2043,"conditions":3336,"interventions":3337},[94],[27],[2816,2836],{"trials":3339,"activeCount":103},[],{"intervention":3341,"totalTrials":323,"cells":3342},"Long-acting bedtime insulin detemir",{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3349,"PHASE4":3351,"NA":3362},{"trials":3344,"activeCount":103},[],{"trials":3346,"activeCount":103},[],{"trials":3348,"activeCount":103},[],{"trials":3350,"activeCount":103},[],{"trials":3352,"activeCount":103},[3353],{"nctId":3354,"briefTitle":3355,"status":115,"phases":3356,"primaryCompletion":3000,"completion":3000,"start":3357,"enrollment":1272,"conditions":3358,"interventions":3360},"NCT00998335","Effect of a Basal\u002FPre-Meal Insulin Strategy (Detemir\u002FAspart) on Insulin Secretion and Action in Type 2 Diabetes",[94],"2007-06",[3359],"Type 2 Diabetes",[3341,3361],"Insulin detemir and pre-meal insulin aspart.",{"trials":3363,"activeCount":103},[],{"intervention":3361,"totalTrials":323,"cells":3365},{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3370,"PHASE3":3372,"PHASE4":3374,"NA":3380},{"trials":3367,"activeCount":103},[],{"trials":3369,"activeCount":103},[],{"trials":3371,"activeCount":103},[],{"trials":3373,"activeCount":103},[],{"trials":3375,"activeCount":103},[3376],{"nctId":3354,"briefTitle":3355,"status":115,"phases":3377,"primaryCompletion":3000,"completion":3000,"start":3357,"enrollment":1272,"conditions":3378,"interventions":3379},[94],[3359],[3341,3361],{"trials":3381,"activeCount":103},[],{"intervention":3383,"totalTrials":323,"cells":3384},"Oral Glucose Tolerance Test",{"EARLY_PHASE1":3385,"PHASE1":3387,"PHASE2":3389,"PHASE3":3391,"PHASE4":3393,"NA":3406},{"trials":3386,"activeCount":103},[],{"trials":3388,"activeCount":103},[],{"trials":3390,"activeCount":103},[],{"trials":3392,"activeCount":103},[],{"trials":3394,"activeCount":103},[3395],{"nctId":3396,"briefTitle":3397,"status":115,"phases":3398,"primaryCompletion":3399,"completion":3399,"start":3400,"enrollment":3401,"conditions":3402,"interventions":3405},"NCT01409434","Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study",[94],"2013-08","2010-06",44,[3403,3404],"Drug Induced Hyperglycemia","Secondary Hyperlipidemia",[3383],{"trials":3407,"activeCount":103},[],{"intervention":2948,"totalTrials":323,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3416,"PHASE4":3418,"NA":3424},{"trials":3411,"activeCount":103},[],{"trials":3413,"activeCount":103},[],{"trials":3415,"activeCount":103},[],{"trials":3417,"activeCount":103},[],{"trials":3419,"activeCount":103},[3420],{"nctId":2940,"briefTitle":2941,"status":115,"phases":3421,"primaryCompletion":2943,"completion":2943,"start":2944,"enrollment":2054,"conditions":3422,"interventions":3423},[94],[2946],[2948,2915],{"trials":3425,"activeCount":103},[],{"intervention":3427,"totalTrials":323,"cells":3428},"Carboxymethylcellulose (CMC) Artificial Tears",{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3435,"PHASE4":3437,"NA":3449},{"trials":3430,"activeCount":103},[],{"trials":3432,"activeCount":103},[],{"trials":3434,"activeCount":103},[],{"trials":3436,"activeCount":103},[],{"trials":3438,"activeCount":103},[3439],{"nctId":3440,"briefTitle":3441,"status":115,"phases":3442,"primaryCompletion":3443,"completion":1810,"start":3444,"enrollment":469,"conditions":3445,"interventions":3447},"NCT05292755","Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome",[94],"2022-05-30","2022-04-22",[3446],"Dry Eye Syndromes",[3427,3448],"Preservative-free, CMC-free Artificial Tears",{"trials":3450,"activeCount":103},[],{"intervention":3448,"totalTrials":323,"cells":3452},{"EARLY_PHASE1":3453,"PHASE1":3455,"PHASE2":3457,"PHASE3":3459,"PHASE4":3461,"NA":3467},{"trials":3454,"activeCount":103},[],{"trials":3456,"activeCount":103},[],{"trials":3458,"activeCount":103},[],{"trials":3460,"activeCount":103},[],{"trials":3462,"activeCount":103},[3463],{"nctId":3440,"briefTitle":3441,"status":115,"phases":3464,"primaryCompletion":3443,"completion":1810,"start":3444,"enrollment":469,"conditions":3465,"interventions":3466},[94],[3446],[3427,3448],{"trials":3468,"activeCount":103},[],{"intervention":3470,"totalTrials":323,"cells":3471},"100 mcg Epinephrine",{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3478,"PHASE4":3480,"NA":3491},{"trials":3473,"activeCount":103},[],{"trials":3475,"activeCount":103},[],{"trials":3477,"activeCount":103},[],{"trials":3479,"activeCount":103},[],{"trials":3481,"activeCount":103},[3482],{"nctId":3483,"briefTitle":3484,"status":257,"phases":3485,"primaryCompletion":301,"completion":301,"start":2655,"enrollment":103,"conditions":3486,"interventions":3489},"NCT03335293","RCT of Epinephrine (None, 100mcg, and 200mcg) in a Hyperbaric Bupivacaine, Fentanyl and Morphine Spinal in C-sections.",[94],[3487,3488],"Pregnancy","Cesarean Section",[3470,3490],"200 mcg Epinephrine",{"trials":3492,"activeCount":103},[],{"intervention":3490,"totalTrials":323,"cells":3494},{"EARLY_PHASE1":3495,"PHASE1":3497,"PHASE2":3499,"PHASE3":3501,"PHASE4":3503,"NA":3509},{"trials":3496,"activeCount":103},[],{"trials":3498,"activeCount":103},[],{"trials":3500,"activeCount":103},[],{"trials":3502,"activeCount":103},[],{"trials":3504,"activeCount":103},[3505],{"nctId":3483,"briefTitle":3484,"status":257,"phases":3506,"primaryCompletion":301,"completion":301,"start":2655,"enrollment":103,"conditions":3507,"interventions":3508},[94],[3487,3488],[3470,3490],{"trials":3510,"activeCount":103},[],{"intervention":3512,"totalTrials":323,"cells":3513},"SOF\u002FLDV",{"EARLY_PHASE1":3514,"PHASE1":3516,"PHASE2":3518,"PHASE3":3520,"PHASE4":3522,"NA":3538},{"trials":3515,"activeCount":103},[],{"trials":3517,"activeCount":103},[],{"trials":3519,"activeCount":103},[],{"trials":3521,"activeCount":103},[],{"trials":3523,"activeCount":103},[3524],{"nctId":3525,"briefTitle":3526,"status":115,"phases":3527,"primaryCompletion":3528,"completion":3529,"start":3530,"enrollment":3531,"conditions":3532,"interventions":3534},"NCT02786537","Study of Oral Treatments for Hepatitis C",[94],"2019-06-13","2020-09-02","2016-06",1275,[3533],"Chronic Hepatitis C",[3512,3535,3536,3537],"PrOD","EBR\u002FGZR","Ribavirin",{"trials":3539,"activeCount":103},[],{"intervention":3535,"totalTrials":323,"cells":3541},{"EARLY_PHASE1":3542,"PHASE1":3544,"PHASE2":3546,"PHASE3":3548,"PHASE4":3550,"NA":3556},{"trials":3543,"activeCount":103},[],{"trials":3545,"activeCount":103},[],{"trials":3547,"activeCount":103},[],{"trials":3549,"activeCount":103},[],{"trials":3551,"activeCount":103},[3552],{"nctId":3525,"briefTitle":3526,"status":115,"phases":3553,"primaryCompletion":3528,"completion":3529,"start":3530,"enrollment":3531,"conditions":3554,"interventions":3555},[94],[3533],[3512,3535,3536,3537],{"trials":3557,"activeCount":103},[],{"intervention":3536,"totalTrials":323,"cells":3559},{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3566,"PHASE4":3568,"NA":3574},{"trials":3561,"activeCount":103},[],{"trials":3563,"activeCount":103},[],{"trials":3565,"activeCount":103},[],{"trials":3567,"activeCount":103},[],{"trials":3569,"activeCount":103},[3570],{"nctId":3525,"briefTitle":3526,"status":115,"phases":3571,"primaryCompletion":3528,"completion":3529,"start":3530,"enrollment":3531,"conditions":3572,"interventions":3573},[94],[3533],[3512,3535,3536,3537],{"trials":3575,"activeCount":103},[],{"intervention":3537,"totalTrials":323,"cells":3577},{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3584,"PHASE4":3586,"NA":3592},{"trials":3579,"activeCount":103},[],{"trials":3581,"activeCount":103},[],{"trials":3583,"activeCount":103},[],{"trials":3585,"activeCount":103},[],{"trials":3587,"activeCount":103},[3588],{"nctId":3525,"briefTitle":3526,"status":115,"phases":3589,"primaryCompletion":3528,"completion":3529,"start":3530,"enrollment":3531,"conditions":3590,"interventions":3591},[94],[3533],[3512,3535,3536,3537],{"trials":3593,"activeCount":103},[],{"intervention":3595,"totalTrials":323,"cells":3596},"brand name metoprolol ER",{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3603,"PHASE4":3605,"NA":3617},{"trials":3598,"activeCount":103},[],{"trials":3600,"activeCount":103},[],{"trials":3602,"activeCount":103},[],{"trials":3604,"activeCount":103},[],{"trials":3606,"activeCount":103},[3607],{"nctId":3608,"briefTitle":3609,"status":115,"phases":3610,"primaryCompletion":3611,"completion":3611,"start":733,"enrollment":203,"conditions":3612,"interventions":3614},"NCT02417246","Open-Labeled PK-PD Studies of Metoprolol ER",[94],"2018-06-06",[3613],"Blood Pressure",[3595,3615,3616],"Generic A","Generic B",{"trials":3618,"activeCount":103},[],{"intervention":3615,"totalTrials":323,"cells":3620},{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3625,"PHASE3":3627,"PHASE4":3629,"NA":3635},{"trials":3622,"activeCount":103},[],{"trials":3624,"activeCount":103},[],{"trials":3626,"activeCount":103},[],{"trials":3628,"activeCount":103},[],{"trials":3630,"activeCount":103},[3631],{"nctId":3608,"briefTitle":3609,"status":115,"phases":3632,"primaryCompletion":3611,"completion":3611,"start":733,"enrollment":203,"conditions":3633,"interventions":3634},[94],[3613],[3595,3615,3616],{"trials":3636,"activeCount":103},[],{"intervention":3616,"totalTrials":323,"cells":3638},{"EARLY_PHASE1":3639,"PHASE1":3641,"PHASE2":3643,"PHASE3":3645,"PHASE4":3647,"NA":3653},{"trials":3640,"activeCount":103},[],{"trials":3642,"activeCount":103},[],{"trials":3644,"activeCount":103},[],{"trials":3646,"activeCount":103},[],{"trials":3648,"activeCount":103},[3649],{"nctId":3608,"briefTitle":3609,"status":115,"phases":3650,"primaryCompletion":3611,"completion":3611,"start":733,"enrollment":203,"conditions":3651,"interventions":3652},[94],[3613],[3595,3615,3616],{"trials":3654,"activeCount":103},[],{"intervention":3656,"totalTrials":323,"cells":3657},"Evolocumab",{"EARLY_PHASE1":3658,"PHASE1":3660,"PHASE2":3662,"PHASE3":3664,"PHASE4":3666,"NA":3678},{"trials":3659,"activeCount":103},[],{"trials":3661,"activeCount":103},[],{"trials":3663,"activeCount":103},[],{"trials":3665,"activeCount":103},[],{"trials":3667,"activeCount":103},[3668],{"nctId":3669,"briefTitle":3670,"status":115,"phases":3671,"primaryCompletion":3672,"completion":3672,"start":3673,"enrollment":3674,"conditions":3675,"interventions":3677},"NCT03096288","Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity",[94],"2020-11-02","2017-10-03",259,[3676],"Atherosclerotic Cardiovascular Disease",[3656],{"trials":3679,"activeCount":103},[],{"intervention":3681,"totalTrials":323,"cells":3682},"Beer",{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3702},{"trials":3684,"activeCount":103},[],{"trials":3686,"activeCount":103},[],{"trials":3688,"activeCount":103},[],{"trials":3690,"activeCount":103},[],{"trials":3692,"activeCount":103},[3693],{"nctId":3694,"briefTitle":3695,"status":1053,"phases":3696,"primaryCompletion":3697,"completion":3698,"start":3699,"enrollment":2099,"conditions":3700,"interventions":3701},"NCT03314454","Alcohol Use and Mental Health - Pilot Test of Video-assisted Drinking Topography",[94],"2022-12-15","2023-06-01","2017-10-12",[1141],[3681],{"trials":3703,"activeCount":103},[],{"intervention":3705,"totalTrials":323,"cells":3706},"omalizumab",{"EARLY_PHASE1":3707,"PHASE1":3709,"PHASE2":3711,"PHASE3":3713,"PHASE4":3715,"NA":3725},{"trials":3708,"activeCount":103},[],{"trials":3710,"activeCount":103},[],{"trials":3712,"activeCount":103},[],{"trials":3714,"activeCount":103},[],{"trials":3716,"activeCount":103},[3717],{"nctId":3718,"briefTitle":3719,"status":115,"phases":3720,"primaryCompletion":3721,"completion":3721,"start":3291,"enrollment":3722,"conditions":3723,"interventions":3724},"NCT00133042","The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma",[94],"2006-12",16,[2716],[3705],{"trials":3726,"activeCount":103},[],{"intervention":3728,"totalTrials":323,"cells":3729},"Obturator block",{"EARLY_PHASE1":3730,"PHASE1":3732,"PHASE2":3734,"PHASE3":3736,"PHASE4":3738,"NA":3750},{"trials":3731,"activeCount":103},[],{"trials":3733,"activeCount":103},[],{"trials":3735,"activeCount":103},[],{"trials":3737,"activeCount":103},[],{"trials":3739,"activeCount":103},[3740],{"nctId":3741,"briefTitle":3742,"status":115,"phases":3743,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":1260,"conditions":3746,"interventions":3748},"NCT03063255","Comparison of Obturator Nerve Blockade and Neuromuscular Blockade",[94],"2019-09-19","2017-04-25",[3747],"Cancer of Bladder",[3728,3749],"Neuromuscular block",{"trials":3751,"activeCount":103},[],{"intervention":3749,"totalTrials":323,"cells":3753},{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3760,"PHASE4":3762,"NA":3768},{"trials":3755,"activeCount":103},[],{"trials":3757,"activeCount":103},[],{"trials":3759,"activeCount":103},[],{"trials":3761,"activeCount":103},[],{"trials":3763,"activeCount":103},[3764],{"nctId":3741,"briefTitle":3742,"status":115,"phases":3765,"primaryCompletion":3744,"completion":3744,"start":3745,"enrollment":1260,"conditions":3766,"interventions":3767},[94],[3747],[3728,3749],{"trials":3769,"activeCount":103},[],{"intervention":3771,"totalTrials":323,"cells":3772},"NatestoTM",{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3779,"PHASE4":3781,"NA":3793},{"trials":3774,"activeCount":103},[],{"trials":3776,"activeCount":103},[],{"trials":3778,"activeCount":103},[],{"trials":3780,"activeCount":103},[],{"trials":3782,"activeCount":103},[3783],{"nctId":3784,"briefTitle":3785,"status":115,"phases":3786,"primaryCompletion":3787,"completion":3787,"start":3788,"enrollment":3789,"conditions":3790,"interventions":3792},"NCT05381831","Natesto Spermatogenesis Reboot",[94],"2025-04-21","2022-06-01",13,[3791],"Hypogonadism, Male",[3771],{"trials":3794,"activeCount":103},[],{"intervention":3030,"totalTrials":323,"cells":3796},{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3811},{"trials":3798,"activeCount":103},[],{"trials":3800,"activeCount":103},[],{"trials":3802,"activeCount":103},[],{"trials":3804,"activeCount":103},[],{"trials":3806,"activeCount":103},[3807],{"nctId":3024,"briefTitle":3025,"status":115,"phases":3808,"primaryCompletion":2771,"completion":2771,"start":3027,"enrollment":1725,"conditions":3809,"interventions":3810},[94],[27],[3030,2846],{"trials":3812,"activeCount":103},[],{"intervention":3814,"totalTrials":323,"cells":3815},"Warfarin Dosing",{"EARLY_PHASE1":3816,"PHASE1":3818,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3835},{"trials":3817,"activeCount":103},[],{"trials":3819,"activeCount":103},[],{"trials":3821,"activeCount":103},[],{"trials":3823,"activeCount":103},[],{"trials":3825,"activeCount":103},[3826],{"nctId":3827,"briefTitle":3828,"status":257,"phases":3829,"primaryCompletion":3830,"start":3831,"enrollment":103,"conditions":3832,"interventions":3834},"NCT00377143","PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care",[94],"2006-08","2006-07",[3833],"Blood Coagulation Disorders",[3814],{"trials":3836,"activeCount":103},[],{"intervention":3838,"totalTrials":323,"cells":3839},"Cefepime, Meropenem, or Piperacillin\u002FTazobactam",{"EARLY_PHASE1":3840,"PHASE1":3842,"PHASE2":3844,"PHASE3":3846,"PHASE4":3848,"NA":3860},{"trials":3841,"activeCount":103},[],{"trials":3843,"activeCount":103},[],{"trials":3845,"activeCount":103},[],{"trials":3847,"activeCount":103},[],{"trials":3849,"activeCount":103},[3850],{"nctId":3851,"briefTitle":3852,"status":1053,"phases":3853,"primaryCompletion":3854,"completion":3854,"start":3855,"enrollment":3856,"conditions":3857,"interventions":3859},"NCT05102162","BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia",[94],"2023-02-28","2021-12-17",35,[3858],"Pneumonia",[3838,3838],{"trials":3861,"activeCount":103},[],{"intervention":3863,"totalTrials":323,"cells":3864},"Prednisolone",{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3886},{"trials":3866,"activeCount":103},[],{"trials":3868,"activeCount":103},[],{"trials":3870,"activeCount":103},[],{"trials":3872,"activeCount":103},[],{"trials":3874,"activeCount":103},[3875],{"nctId":3876,"briefTitle":3877,"status":115,"phases":3878,"primaryCompletion":3879,"completion":3880,"start":3881,"enrollment":3882,"conditions":3883,"interventions":3885},"NCT03962894","Early Administration of Steroids in the Ambulance Setting",[94],"2024-05-31","2024-12-31","2019-04-01",834,[3884],"Asthma in Children",[3863],{"trials":3887,"activeCount":103},[],{"intervention":3889,"totalTrials":323,"cells":3890},"Regional Anesthesia",{"EARLY_PHASE1":3891,"PHASE1":3893,"PHASE2":3895,"PHASE3":3897,"PHASE4":3899,"NA":3907},{"trials":3892,"activeCount":103},[],{"trials":3894,"activeCount":103},[],{"trials":3896,"activeCount":103},[],{"trials":3898,"activeCount":103},[],{"trials":3900,"activeCount":103},[3901],{"nctId":3902,"briefTitle":3903,"status":257,"phases":3904,"primaryCompletion":2780,"completion":2780,"start":1213,"enrollment":103,"conditions":3905,"interventions":3906},"NCT04304716","Regional Anesthesia for Head and Neck Reconstruction",[94],[265],[3889],{"trials":3908,"activeCount":103},[],{"intervention":3910,"totalTrials":323,"cells":3911},"dl-Methylphenidate plus Cannabidiol",{"EARLY_PHASE1":3912,"PHASE1":3914,"PHASE2":3916,"PHASE3":3918,"PHASE4":3920,"NA":3932},{"trials":3913,"activeCount":103},[],{"trials":3915,"activeCount":103},[],{"trials":3917,"activeCount":103},[],{"trials":3919,"activeCount":103},[],{"trials":3921,"activeCount":103},[3922],{"nctId":3923,"briefTitle":3924,"status":115,"phases":3925,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":759,"conditions":3928,"interventions":3930},"NCT04603391","Cannabidiol and CES1 Interactions in Healthy Subjects",[94],"2021-12-31","2021-02-25",[3929],"Drug Interaction",[3910,3931],"dl-Methylphenidate plus Cannabidiol Placebo solution",{"trials":3933,"activeCount":103},[],{"intervention":3931,"totalTrials":323,"cells":3935},{"EARLY_PHASE1":3936,"PHASE1":3938,"PHASE2":3940,"PHASE3":3942,"PHASE4":3944,"NA":3950},{"trials":3937,"activeCount":103},[],{"trials":3939,"activeCount":103},[],{"trials":3941,"activeCount":103},[],{"trials":3943,"activeCount":103},[],{"trials":3945,"activeCount":103},[3946],{"nctId":3923,"briefTitle":3924,"status":115,"phases":3947,"primaryCompletion":3926,"completion":3926,"start":3927,"enrollment":759,"conditions":3948,"interventions":3949},[94],[3929],[3910,3931],{"trials":3951,"activeCount":103},[],{"intervention":3953,"totalTrials":323,"cells":3954},"Celecoxib",{"EARLY_PHASE1":3955,"PHASE1":3957,"PHASE2":3959,"PHASE3":3961,"PHASE4":3963,"NA":3974},{"trials":3956,"activeCount":103},[],{"trials":3958,"activeCount":103},[],{"trials":3960,"activeCount":103},[],{"trials":3962,"activeCount":103},[],{"trials":3964,"activeCount":103},[3965],{"nctId":3966,"briefTitle":3967,"status":115,"phases":3968,"completion":3291,"start":3969,"enrollment":3970,"conditions":3971,"interventions":3973},"NCT00471341","Effect of Celecoxib on Markers of Vascular Inflammation",[94],"2002-07",75,[3972],"Hypertension and Coronary Artery Disease",[3953],{"trials":3975,"activeCount":103},[],{"intervention":3977,"totalTrials":323,"cells":3978},"Pioglitazone study drug",{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3987,"NA":3997},{"trials":3980,"activeCount":103},[],{"trials":3982,"activeCount":103},[],{"trials":3984,"activeCount":103},[],{"trials":3986,"activeCount":103},[],{"trials":3988,"activeCount":103},[3989],{"nctId":3990,"briefTitle":3991,"status":115,"phases":3992,"primaryCompletion":169,"completion":169,"start":3059,"enrollment":3993,"conditions":3994,"interventions":3995},"NCT00994682","University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)",[94],176,[1405,3003,2633],[3977,3996],"Pioglitazone Open Label",{"trials":3998,"activeCount":103},[],{"intervention":3996,"totalTrials":323,"cells":4000},{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4007,"PHASE4":4009,"NA":4015},{"trials":4002,"activeCount":103},[],{"trials":4004,"activeCount":103},[],{"trials":4006,"activeCount":103},[],{"trials":4008,"activeCount":103},[],{"trials":4010,"activeCount":103},[4011],{"nctId":3990,"briefTitle":3991,"status":115,"phases":4012,"primaryCompletion":169,"completion":169,"start":3059,"enrollment":3993,"conditions":4013,"interventions":4014},[94],[1405,3003,2633],[3977,3996],{"trials":4016,"activeCount":103},[],{"intervention":4018,"totalTrials":323,"cells":4019},"Tolvaptan",{"EARLY_PHASE1":4020,"PHASE1":4022,"PHASE2":4024,"PHASE3":4026,"PHASE4":4028,"NA":4040},{"trials":4021,"activeCount":103},[],{"trials":4023,"activeCount":103},[],{"trials":4025,"activeCount":103},[],{"trials":4027,"activeCount":103},[],{"trials":4029,"activeCount":103},[4030],{"nctId":4031,"briefTitle":4032,"status":115,"phases":4033,"primaryCompletion":169,"completion":4034,"start":4035,"enrollment":695,"conditions":4036,"interventions":4039},"NCT01292304","Tolvaptan for Ascites in Cirrhotic Patients",[94],"2015-01","2012-03",[4037,4038],"Ascites","Cirrhosis",[4018],{"trials":4041,"activeCount":103},[],{"intervention":4043,"totalTrials":323,"cells":4044},"1% preservative-free lidocaine",{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4051,"PHASE4":4053,"NA":4065},{"trials":4046,"activeCount":103},[],{"trials":4048,"activeCount":103},[],{"trials":4050,"activeCount":103},[],{"trials":4052,"activeCount":103},[],{"trials":4054,"activeCount":103},[4055],{"nctId":4056,"briefTitle":4057,"status":257,"phases":4058,"primaryCompletion":4059,"completion":4059,"start":4060,"enrollment":103,"conditions":4061,"interventions":4063},"NCT04829799","Effect of Intracameral Phenylephrine\u002FKetorolac on Intraoperative Pain",[94],"2023-08","2022-02",[4062],"Pain Reduction",[4043,4064],"Phenylephrine 1.0%\u002F Ketorolac 0.3%",{"trials":4066,"activeCount":103},[],{"intervention":4064,"totalTrials":323,"cells":4068},{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4073,"PHASE3":4075,"PHASE4":4077,"NA":4083},{"trials":4070,"activeCount":103},[],{"trials":4072,"activeCount":103},[],{"trials":4074,"activeCount":103},[],{"trials":4076,"activeCount":103},[],{"trials":4078,"activeCount":103},[4079],{"nctId":4056,"briefTitle":4057,"status":257,"phases":4080,"primaryCompletion":4059,"completion":4059,"start":4060,"enrollment":103,"conditions":4081,"interventions":4082},[94],[4062],[4043,4064],{"trials":4084,"activeCount":103},[],{"intervention":4086,"totalTrials":323,"cells":4087},"olanzapine + fluoxetine",{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4094,"PHASE4":4096,"NA":4108},{"trials":4089,"activeCount":103},[],{"trials":4091,"activeCount":103},[],{"trials":4093,"activeCount":103},[],{"trials":4095,"activeCount":103},[],{"trials":4097,"activeCount":103},[4098],{"nctId":4099,"briefTitle":4100,"status":115,"phases":4101,"primaryCompletion":4102,"completion":4103,"start":4104,"enrollment":1204,"conditions":4105,"interventions":4107},"NCT00000373","Treatment of Obsessive-Compulsive Disorder",[94],"2003-01","2003-07","1992-09",[4106],"Obsessive-Compulsive Disorder",[4086],{"trials":4109,"activeCount":103},[],{"intervention":4111,"totalTrials":323,"cells":4112},"Plasma Rich in Growth Factor (PRGF) Supplementation",{"EARLY_PHASE1":4113,"PHASE1":4115,"PHASE2":4117,"PHASE3":4119,"PHASE4":4121,"NA":4134},{"trials":4114,"activeCount":103},[],{"trials":4116,"activeCount":103},[],{"trials":4118,"activeCount":103},[],{"trials":4120,"activeCount":103},[],{"trials":4122,"activeCount":103},[4123],{"nctId":4124,"briefTitle":4125,"status":1053,"phases":4126,"primaryCompletion":4127,"completion":4127,"start":4128,"enrollment":250,"conditions":4129,"interventions":4132},"NCT04731233","Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis",[94],"2024-02-21","2021-03-30",[4130,4131],"TMJ","Osteoarthritis",[4111,4133],"Triamcinolone Acetonide",{"trials":4135,"activeCount":103},[],{"intervention":4133,"totalTrials":323,"cells":4137},{"EARLY_PHASE1":4138,"PHASE1":4140,"PHASE2":4142,"PHASE3":4144,"PHASE4":4146,"NA":4152},{"trials":4139,"activeCount":103},[],{"trials":4141,"activeCount":103},[],{"trials":4143,"activeCount":103},[],{"trials":4145,"activeCount":103},[],{"trials":4147,"activeCount":103},[4148],{"nctId":4124,"briefTitle":4125,"status":1053,"phases":4149,"primaryCompletion":4127,"completion":4127,"start":4128,"enrollment":250,"conditions":4150,"interventions":4151},[94],[4130,4131],[4111,4133],{"trials":4153,"activeCount":103},[],{"intervention":4155,"totalTrials":323,"cells":4156},"corticosteroid injections",{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4176},{"trials":4158,"activeCount":103},[],{"trials":4160,"activeCount":103},[],{"trials":4162,"activeCount":103},[],{"trials":4164,"activeCount":103},[],{"trials":4166,"activeCount":103},[4167],{"nctId":4168,"briefTitle":4169,"status":1053,"phases":4170,"primaryCompletion":4171,"completion":4171,"start":4172,"enrollment":814,"conditions":4173,"interventions":4175},"NCT03232749","Predicting Response to Intra-Articular Corticosteroid Injection in Patients With Osteoarthritis of the Glenohumeral Joint",[94],"2019-06-06","2018-04-18",[4174],"Osteoarthritis of the Glenohumeral Joint",[4155],{"trials":4177,"activeCount":103},[],{"intervention":4179,"totalTrials":323,"cells":4180},"Methylnaltrexone",{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4187,"PHASE4":4189,"NA":4199},{"trials":4182,"activeCount":103},[],{"trials":4184,"activeCount":103},[],{"trials":4186,"activeCount":103},[],{"trials":4188,"activeCount":103},[],{"trials":4190,"activeCount":103},[4191],{"nctId":4192,"briefTitle":4193,"status":115,"phases":4194,"primaryCompletion":4195,"completion":4195,"start":733,"enrollment":1272,"conditions":4196,"interventions":4197},"NCT02403830","Effect of Methylnaltrexone on the PK\u002FPD Profiles of Ticagrelor in Patients Treated With Morphine",[94],"2016-05",[18],[4179,4198,162],"Morphine",{"trials":4200,"activeCount":103},[],{"intervention":4198,"totalTrials":323,"cells":4202},{"EARLY_PHASE1":4203,"PHASE1":4205,"PHASE2":4207,"PHASE3":4209,"PHASE4":4211,"NA":4217},{"trials":4204,"activeCount":103},[],{"trials":4206,"activeCount":103},[],{"trials":4208,"activeCount":103},[],{"trials":4210,"activeCount":103},[],{"trials":4212,"activeCount":103},[4213],{"nctId":4192,"briefTitle":4193,"status":115,"phases":4214,"primaryCompletion":4195,"completion":4195,"start":733,"enrollment":1272,"conditions":4215,"interventions":4216},[94],[18],[4179,4198,162],{"trials":4218,"activeCount":103},[],{"intervention":4220,"totalTrials":323,"cells":4221},"Bolus dose of Cefazolin",{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4242},{"trials":4223,"activeCount":103},[],{"trials":4225,"activeCount":103},[],{"trials":4227,"activeCount":103},[],{"trials":4229,"activeCount":103},[],{"trials":4231,"activeCount":103},[4232],{"nctId":4233,"briefTitle":4234,"status":115,"phases":4235,"primaryCompletion":4236,"completion":4236,"start":4237,"enrollment":926,"conditions":4238,"interventions":4240},"NCT03190668","Skeletal Muscle and Adipose Tissue Study",[94],"2022-06-23","2018-05-29",[4239],"Idiopathic Scoliosis",[4220,4241],"Continuous Cefazolin drip",{"trials":4243,"activeCount":103},[],{"intervention":4241,"totalTrials":323,"cells":4245},{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4252,"PHASE4":4254,"NA":4260},{"trials":4247,"activeCount":103},[],{"trials":4249,"activeCount":103},[],{"trials":4251,"activeCount":103},[],{"trials":4253,"activeCount":103},[],{"trials":4255,"activeCount":103},[4256],{"nctId":4233,"briefTitle":4234,"status":115,"phases":4257,"primaryCompletion":4236,"completion":4236,"start":4237,"enrollment":926,"conditions":4258,"interventions":4259},[94],[4239],[4220,4241],{"trials":4261,"activeCount":103},[],{"intervention":4263,"totalTrials":323,"cells":4264},"Ticagrelor monotherapy",{"EARLY_PHASE1":4265,"PHASE1":4267,"PHASE2":4269,"PHASE3":4271,"PHASE4":4273,"NA":4287},{"trials":4266,"activeCount":103},[],{"trials":4268,"activeCount":103},[],{"trials":4270,"activeCount":103},[],{"trials":4272,"activeCount":103},[],{"trials":4274,"activeCount":103},[4275],{"nctId":4276,"briefTitle":4277,"status":115,"phases":4278,"primaryCompletion":4279,"completion":4280,"start":4281,"enrollment":4282,"conditions":4283,"interventions":4284},"NCT04484259","Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus",[94],"2024-01-29","2024-06-15","2021-03-31",105,[160,18],[4263,4285,4286],"Ticagrelor plus aspirin","Clopidogrel with aspirin",{"trials":4288,"activeCount":103},[],{"intervention":4285,"totalTrials":323,"cells":4290},{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4295,"PHASE3":4297,"PHASE4":4299,"NA":4305},{"trials":4292,"activeCount":103},[],{"trials":4294,"activeCount":103},[],{"trials":4296,"activeCount":103},[],{"trials":4298,"activeCount":103},[],{"trials":4300,"activeCount":103},[4301],{"nctId":4276,"briefTitle":4277,"status":115,"phases":4302,"primaryCompletion":4279,"completion":4280,"start":4281,"enrollment":4282,"conditions":4303,"interventions":4304},[94],[160,18],[4263,4285,4286],{"trials":4306,"activeCount":103},[],{"intervention":4286,"totalTrials":323,"cells":4308},{"EARLY_PHASE1":4309,"PHASE1":4311,"PHASE2":4313,"PHASE3":4315,"PHASE4":4317,"NA":4323},{"trials":4310,"activeCount":103},[],{"trials":4312,"activeCount":103},[],{"trials":4314,"activeCount":103},[],{"trials":4316,"activeCount":103},[],{"trials":4318,"activeCount":103},[4319],{"nctId":4276,"briefTitle":4277,"status":115,"phases":4320,"primaryCompletion":4279,"completion":4280,"start":4281,"enrollment":4282,"conditions":4321,"interventions":4322},[94],[160,18],[4263,4285,4286],{"trials":4324,"activeCount":103},[],{"intervention":4326,"totalTrials":323,"cells":4327},"Sorafenib Standard Dosing Regimen",{"EARLY_PHASE1":4328,"PHASE1":4330,"PHASE2":4332,"PHASE3":4334,"PHASE4":4336,"NA":4345},{"trials":4329,"activeCount":103},[],{"trials":4331,"activeCount":103},[],{"trials":4333,"activeCount":103},[],{"trials":4335,"activeCount":103},[],{"trials":4337,"activeCount":103},[4338],{"nctId":4339,"briefTitle":4340,"status":115,"phases":4341,"primaryCompletion":2654,"completion":712,"start":2841,"enrollment":533,"conditions":4342,"interventions":4343},"NCT01203787","Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)",[94],[1263],[4326,4344],"Sorafenib Ramp-Up Regimen",{"trials":4346,"activeCount":103},[],{"intervention":4344,"totalTrials":323,"cells":4348},{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4363},{"trials":4350,"activeCount":103},[],{"trials":4352,"activeCount":103},[],{"trials":4354,"activeCount":103},[],{"trials":4356,"activeCount":103},[],{"trials":4358,"activeCount":103},[4359],{"nctId":4339,"briefTitle":4340,"status":115,"phases":4360,"primaryCompletion":2654,"completion":712,"start":2841,"enrollment":533,"conditions":4361,"interventions":4362},[94],[1263],[4326,4344],{"trials":4364,"activeCount":103},[],{"intervention":4366,"totalTrials":323,"cells":4367},"Narcotics",{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4372,"PHASE3":4374,"PHASE4":4376,"NA":4389},{"trials":4369,"activeCount":103},[],{"trials":4371,"activeCount":103},[],{"trials":4373,"activeCount":103},[],{"trials":4375,"activeCount":103},[],{"trials":4377,"activeCount":103},[4378],{"nctId":4379,"briefTitle":4380,"status":115,"phases":4381,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":4384,"conditions":4385,"interventions":4387},"NCT03001843","Ketamine vs Hydromorphone",[94],"2018-12-21","2017-02-22",54,[4386,24,265],"Laparoscopic Gastric Bypass",[4388,4366],"Ketamine",{"trials":4390,"activeCount":103},[],{"intervention":308,"totalTrials":323,"cells":4392},{"EARLY_PHASE1":4393,"PHASE1":4395,"PHASE2":4397,"PHASE3":4399,"PHASE4":4401,"NA":4407},{"trials":4394,"activeCount":103},[],{"trials":4396,"activeCount":103},[],{"trials":4398,"activeCount":103},[],{"trials":4400,"activeCount":103},[],{"trials":4402,"activeCount":103},[4403],{"nctId":298,"briefTitle":299,"status":257,"phases":4404,"primaryCompletion":301,"completion":301,"start":302,"enrollment":103,"conditions":4405,"interventions":4406},[94],[304,305,306],[308,309],{"trials":4408,"activeCount":103},[],{"intervention":4410,"totalTrials":323,"cells":4411},"Transdermal Nicotine Patch",{"EARLY_PHASE1":4412,"PHASE1":4414,"PHASE2":4416,"PHASE3":4418,"PHASE4":4420,"NA":4430},{"trials":4413,"activeCount":103},[],{"trials":4415,"activeCount":103},[],{"trials":4417,"activeCount":103},[],{"trials":4419,"activeCount":103},[],{"trials":4421,"activeCount":103},[4422],{"nctId":4423,"briefTitle":4424,"status":1053,"phases":4425,"primaryCompletion":4426,"completion":4426,"start":4427,"enrollment":28,"conditions":4428,"interventions":4429},"NCT03072511","Smoking Cessation Intervention",[94],"2018-08-01","2016-12-13",[2575],[4410],{"trials":4431,"activeCount":103},[],{"intervention":4433,"totalTrials":323,"cells":4434},"Advair Diskus100\u002F50 µg",{"EARLY_PHASE1":4435,"PHASE1":4437,"PHASE2":4439,"PHASE3":4441,"PHASE4":4443,"NA":4455},{"trials":4436,"activeCount":103},[],{"trials":4438,"activeCount":103},[],{"trials":4440,"activeCount":103},[],{"trials":4442,"activeCount":103},[],{"trials":4444,"activeCount":103},[4445],{"nctId":4446,"briefTitle":4447,"status":115,"phases":4448,"primaryCompletion":4449,"completion":781,"start":3399,"enrollment":695,"conditions":4450,"interventions":4451},"NCT01907334","Dose-Response of Salmeterol in Children",[94],"2014-05",[2716],[4433,4452,4453,4454],"Flovent Diskus 100 µg","Methacholine Chloride","Albuterol",{"trials":4456,"activeCount":103},[],{"intervention":4452,"totalTrials":323,"cells":4458},{"EARLY_PHASE1":4459,"PHASE1":4461,"PHASE2":4463,"PHASE3":4465,"PHASE4":4467,"NA":4473},{"trials":4460,"activeCount":103},[],{"trials":4462,"activeCount":103},[],{"trials":4464,"activeCount":103},[],{"trials":4466,"activeCount":103},[],{"trials":4468,"activeCount":103},[4469],{"nctId":4446,"briefTitle":4447,"status":115,"phases":4470,"primaryCompletion":4449,"completion":781,"start":3399,"enrollment":695,"conditions":4471,"interventions":4472},[94],[2716],[4433,4452,4453,4454],{"trials":4474,"activeCount":103},[],{"intervention":4453,"totalTrials":323,"cells":4476},{"EARLY_PHASE1":4477,"PHASE1":4479,"PHASE2":4481,"PHASE3":4483,"PHASE4":4485,"NA":4491},{"trials":4478,"activeCount":103},[],{"trials":4480,"activeCount":103},[],{"trials":4482,"activeCount":103},[],{"trials":4484,"activeCount":103},[],{"trials":4486,"activeCount":103},[4487],{"nctId":4446,"briefTitle":4447,"status":115,"phases":4488,"primaryCompletion":4449,"completion":781,"start":3399,"enrollment":695,"conditions":4489,"interventions":4490},[94],[2716],[4433,4452,4453,4454],{"trials":4492,"activeCount":103},[],{"intervention":4454,"totalTrials":323,"cells":4494},{"EARLY_PHASE1":4495,"PHASE1":4497,"PHASE2":4499,"PHASE3":4501,"PHASE4":4503,"NA":4509},{"trials":4496,"activeCount":103},[],{"trials":4498,"activeCount":103},[],{"trials":4500,"activeCount":103},[],{"trials":4502,"activeCount":103},[],{"trials":4504,"activeCount":103},[4505],{"nctId":4446,"briefTitle":4447,"status":115,"phases":4506,"primaryCompletion":4449,"completion":781,"start":3399,"enrollment":695,"conditions":4507,"interventions":4508},[94],[2716],[4433,4452,4453,4454],{"trials":4510,"activeCount":103},[],{"intervention":4512,"totalTrials":323,"cells":4513},"Botox",{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4518,"PHASE3":4520,"PHASE4":4522,"NA":4531},{"trials":4515,"activeCount":103},[],{"trials":4517,"activeCount":103},[],{"trials":4519,"activeCount":103},[],{"trials":4521,"activeCount":103},[],{"trials":4523,"activeCount":103},[4524],{"nctId":4525,"briefTitle":4526,"status":115,"phases":4527,"primaryCompletion":4528,"completion":4528,"start":169,"enrollment":3722,"conditions":4529,"interventions":4530},"NCT02177617","Neurotoxin and Physical Therapy",[94],"2017-01-07",[1614],[4512],{"trials":4532,"activeCount":103},[],{"intervention":472,"totalTrials":323,"cells":4534},{"EARLY_PHASE1":4535,"PHASE1":4537,"PHASE2":4539,"PHASE3":4541,"PHASE4":4543,"NA":4549},{"trials":4536,"activeCount":103},[],{"trials":4538,"activeCount":103},[],{"trials":4540,"activeCount":103},[],{"trials":4542,"activeCount":103},[],{"trials":4544,"activeCount":103},[4545],{"nctId":464,"briefTitle":465,"status":115,"phases":4546,"primaryCompletion":167,"completion":467,"start":468,"enrollment":469,"conditions":4547,"interventions":4548},[94],[18],[472,473,474,475],{"trials":4550,"activeCount":103},[],{"intervention":473,"totalTrials":323,"cells":4552},{"EARLY_PHASE1":4553,"PHASE1":4555,"PHASE2":4557,"PHASE3":4559,"PHASE4":4561,"NA":4567},{"trials":4554,"activeCount":103},[],{"trials":4556,"activeCount":103},[],{"trials":4558,"activeCount":103},[],{"trials":4560,"activeCount":103},[],{"trials":4562,"activeCount":103},[4563],{"nctId":464,"briefTitle":465,"status":115,"phases":4564,"primaryCompletion":167,"completion":467,"start":468,"enrollment":469,"conditions":4565,"interventions":4566},[94],[18],[472,473,474,475],{"trials":4568,"activeCount":103},[],{"intervention":475,"totalTrials":323,"cells":4570},{"EARLY_PHASE1":4571,"PHASE1":4573,"PHASE2":4575,"PHASE3":4577,"PHASE4":4579,"NA":4585},{"trials":4572,"activeCount":103},[],{"trials":4574,"activeCount":103},[],{"trials":4576,"activeCount":103},[],{"trials":4578,"activeCount":103},[],{"trials":4580,"activeCount":103},[4581],{"nctId":464,"briefTitle":465,"status":115,"phases":4582,"primaryCompletion":167,"completion":467,"start":468,"enrollment":469,"conditions":4583,"interventions":4584},[94],[18],[472,473,474,475],{"trials":4586,"activeCount":103},[],{"intervention":195,"totalTrials":323,"cells":4588},{"EARLY_PHASE1":4589,"PHASE1":4591,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4603},{"trials":4590,"activeCount":103},[],{"trials":4592,"activeCount":103},[],{"trials":4594,"activeCount":103},[],{"trials":4596,"activeCount":103},[],{"trials":4598,"activeCount":103},[4599],{"nctId":184,"briefTitle":185,"status":115,"phases":4600,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":4601,"interventions":4602},[94],[18],[98,151,193,194,195],{"trials":4604,"activeCount":103},[],{"intervention":4606,"totalTrials":323,"cells":4607},"Ranolazine",{"EARLY_PHASE1":4608,"PHASE1":4610,"PHASE2":4612,"PHASE3":4614,"PHASE4":4616,"NA":4629},{"trials":4609,"activeCount":103},[],{"trials":4611,"activeCount":103},[],{"trials":4613,"activeCount":103},[],{"trials":4615,"activeCount":103},[],{"trials":4617,"activeCount":103},[4618],{"nctId":4619,"briefTitle":4620,"status":115,"phases":4621,"primaryCompletion":4622,"completion":4623,"start":4624,"enrollment":22,"conditions":4625,"interventions":4628},"NCT02252406","Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome",[94],"2018-12-17","2019-05-17","2015-09",[4626,4627],"Stable Angina","Metabolic Syndrome",[4606],{"trials":4630,"activeCount":103},[],{"intervention":4632,"totalTrials":323,"cells":4633},"Eplerenone",{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4640,"PHASE4":4642,"NA":4652},{"trials":4635,"activeCount":103},[],{"trials":4637,"activeCount":103},[],{"trials":4639,"activeCount":103},[],{"trials":4641,"activeCount":103},[],{"trials":4643,"activeCount":103},[4644],{"nctId":4645,"briefTitle":4646,"status":115,"phases":4647,"primaryCompletion":4648,"completion":1056,"start":4649,"enrollment":2529,"conditions":4650,"interventions":4651},"NCT00187889","EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia",[94],"2009-02","2004-08",[3294],[4632],{"trials":4653,"activeCount":103},[],{"intervention":209,"totalTrials":323,"cells":4655},{"EARLY_PHASE1":4656,"PHASE1":4658,"PHASE2":4660,"PHASE3":4662,"PHASE4":4664,"NA":4670},{"trials":4657,"activeCount":103},[],{"trials":4659,"activeCount":103},[],{"trials":4661,"activeCount":103},[],{"trials":4663,"activeCount":103},[],{"trials":4665,"activeCount":103},[4666],{"nctId":197,"briefTitle":198,"status":115,"phases":4667,"primaryCompletion":200,"completion":201,"start":202,"enrollment":203,"conditions":4668,"interventions":4669},[94],[205,206,207],[98,209],{"trials":4671,"activeCount":103},[],{"intervention":4673,"totalTrials":323,"cells":4674},"Regular Titration",{"EARLY_PHASE1":4675,"PHASE1":4677,"PHASE2":4679,"PHASE3":4681,"PHASE4":4683,"NA":4694},{"trials":4676,"activeCount":103},[],{"trials":4678,"activeCount":103},[],{"trials":4680,"activeCount":103},[],{"trials":4682,"activeCount":103},[],{"trials":4684,"activeCount":103},[4685],{"nctId":4686,"briefTitle":4687,"status":115,"phases":4688,"primaryCompletion":4689,"completion":4689,"start":4648,"enrollment":4690,"conditions":4691,"interventions":4692},"NCT00382291","Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder",[94],"2011-02",56,[4106],[4673,4693],"Slow Titration",{"trials":4695,"activeCount":103},[],{"intervention":4693,"totalTrials":323,"cells":4697},{"EARLY_PHASE1":4698,"PHASE1":4700,"PHASE2":4702,"PHASE3":4704,"PHASE4":4706,"NA":4712},{"trials":4699,"activeCount":103},[],{"trials":4701,"activeCount":103},[],{"trials":4703,"activeCount":103},[],{"trials":4705,"activeCount":103},[],{"trials":4707,"activeCount":103},[4708],{"nctId":4686,"briefTitle":4687,"status":115,"phases":4709,"primaryCompletion":4689,"completion":4689,"start":4648,"enrollment":4690,"conditions":4710,"interventions":4711},[94],[4106],[4673,4693],{"trials":4713,"activeCount":103},[],{"intervention":4715,"totalTrials":323,"cells":4716},"tPA",{"EARLY_PHASE1":4717,"PHASE1":4719,"PHASE2":4721,"PHASE3":4723,"PHASE4":4725,"NA":4737},{"trials":4718,"activeCount":103},[],{"trials":4720,"activeCount":103},[],{"trials":4722,"activeCount":103},[],{"trials":4724,"activeCount":103},[],{"trials":4726,"activeCount":103},[4727],{"nctId":4728,"briefTitle":4729,"status":115,"phases":4730,"primaryCompletion":4731,"completion":4731,"start":4732,"enrollment":250,"conditions":4733,"interventions":4735},"NCT03213834","Fibrinolytic Therapy Versus Medical Thoracoscopy",[94],"2020-02-04","2017-09-14",[4734],"Pleural Diseases",[4715,4736],"DNase",{"trials":4738,"activeCount":103},[],{"intervention":4736,"totalTrials":323,"cells":4740},{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4747,"PHASE4":4749,"NA":4755},{"trials":4742,"activeCount":103},[],{"trials":4744,"activeCount":103},[],{"trials":4746,"activeCount":103},[],{"trials":4748,"activeCount":103},[],{"trials":4750,"activeCount":103},[4751],{"nctId":4728,"briefTitle":4729,"status":115,"phases":4752,"primaryCompletion":4731,"completion":4731,"start":4732,"enrollment":250,"conditions":4753,"interventions":4754},[94],[4734],[4715,4736],{"trials":4756,"activeCount":103},[],{"intervention":4758,"totalTrials":323,"cells":4759},"Inhaled nitric oxide",{"EARLY_PHASE1":4760,"PHASE1":4762,"PHASE2":4764,"PHASE3":4766,"PHASE4":4768,"NA":4782},{"trials":4761,"activeCount":103},[],{"trials":4763,"activeCount":103},[],{"trials":4765,"activeCount":103},[],{"trials":4767,"activeCount":103},[],{"trials":4769,"activeCount":103},[4770],{"nctId":4771,"briefTitle":4772,"status":257,"phases":4773,"primaryCompletion":4774,"completion":3744,"start":4195,"enrollment":103,"conditions":4775,"interventions":4779},"NCT01891500","Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure",[94],"2019-09-18",[4776,4777,4778],"Persistent Fetal Circulation Syndrome","Hypertension, Pulmonary, of Newborn, Persistent","Persistent Pulmonary Hypertension of Newborn",[4758,4780,4781],"Nitrogen Gas","Crossover iNO",{"trials":4783,"activeCount":103},[],{"intervention":4780,"totalTrials":323,"cells":4785},{"EARLY_PHASE1":4786,"PHASE1":4788,"PHASE2":4790,"PHASE3":4792,"PHASE4":4794,"NA":4800},{"trials":4787,"activeCount":103},[],{"trials":4789,"activeCount":103},[],{"trials":4791,"activeCount":103},[],{"trials":4793,"activeCount":103},[],{"trials":4795,"activeCount":103},[4796],{"nctId":4771,"briefTitle":4772,"status":257,"phases":4797,"primaryCompletion":4774,"completion":3744,"start":4195,"enrollment":103,"conditions":4798,"interventions":4799},[94],[4776,4777,4778],[4758,4780,4781],{"trials":4801,"activeCount":103},[],{"intervention":4781,"totalTrials":323,"cells":4803},{"EARLY_PHASE1":4804,"PHASE1":4806,"PHASE2":4808,"PHASE3":4810,"PHASE4":4812,"NA":4818},{"trials":4805,"activeCount":103},[],{"trials":4807,"activeCount":103},[],{"trials":4809,"activeCount":103},[],{"trials":4811,"activeCount":103},[],{"trials":4813,"activeCount":103},[4814],{"nctId":4771,"briefTitle":4772,"status":257,"phases":4815,"primaryCompletion":4774,"completion":3744,"start":4195,"enrollment":103,"conditions":4816,"interventions":4817},[94],[4776,4777,4778],[4758,4780,4781],{"trials":4819,"activeCount":103},[],{"intervention":4821,"totalTrials":323,"cells":4822},"5% Minoxidil",{"EARLY_PHASE1":4823,"PHASE1":4825,"PHASE2":4827,"PHASE3":4829,"PHASE4":4831,"NA":4844},{"trials":4824,"activeCount":103},[],{"trials":4826,"activeCount":103},[],{"trials":4828,"activeCount":103},[],{"trials":4830,"activeCount":103},[],{"trials":4832,"activeCount":103},[4833],{"nctId":4834,"briefTitle":4835,"status":257,"phases":4836,"primaryCompletion":4837,"completion":4837,"start":4838,"enrollment":103,"conditions":4839,"interventions":4841},"NCT02483195","The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia",[94],"2018-08","2016-08",[4840],"Female Androgenetic Alopecia",[4821,4842,4843],"200mg Spironolactone","5mg Finasteride",{"trials":4845,"activeCount":103},[],{"intervention":4842,"totalTrials":323,"cells":4847},{"EARLY_PHASE1":4848,"PHASE1":4850,"PHASE2":4852,"PHASE3":4854,"PHASE4":4856,"NA":4862},{"trials":4849,"activeCount":103},[],{"trials":4851,"activeCount":103},[],{"trials":4853,"activeCount":103},[],{"trials":4855,"activeCount":103},[],{"trials":4857,"activeCount":103},[4858],{"nctId":4834,"briefTitle":4835,"status":257,"phases":4859,"primaryCompletion":4837,"completion":4837,"start":4838,"enrollment":103,"conditions":4860,"interventions":4861},[94],[4840],[4821,4842,4843],{"trials":4863,"activeCount":103},[],{"intervention":4843,"totalTrials":323,"cells":4865},{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4872,"PHASE4":4874,"NA":4880},{"trials":4867,"activeCount":103},[],{"trials":4869,"activeCount":103},[],{"trials":4871,"activeCount":103},[],{"trials":4873,"activeCount":103},[],{"trials":4875,"activeCount":103},[4876],{"nctId":4834,"briefTitle":4835,"status":257,"phases":4877,"primaryCompletion":4837,"completion":4837,"start":4838,"enrollment":103,"conditions":4878,"interventions":4879},[94],[4840],[4821,4842,4843],{"trials":4881,"activeCount":103},[],{"intervention":4883,"totalTrials":323,"cells":4884},"Fycompa",{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4889,"PHASE3":4891,"PHASE4":4893,"NA":4905},{"trials":4886,"activeCount":103},[],{"trials":4888,"activeCount":103},[],{"trials":4890,"activeCount":103},[],{"trials":4892,"activeCount":103},[],{"trials":4894,"activeCount":103},[4895],{"nctId":4896,"briefTitle":4897,"status":1053,"phases":4898,"primaryCompletion":4899,"completion":4899,"start":4900,"enrollment":1933,"conditions":4901,"interventions":4903},"NCT05201703","Fycompa in Catamenial Epilepsy",[94],"2023-12-15","2022-03-09",[4902],"Catamenial Epilepsy",[4883,4904],"Fycompa with a boost",{"trials":4906,"activeCount":103},[],{"intervention":4904,"totalTrials":323,"cells":4908},{"EARLY_PHASE1":4909,"PHASE1":4911,"PHASE2":4913,"PHASE3":4915,"PHASE4":4917,"NA":4923},{"trials":4910,"activeCount":103},[],{"trials":4912,"activeCount":103},[],{"trials":4914,"activeCount":103},[],{"trials":4916,"activeCount":103},[],{"trials":4918,"activeCount":103},[4919],{"nctId":4896,"briefTitle":4897,"status":1053,"phases":4920,"primaryCompletion":4899,"completion":4899,"start":4900,"enrollment":1933,"conditions":4921,"interventions":4922},[94],[4902],[4883,4904],{"trials":4924,"activeCount":103},[],{"intervention":4926,"totalTrials":210,"cells":4927},"Carboplatin",{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4946,"PHASE4":4958,"NA":4960},{"trials":4929,"activeCount":103},[],{"trials":4931,"activeCount":103},[],{"trials":4933,"activeCount":103},[4934],{"nctId":4935,"briefTitle":4936,"status":1053,"phases":4937,"primaryCompletion":4938,"completion":4939,"start":4940,"enrollment":1016,"conditions":4941,"interventions":4943},"NCT02920450","Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)",[91,92],"2019-01-02","2019-04-04","2017-09-25",[4942],"Non-Small Cell Lung Cancer",[4944,4945,4926],"Gedatolisib","Paclitaxel",{"trials":4947,"activeCount":103},[4948],{"nctId":4949,"briefTitle":4950,"status":1053,"phases":4951,"primaryCompletion":4952,"completion":4952,"start":780,"enrollment":323,"conditions":4953,"interventions":4955},"NCT02137096","Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma",[93],"2017-05-09",[4954],"Recurrent Nasopharynx Carcinoma",[4956,4926,4957],"Etoposide phosphate","Ifosfamide",{"trials":4959,"activeCount":103},[],{"trials":4961,"activeCount":103},[],{"intervention":4963,"totalTrials":210,"cells":4964},"Oxytocin",{"EARLY_PHASE1":4965,"PHASE1":4967,"PHASE2":4969,"PHASE3":4980,"PHASE4":4992,"NA":4994},{"trials":4966,"activeCount":103},[],{"trials":4968,"activeCount":103},[],{"trials":4970,"activeCount":103},[4971],{"nctId":4972,"briefTitle":4973,"status":115,"phases":4974,"primaryCompletion":4975,"completion":4975,"start":4976,"enrollment":1953,"conditions":4977,"interventions":4979},"NCT03245762","Intranasal Oxytocin for Infants With Prader-Willi Syndrome",[91,92],"2018-01-04","2017-08-01",[4978],"Prader-Willi Syndrome",[4963],{"trials":4981,"activeCount":103},[4982],{"nctId":4983,"briefTitle":4984,"status":115,"phases":4985,"primaryCompletion":4986,"completion":4986,"start":4987,"enrollment":4988,"conditions":4989,"interventions":4991},"NCT03878589","Understanding Cognition, Oxytocin & Pain in Elders",[92,93],"2024-12-19","2019-08-06",83,[4990,4131],"Knee Osteoarthritis",[4963],{"trials":4993,"activeCount":103},[],{"trials":4995,"activeCount":103},[],{"intervention":4997,"totalTrials":210,"cells":4998},"Topiramate",{"EARLY_PHASE1":4999,"PHASE1":5001,"PHASE2":5011,"PHASE3":5013,"PHASE4":5022,"NA":5024},{"trials":5000,"activeCount":103},[],{"trials":5002,"activeCount":103},[5003],{"nctId":5004,"briefTitle":5005,"status":115,"phases":5006,"primaryCompletion":2841,"completion":1174,"start":5007,"enrollment":2099,"conditions":5008,"interventions":5010},"NCT02884050","Physiologic Effects of Topiramate on Cognition",[91],"2009-04",[5009],"Alteration of Cognitive Function",[4997],{"trials":5012,"activeCount":103},[],{"trials":5014,"activeCount":103},[5015],{"nctId":5016,"briefTitle":5017,"status":115,"phases":5018,"primaryCompletion":5019,"completion":5019,"start":4102,"enrollment":3080,"conditions":5020,"interventions":5021},"NCT00187928","Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder",[93],"2006-03",[4106],[4997],{"trials":5023,"activeCount":103},[],{"trials":5025,"activeCount":103},[],{"intervention":4956,"totalTrials":323,"cells":5027},{"EARLY_PHASE1":5028,"PHASE1":5030,"PHASE2":5032,"PHASE3":5034,"PHASE4":5040,"NA":5042},{"trials":5029,"activeCount":103},[],{"trials":5031,"activeCount":103},[],{"trials":5033,"activeCount":103},[],{"trials":5035,"activeCount":103},[5036],{"nctId":4949,"briefTitle":4950,"status":1053,"phases":5037,"primaryCompletion":4952,"completion":4952,"start":780,"enrollment":323,"conditions":5038,"interventions":5039},[93],[4954],[4956,4926,4957],{"trials":5041,"activeCount":103},[],{"trials":5043,"activeCount":103},[],{"intervention":4957,"totalTrials":323,"cells":5045},{"EARLY_PHASE1":5046,"PHASE1":5048,"PHASE2":5050,"PHASE3":5052,"PHASE4":5058,"NA":5060},{"trials":5047,"activeCount":103},[],{"trials":5049,"activeCount":103},[],{"trials":5051,"activeCount":103},[],{"trials":5053,"activeCount":103},[5054],{"nctId":4949,"briefTitle":4950,"status":1053,"phases":5055,"primaryCompletion":4952,"completion":4952,"start":780,"enrollment":323,"conditions":5056,"interventions":5057},[93],[4954],[4956,4926,4957],{"trials":5059,"activeCount":103},[],{"trials":5061,"activeCount":103},[],{"intervention":2869,"totalTrials":323,"cells":5063},{"EARLY_PHASE1":5064,"PHASE1":5066,"PHASE2":5068,"PHASE3":5070,"PHASE4":5076,"NA":5078},{"trials":5065,"activeCount":103},[],{"trials":5067,"activeCount":103},[],{"trials":5069,"activeCount":103},[],{"trials":5071,"activeCount":103},[5072],{"nctId":2860,"briefTitle":2861,"status":115,"phases":5073,"primaryCompletion":720,"completion":720,"start":2863,"enrollment":2864,"conditions":5074,"interventions":5075},[93],[2866,2867,27],[2869,2812,2870],{"trials":5077,"activeCount":103},[],{"trials":5079,"activeCount":103},[],{"intervention":2870,"totalTrials":323,"cells":5081},{"EARLY_PHASE1":5082,"PHASE1":5084,"PHASE2":5086,"PHASE3":5088,"PHASE4":5094,"NA":5096},{"trials":5083,"activeCount":103},[],{"trials":5085,"activeCount":103},[],{"trials":5087,"activeCount":103},[],{"trials":5089,"activeCount":103},[5090],{"nctId":2860,"briefTitle":2861,"status":115,"phases":5091,"primaryCompletion":720,"completion":720,"start":2863,"enrollment":2864,"conditions":5092,"interventions":5093},[93],[2866,2867,27],[2869,2812,2870],{"trials":5095,"activeCount":103},[],{"trials":5097,"activeCount":103},[],{"intervention":5099,"totalTrials":323,"cells":5100},"Glecaprevir\u002FPibrentasvir (G\u002FP) 300mg\u002F120mg",{"EARLY_PHASE1":5101,"PHASE1":5103,"PHASE2":5105,"PHASE3":5107,"PHASE4":5121,"NA":5123},{"trials":5102,"activeCount":103},[],{"trials":5104,"activeCount":103},[],{"trials":5106,"activeCount":103},[],{"trials":5108,"activeCount":103},[5109],{"nctId":5110,"briefTitle":5111,"status":115,"phases":5112,"primaryCompletion":5113,"completion":5114,"start":5115,"enrollment":5116,"conditions":5117,"interventions":5119},"NCT03092375","Multi-Center, Randomized, Open-Label Study of G\u002FP +\u002F- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects",[93],"2018-12-28","2020-02-06","2017-04-20",177,[2946,5118],"HCV",[5099,5120],"Ribavirin 200Mg",{"trials":5122,"activeCount":103},[],{"trials":5124,"activeCount":103},[],{"intervention":5120,"totalTrials":323,"cells":5126},{"EARLY_PHASE1":5127,"PHASE1":5129,"PHASE2":5131,"PHASE3":5133,"PHASE4":5139,"NA":5141},{"trials":5128,"activeCount":103},[],{"trials":5130,"activeCount":103},[],{"trials":5132,"activeCount":103},[],{"trials":5134,"activeCount":103},[5135],{"nctId":5110,"briefTitle":5111,"status":115,"phases":5136,"primaryCompletion":5113,"completion":5114,"start":5115,"enrollment":5116,"conditions":5137,"interventions":5138},[93],[2946,5118],[5099,5120],{"trials":5140,"activeCount":103},[],{"trials":5142,"activeCount":103},[],{"intervention":5144,"totalTrials":323,"cells":5145},"Curcumin",{"EARLY_PHASE1":5146,"PHASE1":5148,"PHASE2":5150,"PHASE3":5152,"PHASE4":5167,"NA":5169},{"trials":5147,"activeCount":103},[],{"trials":5149,"activeCount":103},[],{"trials":5151,"activeCount":103},[],{"trials":5153,"activeCount":103},[5154],{"nctId":5155,"briefTitle":5156,"status":115,"phases":5157,"primaryCompletion":5158,"completion":5158,"start":5159,"enrollment":5160,"conditions":5161,"interventions":5165},"NCT03085680","Curcumin and Function in Older Adults",[92,93],"2019-10-18","2017-08-11",17,[5162,5163,5164],"Older Adults","Physical Function","Cognitive Function",[5144,5166],"microcrystalline cellulose",{"trials":5168,"activeCount":103},[],{"trials":5170,"activeCount":103},[],{"intervention":5166,"totalTrials":323,"cells":5172},{"EARLY_PHASE1":5173,"PHASE1":5175,"PHASE2":5177,"PHASE3":5179,"PHASE4":5185,"NA":5187},{"trials":5174,"activeCount":103},[],{"trials":5176,"activeCount":103},[],{"trials":5178,"activeCount":103},[],{"trials":5180,"activeCount":103},[5181],{"nctId":5155,"briefTitle":5156,"status":115,"phases":5182,"primaryCompletion":5158,"completion":5158,"start":5159,"enrollment":5160,"conditions":5183,"interventions":5184},[92,93],[5162,5163,5164],[5144,5166],{"trials":5186,"activeCount":103},[],{"trials":5188,"activeCount":103},[],{"intervention":5190,"totalTrials":323,"cells":5191},"Next Generation ORS (oral rehydration solution) (including placebo",{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5198,"PHASE4":5211,"NA":5213},{"trials":5193,"activeCount":103},[],{"trials":5195,"activeCount":103},[],{"trials":5197,"activeCount":103},[],{"trials":5199,"activeCount":103},[5200],{"nctId":5201,"briefTitle":5202,"status":115,"phases":5203,"primaryCompletion":3880,"completion":3880,"start":5204,"enrollment":5205,"conditions":5206,"interventions":5209},"NCT05814042","Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea",[92,93],"2023-08-21",396,[5207,5208],"Diarrhea","Cholera",[5190,5210],"Current standard control ORS",{"trials":5212,"activeCount":103},[],{"trials":5214,"activeCount":103},[],{"intervention":5210,"totalTrials":323,"cells":5216},{"EARLY_PHASE1":5217,"PHASE1":5219,"PHASE2":5221,"PHASE3":5223,"PHASE4":5229,"NA":5231},{"trials":5218,"activeCount":103},[],{"trials":5220,"activeCount":103},[],{"trials":5222,"activeCount":103},[],{"trials":5224,"activeCount":103},[5225],{"nctId":5201,"briefTitle":5202,"status":115,"phases":5226,"primaryCompletion":3880,"completion":3880,"start":5204,"enrollment":5205,"conditions":5227,"interventions":5228},[92,93],[5207,5208],[5190,5210],{"trials":5230,"activeCount":103},[],{"trials":5232,"activeCount":103},[],{"intervention":5234,"totalTrials":323,"cells":5235},"Liposomal curcumin",{"EARLY_PHASE1":5236,"PHASE1":5238,"PHASE2":5240,"PHASE3":5242,"PHASE4":5254,"NA":5256},{"trials":5237,"activeCount":103},[],{"trials":5239,"activeCount":103},[],{"trials":5241,"activeCount":103},[],{"trials":5243,"activeCount":103},[5244],{"nctId":5245,"briefTitle":5246,"status":115,"phases":5247,"primaryCompletion":5248,"completion":5248,"start":5249,"enrollment":2054,"conditions":5250,"interventions":5252},"NCT06381076","High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.",[93],"2025-05-13","2025-02-03",[5251],"Chronic Kidney Disease 5D",[5234,5253],"Food colorant",{"trials":5255,"activeCount":103},[],{"trials":5257,"activeCount":103},[],{"intervention":5253,"totalTrials":323,"cells":5259},{"EARLY_PHASE1":5260,"PHASE1":5262,"PHASE2":5264,"PHASE3":5266,"PHASE4":5272,"NA":5274},{"trials":5261,"activeCount":103},[],{"trials":5263,"activeCount":103},[],{"trials":5265,"activeCount":103},[],{"trials":5267,"activeCount":103},[5268],{"nctId":5245,"briefTitle":5246,"status":115,"phases":5269,"primaryCompletion":5248,"completion":5248,"start":5249,"enrollment":2054,"conditions":5270,"interventions":5271},[93],[5251],[5234,5253],{"trials":5273,"activeCount":103},[],{"trials":5275,"activeCount":103},[],{"intervention":5277,"totalTrials":323,"cells":5278},"Phentermine \u002F Topiramate Oral Product",{"EARLY_PHASE1":5279,"PHASE1":5281,"PHASE2":5283,"PHASE3":5285,"PHASE4":5298,"NA":5300},{"trials":5280,"activeCount":103},[],{"trials":5282,"activeCount":103},[],{"trials":5284,"activeCount":103},[],{"trials":5286,"activeCount":103},[5287],{"nctId":5288,"briefTitle":5289,"status":115,"phases":5290,"primaryCompletion":5291,"completion":5291,"start":4281,"enrollment":37,"conditions":5292,"interventions":5296},"NCT04621929","Phentermine\u002FTopiramate for Uric Acid Stones",[93],"2024-11-14",[24,5293,5294,5295],"Uric Acid Stones","Type 2 Diabetes Mellitus in Obese","Pre-Diabetes",[5277,5297],"Citrate Salts, Allopurinol, Diet",{"trials":5299,"activeCount":103},[],{"trials":5301,"activeCount":103},[],{"intervention":5297,"totalTrials":323,"cells":5303},{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5308,"PHASE3":5310,"PHASE4":5316,"NA":5318},{"trials":5305,"activeCount":103},[],{"trials":5307,"activeCount":103},[],{"trials":5309,"activeCount":103},[],{"trials":5311,"activeCount":103},[5312],{"nctId":5288,"briefTitle":5289,"status":115,"phases":5313,"primaryCompletion":5291,"completion":5291,"start":4281,"enrollment":37,"conditions":5314,"interventions":5315},[93],[24,5293,5294,5295],[5277,5297],{"trials":5317,"activeCount":103},[],{"trials":5319,"activeCount":103},[],{"intervention":5321,"totalTrials":323,"cells":5322},"Bicalutamide 150 Mg Oral",{"EARLY_PHASE1":5323,"PHASE1":5325,"PHASE2":5327,"PHASE3":5329,"PHASE4":5340,"NA":5342},{"trials":5324,"activeCount":103},[],{"trials":5326,"activeCount":103},[],{"trials":5328,"activeCount":103},[],{"trials":5330,"activeCount":103},[5331],{"nctId":5332,"briefTitle":5333,"status":257,"phases":5334,"primaryCompletion":5335,"completion":5335,"start":5336,"enrollment":103,"conditions":5337,"interventions":5339},"NCT04509999","Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection",[93],"2021-06-30","2020-10-26",[5338],"COVID-19",[5321],{"trials":5341,"activeCount":103},[],{"trials":5343,"activeCount":103},[],{"intervention":5345,"totalTrials":323,"cells":5346},"CoenzymeQ10",{"EARLY_PHASE1":5347,"PHASE1":5349,"PHASE2":5351,"PHASE3":5353,"PHASE4":5364,"NA":5366},{"trials":5348,"activeCount":103},[],{"trials":5350,"activeCount":103},[],{"trials":5352,"activeCount":103},[],{"trials":5354,"activeCount":103},[5355],{"nctId":5356,"briefTitle":5357,"status":115,"phases":5358,"primaryCompletion":5359,"completion":5359,"start":5360,"enrollment":2043,"conditions":5361,"interventions":5363},"NCT00432744","Phase III Trial of Coenzyme Q10 in Mitochondrial Disease",[93],"2013-05","2007-01",[5362],"Mitochondrial Diseases",[5345],{"trials":5365,"activeCount":103},[],{"trials":5367,"activeCount":103},[],{"intervention":5369,"totalTrials":323,"cells":5370},"Saline Nasal",{"EARLY_PHASE1":5371,"PHASE1":5373,"PHASE2":5375,"PHASE3":5377,"PHASE4":5390,"NA":5392},{"trials":5372,"activeCount":103},[],{"trials":5374,"activeCount":103},[],{"trials":5376,"activeCount":103},[],{"trials":5378,"activeCount":103},[5379],{"nctId":5380,"briefTitle":5381,"status":257,"phases":5382,"primaryCompletion":5383,"completion":5384,"start":5385,"enrollment":103,"conditions":5386,"interventions":5387},"NCT03303677","Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients",[93],"2018-11-01","2019-11-01","2018-04-01",[1571],[5369,5388,5389],"Budesonide Nasal","Topical Antibacterial",{"trials":5391,"activeCount":103},[],{"trials":5393,"activeCount":103},[],{"intervention":5388,"totalTrials":323,"cells":5395},{"EARLY_PHASE1":5396,"PHASE1":5398,"PHASE2":5400,"PHASE3":5402,"PHASE4":5408,"NA":5410},{"trials":5397,"activeCount":103},[],{"trials":5399,"activeCount":103},[],{"trials":5401,"activeCount":103},[],{"trials":5403,"activeCount":103},[5404],{"nctId":5380,"briefTitle":5381,"status":257,"phases":5405,"primaryCompletion":5383,"completion":5384,"start":5385,"enrollment":103,"conditions":5406,"interventions":5407},[93],[1571],[5369,5388,5389],{"trials":5409,"activeCount":103},[],{"trials":5411,"activeCount":103},[],{"intervention":5389,"totalTrials":323,"cells":5413},{"EARLY_PHASE1":5414,"PHASE1":5416,"PHASE2":5418,"PHASE3":5420,"PHASE4":5426,"NA":5428},{"trials":5415,"activeCount":103},[],{"trials":5417,"activeCount":103},[],{"trials":5419,"activeCount":103},[],{"trials":5421,"activeCount":103},[5422],{"nctId":5380,"briefTitle":5381,"status":257,"phases":5423,"primaryCompletion":5383,"completion":5384,"start":5385,"enrollment":103,"conditions":5424,"interventions":5425},[93],[1571],[5369,5388,5389],{"trials":5427,"activeCount":103},[],{"trials":5429,"activeCount":103},[],{"intervention":5431,"totalTrials":323,"cells":5432},"sodium dichloroacetate",{"EARLY_PHASE1":5433,"PHASE1":5435,"PHASE2":5437,"PHASE3":5439,"PHASE4":5450,"NA":5452},{"trials":5434,"activeCount":103},[],{"trials":5436,"activeCount":103},[],{"trials":5438,"activeCount":103},[],{"trials":5440,"activeCount":103},[5441],{"nctId":5442,"briefTitle":5443,"status":115,"phases":5444,"completion":5445,"start":5446,"enrollment":1291,"conditions":5447,"interventions":5449},"NCT00004490","Phase III Randomized Study of Sodium Dichloroacetate in Children With Congenital Lactic Acidosis",[93],"2002-09","1998-10",[5448],"Lactic Acidosis",[5431],{"trials":5451,"activeCount":103},[],{"trials":5453,"activeCount":103},[],{"intervention":5455,"totalTrials":1016,"cells":5456},"Cytarabine",{"EARLY_PHASE1":5457,"PHASE1":5459,"PHASE2":5461,"PHASE3":5492,"PHASE4":5494,"NA":5496},{"trials":5458,"activeCount":103},[],{"trials":5460,"activeCount":103},[],{"trials":5462,"activeCount":103},[5463,5473,5481],{"nctId":5464,"briefTitle":5465,"status":257,"phases":5466,"primaryCompletion":1108,"completion":5467,"start":5468,"enrollment":103,"conditions":5469,"interventions":5471},"NCT03207334","iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)",[92],"2022-01","2018-11",[5470],"Acute Myeloid Leukemia",[5472,5455],"Midostaurin",{"nctId":5474,"briefTitle":5475,"status":1053,"phases":5476,"primaryCompletion":5477,"completion":52,"start":5478,"enrollment":250,"conditions":5479,"interventions":5480},"NCT04914676","Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission",[92],"2024-01-12","2022-03-08",[5470],[5455,5455],{"nctId":5482,"briefTitle":5483,"status":257,"phases":5484,"primaryCompletion":2061,"completion":2041,"start":944,"enrollment":103,"conditions":5485,"interventions":5487},"NCT05766514","Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction",[92],[5470,5486],"Myelodysplastic Syndromes",[5488,5455,5489,5490,5491],"Cladribine","Decitabine","azacitidine or decitabine","Venetoclax",{"trials":5493,"activeCount":103},[],{"trials":5495,"activeCount":103},[],{"trials":5497,"activeCount":103},[],{"intervention":5499,"totalTrials":210,"cells":5500},"Diphenhydramine",{"EARLY_PHASE1":5501,"PHASE1":5503,"PHASE2":5520,"PHASE3":5533,"PHASE4":5535,"NA":5537},{"trials":5502,"activeCount":103},[],{"trials":5504,"activeCount":103},[5505],{"nctId":5506,"briefTitle":5507,"status":115,"phases":5508,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":210,"conditions":5511,"interventions":5513},"NCT02240407","Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease",[91],"2021-08-26","2017-10-17",[5512],"Pompe Disease",[5514,5515,5516,5499,5517,5518,5519],"Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase","Rapamycin","Rituxan","Acetaminophen","Lidocaine","LMX 4 Topical Cream",{"trials":5521,"activeCount":103},[5522],{"nctId":5523,"briefTitle":5524,"status":115,"phases":5525,"primaryCompletion":169,"completion":169,"start":169,"enrollment":1016,"conditions":5526,"interventions":5529},"NCT02142712","Histamine Glutamate Antagonism in Stroke",[92],[5527,5528],"Acute Cerebrovascular Accident","Cerebral Edema",[5499,5530,5531,5532],"Pantoprazole","Famotidine","Dextromethorphan",{"trials":5534,"activeCount":103},[],{"trials":5536,"activeCount":103},[],{"trials":5538,"activeCount":103},[],{"intervention":1037,"totalTrials":210,"cells":5540},{"EARLY_PHASE1":5541,"PHASE1":5543,"PHASE2":5545,"PHASE3":5566,"PHASE4":5568,"NA":5570},{"trials":5542,"activeCount":103},[],{"trials":5544,"activeCount":103},[],{"trials":5546,"activeCount":103},[5547,5551],{"nctId":1025,"briefTitle":1026,"status":1027,"phases":5548,"start":1029,"enrollment":34,"conditions":5549,"interventions":5550},[92],[1031,1032,1033],[1035,1036,1037],{"nctId":5552,"briefTitle":5553,"status":1053,"phases":5554,"primaryCompletion":5555,"completion":5556,"start":5557,"enrollment":2099,"conditions":5558,"interventions":5561},"NCT02773732","Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)",[91,92],"2021-09-07","2021-11-15","2016-12-16",[5559,5560,5470],"Leukemia","Acute Myelogenous Leukemia",[5562,5563,5564,5565],"Ciprofloxacin 750 MG","Etoposide","Ciprofloxacin 1000 MG","Ciprofloxacin 500 mg",{"trials":5567,"activeCount":103},[],{"trials":5569,"activeCount":103},[],{"trials":5571,"activeCount":103},[],{"intervention":5573,"totalTrials":210,"cells":5574},"Kava Dietary Supplement",{"EARLY_PHASE1":5575,"PHASE1":5577,"PHASE2":5589,"PHASE3":5599,"PHASE4":5601,"NA":5603},{"trials":5576,"activeCount":103},[],{"trials":5578,"activeCount":103},[5579],{"nctId":5580,"briefTitle":5581,"status":115,"phases":5582,"primaryCompletion":5583,"completion":5584,"start":5585,"enrollment":695,"conditions":5586,"interventions":5588},"NCT03843502","A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics",[91],"2021-04-21","2021-07-13","2020-02-26",[5587],"Pharmacokinetics",[5573],{"trials":5590,"activeCount":103},[5591],{"nctId":5592,"briefTitle":5593,"status":115,"phases":5594,"primaryCompletion":5595,"completion":5595,"start":5596,"enrollment":2054,"conditions":5597,"interventions":5598},"NCT04565145","Biomarker Changes and Anxiolytic Effects-Phase 2",[92],"2023-07-01","2021-04-05",[5587],[5573],{"trials":5600,"activeCount":103},[],{"trials":5602,"activeCount":103},[],{"trials":5604,"activeCount":103},[],{"intervention":5606,"totalTrials":210,"cells":5607},"Smoflipid",{"EARLY_PHASE1":5608,"PHASE1":5610,"PHASE2":5612,"PHASE3":5635,"PHASE4":5637,"NA":5639},{"trials":5609,"activeCount":103},[],{"trials":5611,"activeCount":103},[],{"trials":5613,"activeCount":103},[5614,5625],{"nctId":5615,"briefTitle":5616,"status":115,"phases":5617,"primaryCompletion":5618,"completion":5618,"start":5619,"enrollment":5620,"conditions":5621,"interventions":5624},"NCT03405870","LIPIDS-P Trial Phase I\u002FII Trial",[91,92],"2023-04-26","2018-08-17",59,[5622,5623],"Sepsis, Severe","Septic Shock",[5606],{"nctId":5626,"briefTitle":5627,"status":1053,"phases":5628,"primaryCompletion":3079,"completion":5629,"start":4195,"enrollment":210,"conditions":5630,"interventions":5633},"NCT02721277","SMOFlipid to Lessen the Severity of Neonatal Cholestasis",[91,92],"2017-02-02",[5631,5632],"Cholestasis","Jaundice, Obstructive",[5634],"SMOFlipid",{"trials":5636,"activeCount":103},[],{"trials":5638,"activeCount":103},[],{"trials":5640,"activeCount":103},[],{"intervention":5642,"totalTrials":210,"cells":5643},"TAS-102",{"EARLY_PHASE1":5644,"PHASE1":5646,"PHASE2":5648,"PHASE3":5668,"PHASE4":5670,"NA":5672},{"trials":5645,"activeCount":103},[],{"trials":5647,"activeCount":103},[],{"trials":5649,"activeCount":103},[5650,5660],{"nctId":5651,"briefTitle":5652,"status":115,"phases":5653,"primaryCompletion":5654,"completion":5655,"start":5656,"enrollment":328,"conditions":5657,"interventions":5659},"NCT02920476","TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)",[92],"2018-12-03","2021-08-14","2017-07-19",[5658],"Squamous Cell Lung Carcinoma",[5642],{"nctId":5661,"briefTitle":5662,"status":1053,"phases":5663,"primaryCompletion":5664,"completion":5664,"start":5665,"enrollment":1933,"conditions":5666,"interventions":5667},"NCT02921737","TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)",[92],"2020-07-26","2017-11-09",[1089],[5642],{"trials":5669,"activeCount":103},[],{"trials":5671,"activeCount":103},[],{"trials":5673,"activeCount":103},[],{"intervention":5675,"totalTrials":210,"cells":5676},"L. johnsonii Probiotic",{"EARLY_PHASE1":5677,"PHASE1":5679,"PHASE2":5681,"PHASE3":5700,"PHASE4":5702,"NA":5704},{"trials":5678,"activeCount":103},[],{"trials":5680,"activeCount":103},[],{"trials":5682,"activeCount":103},[5683,5693],{"nctId":5684,"briefTitle":5685,"status":115,"phases":5686,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5690,"interventions":5692},"NCT03961347","Lactobacillus Johnsonii Supplementation in Adults With T1D",[92],"2026-03-18","2020-02-01",46,[5691],"Type 1 Diabetes (T1D)",[5675],{"nctId":5694,"briefTitle":5695,"status":115,"phases":5696,"primaryCompletion":82,"completion":82,"start":5697,"enrollment":1272,"conditions":5698,"interventions":5699},"NCT03961854","Lactobacillus Johnsonii in Children and Adolescents With T1D",[92],"2019-10-10",[5691],[5675],{"trials":5701,"activeCount":103},[],{"trials":5703,"activeCount":103},[],{"trials":5705,"activeCount":103},[],{"intervention":5707,"totalTrials":210,"cells":5708},"Dasatinib",{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5721,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5710,"activeCount":103},[],{"trials":5712,"activeCount":103},[5713],{"nctId":5714,"briefTitle":5715,"status":257,"phases":5716,"primaryCompletion":734,"completion":734,"start":3044,"enrollment":103,"conditions":5717,"interventions":5719},"NCT02129166","Explore the Synergy of Combination TKI Therapy",[91],[5718],"Healthy Volunteers",[5707,5720],"Dasatinib+Imatinib",{"trials":5722,"activeCount":103},[5723],{"nctId":5724,"briefTitle":5725,"status":115,"phases":5726,"primaryCompletion":5727,"completion":5728,"start":5729,"enrollment":3401,"conditions":5730,"interventions":5732},"NCT01652976","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",[92],"2018-02","2020-07","2012-07",[5731],"Pancreatic Cancer Metastatic",[5707,5733],"mFOLFOX6",{"trials":5735,"activeCount":103},[],{"trials":5737,"activeCount":103},[],{"trials":5739,"activeCount":103},[],{"intervention":5741,"totalTrials":210,"cells":5742},"Fermented Papaya Preparation",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5755,"PHASE3":5765,"PHASE4":5767,"NA":5769},{"trials":5744,"activeCount":103},[],{"trials":5746,"activeCount":103},[5747],{"nctId":5748,"briefTitle":5749,"status":115,"phases":5750,"primaryCompletion":3079,"completion":3079,"start":734,"enrollment":1272,"conditions":5751,"interventions":5753},"NCT02051634","Papaya Study ID:20140628",[91],[5752,21],"Systemic Inflammation",[5741,5754],"Sugar Pill",{"trials":5756,"activeCount":103},[5757],{"nctId":5758,"briefTitle":5759,"status":115,"phases":5760,"primaryCompletion":5761,"completion":5761,"start":2528,"enrollment":1272,"conditions":5762,"interventions":5764},"NCT02771366","The Efficient Brain Study",[92],"2018-07-27",[5763],"Metabolism - Cerebral Energy",[5741],{"trials":5766,"activeCount":103},[],{"trials":5768,"activeCount":103},[],{"trials":5770,"activeCount":103},[],{"intervention":5489,"totalTrials":210,"cells":5772},{"EARLY_PHASE1":5773,"PHASE1":5775,"PHASE2":5788,"PHASE3":5794,"PHASE4":5796,"NA":5798},{"trials":5774,"activeCount":103},[],{"trials":5776,"activeCount":103},[5777],{"nctId":5778,"briefTitle":5779,"status":115,"phases":5780,"primaryCompletion":5781,"completion":5782,"start":734,"enrollment":1016,"conditions":5783,"interventions":5787},"NCT02264873","Phase I, Dose Escalation Study of Decitabine",[91],"2016-10","2018-09-18",[5784,5785,5786],"Leukemia, Lymphoblastic, Acute","Leukemia, Myeloid Acute","Hematopoetic Myelodysplasia",[5489],{"trials":5789,"activeCount":103},[5790],{"nctId":5482,"briefTitle":5483,"status":257,"phases":5791,"primaryCompletion":2061,"completion":2041,"start":944,"enrollment":103,"conditions":5792,"interventions":5793},[92],[5470,5486],[5488,5455,5489,5490,5491],{"trials":5795,"activeCount":103},[],{"trials":5797,"activeCount":103},[],{"trials":5799,"activeCount":103},[],{"intervention":5801,"totalTrials":323,"cells":5802},"Telaprevir and Sofosbuvir",{"EARLY_PHASE1":5803,"PHASE1":5805,"PHASE2":5807,"PHASE3":5817,"PHASE4":5819,"NA":5821},{"trials":5804,"activeCount":103},[],{"trials":5806,"activeCount":103},[],{"trials":5808,"activeCount":103},[5809],{"nctId":5810,"briefTitle":5811,"status":115,"phases":5812,"primaryCompletion":2808,"completion":3044,"start":5813,"enrollment":34,"conditions":5814,"interventions":5816},"NCT01994486","Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1",[92],"2013-12",[5815],"Hepatitis C, Chronic",[5801],{"trials":5818,"activeCount":103},[],{"trials":5820,"activeCount":103},[],{"trials":5822,"activeCount":103},[],{"intervention":5824,"totalTrials":323,"cells":5825},"Intravenous Ibuprofen",{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5830,"PHASE3":5842,"PHASE4":5844,"NA":5846},{"trials":5827,"activeCount":103},[],{"trials":5829,"activeCount":103},[],{"trials":5831,"activeCount":103},[5832],{"nctId":5833,"briefTitle":5834,"status":257,"phases":5835,"primaryCompletion":5836,"completion":5836,"start":5837,"enrollment":103,"conditions":5838,"interventions":5840},"NCT04026464","Addition of Acetaminophen in Standard PDA Management",[92],"2021-05-12","2021-04",[5839],"Patent Ductus Arteriosus",[5824,5841],"Intravenous Ibuprofen + Oral Acetaminophen",{"trials":5843,"activeCount":103},[],{"trials":5845,"activeCount":103},[],{"trials":5847,"activeCount":103},[],{"intervention":5841,"totalTrials":323,"cells":5849},{"EARLY_PHASE1":5850,"PHASE1":5852,"PHASE2":5854,"PHASE3":5860,"PHASE4":5862,"NA":5864},{"trials":5851,"activeCount":103},[],{"trials":5853,"activeCount":103},[],{"trials":5855,"activeCount":103},[5856],{"nctId":5833,"briefTitle":5834,"status":257,"phases":5857,"primaryCompletion":5836,"completion":5836,"start":5837,"enrollment":103,"conditions":5858,"interventions":5859},[92],[5839],[5824,5841],{"trials":5861,"activeCount":103},[],{"trials":5863,"activeCount":103},[],{"trials":5865,"activeCount":103},[],{"intervention":949,"totalTrials":323,"cells":5867},{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5872,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5869,"activeCount":103},[],{"trials":5871,"activeCount":103},[],{"trials":5873,"activeCount":103},[5874],{"nctId":938,"briefTitle":939,"status":940,"phases":5875,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":5876,"interventions":5877},[91,92],[947],[949,913],{"trials":5879,"activeCount":103},[],{"trials":5881,"activeCount":103},[],{"trials":5883,"activeCount":103},[],{"intervention":5885,"totalTrials":323,"cells":5886},"Nanodox 1%",{"EARLY_PHASE1":5887,"PHASE1":5889,"PHASE2":5891,"PHASE3":5902,"PHASE4":5904,"NA":5906},{"trials":5888,"activeCount":103},[],{"trials":5890,"activeCount":103},[],{"trials":5892,"activeCount":103},[5893],{"nctId":5894,"briefTitle":5895,"status":115,"phases":5896,"primaryCompletion":5897,"completion":5897,"start":5898,"enrollment":28,"conditions":5899,"interventions":5901},"NCT02910011","Topical NanoDox® for Atopic Dermatitis",[92],"2018-11-30","2017-05-18",[5900],"Dermatitis, Atopic",[5885],{"trials":5903,"activeCount":103},[],{"trials":5905,"activeCount":103},[],{"trials":5907,"activeCount":103},[],{"intervention":5530,"totalTrials":323,"cells":5909},{"EARLY_PHASE1":5910,"PHASE1":5912,"PHASE2":5914,"PHASE3":5920,"PHASE4":5922,"NA":5924},{"trials":5911,"activeCount":103},[],{"trials":5913,"activeCount":103},[],{"trials":5915,"activeCount":103},[5916],{"nctId":5523,"briefTitle":5524,"status":115,"phases":5917,"primaryCompletion":169,"completion":169,"start":169,"enrollment":1016,"conditions":5918,"interventions":5919},[92],[5527,5528],[5499,5530,5531,5532],{"trials":5921,"activeCount":103},[],{"trials":5923,"activeCount":103},[],{"trials":5925,"activeCount":103},[],{"intervention":5531,"totalTrials":323,"cells":5927},{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5938,"PHASE4":5940,"NA":5942},{"trials":5929,"activeCount":103},[],{"trials":5931,"activeCount":103},[],{"trials":5933,"activeCount":103},[5934],{"nctId":5523,"briefTitle":5524,"status":115,"phases":5935,"primaryCompletion":169,"completion":169,"start":169,"enrollment":1016,"conditions":5936,"interventions":5937},[92],[5527,5528],[5499,5530,5531,5532],{"trials":5939,"activeCount":103},[],{"trials":5941,"activeCount":103},[],{"trials":5943,"activeCount":103},[],{"intervention":5532,"totalTrials":323,"cells":5945},{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5950,"PHASE3":5956,"PHASE4":5958,"NA":5960},{"trials":5947,"activeCount":103},[],{"trials":5949,"activeCount":103},[],{"trials":5951,"activeCount":103},[5952],{"nctId":5523,"briefTitle":5524,"status":115,"phases":5953,"primaryCompletion":169,"completion":169,"start":169,"enrollment":1016,"conditions":5954,"interventions":5955},[92],[5527,5528],[5499,5530,5531,5532],{"trials":5957,"activeCount":103},[],{"trials":5959,"activeCount":103},[],{"trials":5961,"activeCount":103},[],{"intervention":1035,"totalTrials":323,"cells":5963},{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5968,"PHASE3":5974,"PHASE4":5976,"NA":5978},{"trials":5965,"activeCount":103},[],{"trials":5967,"activeCount":103},[],{"trials":5969,"activeCount":103},[5970],{"nctId":1025,"briefTitle":1026,"status":1027,"phases":5971,"start":1029,"enrollment":34,"conditions":5972,"interventions":5973},[92],[1031,1032,1033],[1035,1036,1037],{"trials":5975,"activeCount":103},[],{"trials":5977,"activeCount":103},[],{"trials":5979,"activeCount":103},[],{"intervention":5981,"totalTrials":323,"cells":5982},"Tranexamic acid",{"EARLY_PHASE1":5983,"PHASE1":5985,"PHASE2":5987,"PHASE3":5997,"PHASE4":5999,"NA":6001},{"trials":5984,"activeCount":103},[],{"trials":5986,"activeCount":103},[],{"trials":5988,"activeCount":103},[5989],{"nctId":5990,"briefTitle":5991,"status":257,"phases":5992,"primaryCompletion":984,"completion":984,"start":5993,"enrollment":103,"conditions":5994,"interventions":5996},"NCT06644079","Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma",[92],"2025-05",[5995],"Cutaneous Squamous Cell Carcinoma",[5981],{"trials":5998,"activeCount":103},[],{"trials":6000,"activeCount":103},[],{"trials":6002,"activeCount":103},[],{"intervention":4944,"totalTrials":323,"cells":6004},{"EARLY_PHASE1":6005,"PHASE1":6007,"PHASE2":6009,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":6006,"activeCount":103},[],{"trials":6008,"activeCount":103},[],{"trials":6010,"activeCount":103},[6011],{"nctId":4935,"briefTitle":4936,"status":1053,"phases":6012,"primaryCompletion":4938,"completion":4939,"start":4940,"enrollment":1016,"conditions":6013,"interventions":6014},[91,92],[4942],[4944,4945,4926],{"trials":6016,"activeCount":103},[],{"trials":6018,"activeCount":103},[],{"trials":6020,"activeCount":103},[],{"intervention":4945,"totalTrials":323,"cells":6022},{"EARLY_PHASE1":6023,"PHASE1":6025,"PHASE2":6027,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6024,"activeCount":103},[],{"trials":6026,"activeCount":103},[],{"trials":6028,"activeCount":103},[6029],{"nctId":4935,"briefTitle":4936,"status":1053,"phases":6030,"primaryCompletion":4938,"completion":4939,"start":4940,"enrollment":1016,"conditions":6031,"interventions":6032},[91,92],[4942],[4944,4945,4926],{"trials":6034,"activeCount":103},[],{"trials":6036,"activeCount":103},[],{"trials":6038,"activeCount":103},[],{"intervention":6040,"totalTrials":323,"cells":6041},"dextromethorphan HBr and quinidine sulfate",{"EARLY_PHASE1":6042,"PHASE1":6044,"PHASE2":6046,"PHASE3":6058,"PHASE4":6060,"NA":6062},{"trials":6043,"activeCount":103},[],{"trials":6045,"activeCount":103},[],{"trials":6047,"activeCount":103},[6048],{"nctId":6049,"briefTitle":6050,"status":115,"phases":6051,"primaryCompletion":6052,"completion":6053,"start":6054,"enrollment":2212,"conditions":6055,"interventions":6057},"NCT03883581","Impact of Nuedexta on Bulbar Physiology and Function in ALS",[91,92],"2021-09-13","2021-11-22","2019-07-25",[6056],"Amyotrophic Lateral Sclerosis",[6040],{"trials":6059,"activeCount":103},[],{"trials":6061,"activeCount":103},[],{"trials":6063,"activeCount":103},[],{"intervention":6065,"totalTrials":323,"cells":6066},"Cord blood",{"EARLY_PHASE1":6067,"PHASE1":6069,"PHASE2":6071,"PHASE3":6080,"PHASE4":6082,"NA":6084},{"trials":6068,"activeCount":103},[],{"trials":6070,"activeCount":103},[],{"trials":6072,"activeCount":103},[6073],{"nctId":6074,"briefTitle":6075,"status":115,"phases":6076,"primaryCompletion":720,"completion":720,"start":2893,"enrollment":28,"conditions":6077,"interventions":6079},"NCT00305344","Umbilical Cord Blood Infusion to Treat Type 1 Diabetes",[91,92],[6078],"Type 1 Diabetes Mellitus",[6065],{"trials":6081,"activeCount":103},[],{"trials":6083,"activeCount":103},[],{"trials":6085,"activeCount":103},[],{"intervention":6087,"totalTrials":323,"cells":6088},"Mesalamine",{"EARLY_PHASE1":6089,"PHASE1":6091,"PHASE2":6093,"PHASE3":6103,"PHASE4":6105,"NA":6107},{"trials":6090,"activeCount":103},[],{"trials":6092,"activeCount":103},[],{"trials":6094,"activeCount":103},[6095],{"nctId":6096,"briefTitle":6097,"status":115,"phases":6098,"primaryCompletion":4035,"completion":4035,"start":6099,"enrollment":1933,"conditions":6100,"interventions":6102},"NCT01327300","Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)",[92],"2010-03",[6101],"Irritable Bowel Syndrome",[6087],{"trials":6104,"activeCount":103},[],{"trials":6106,"activeCount":103},[],{"trials":6108,"activeCount":103},[],{"intervention":6110,"totalTrials":323,"cells":6111},"IV meropenem",{"EARLY_PHASE1":6112,"PHASE1":6114,"PHASE2":6116,"PHASE3":6130,"PHASE4":6132,"NA":6134},{"trials":6113,"activeCount":103},[],{"trials":6115,"activeCount":103},[],{"trials":6117,"activeCount":103},[6118],{"nctId":6119,"briefTitle":6120,"status":1053,"phases":6121,"primaryCompletion":6122,"completion":6122,"start":2630,"enrollment":6123,"conditions":6124,"interventions":6126},"NCT01570192","Clinical Trials to Reduce the Risk of Antimicrobial Resistance",[92],"2015-04",43,[6125],"Bacterial Pneumonia",[6110,6127,6128,6129],"I.V. Meropenem","Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg\u002Fkg IV q24h","Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.",{"trials":6131,"activeCount":103},[],{"trials":6133,"activeCount":103},[],{"trials":6135,"activeCount":103},[],{"intervention":6127,"totalTrials":323,"cells":6137},{"EARLY_PHASE1":6138,"PHASE1":6140,"PHASE2":6142,"PHASE3":6148,"PHASE4":6150,"NA":6152},{"trials":6139,"activeCount":103},[],{"trials":6141,"activeCount":103},[],{"trials":6143,"activeCount":103},[6144],{"nctId":6119,"briefTitle":6120,"status":1053,"phases":6145,"primaryCompletion":6122,"completion":6122,"start":2630,"enrollment":6123,"conditions":6146,"interventions":6147},[92],[6125],[6110,6127,6128,6129],{"trials":6149,"activeCount":103},[],{"trials":6151,"activeCount":103},[],{"trials":6153,"activeCount":103},[],{"intervention":6128,"totalTrials":323,"cells":6155},{"EARLY_PHASE1":6156,"PHASE1":6158,"PHASE2":6160,"PHASE3":6166,"PHASE4":6168,"NA":6170},{"trials":6157,"activeCount":103},[],{"trials":6159,"activeCount":103},[],{"trials":6161,"activeCount":103},[6162],{"nctId":6119,"briefTitle":6120,"status":1053,"phases":6163,"primaryCompletion":6122,"completion":6122,"start":2630,"enrollment":6123,"conditions":6164,"interventions":6165},[92],[6125],[6110,6127,6128,6129],{"trials":6167,"activeCount":103},[],{"trials":6169,"activeCount":103},[],{"trials":6171,"activeCount":103},[],{"intervention":6129,"totalTrials":323,"cells":6173},{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6178,"PHASE3":6184,"PHASE4":6186,"NA":6188},{"trials":6175,"activeCount":103},[],{"trials":6177,"activeCount":103},[],{"trials":6179,"activeCount":103},[6180],{"nctId":6119,"briefTitle":6120,"status":1053,"phases":6181,"primaryCompletion":6122,"completion":6122,"start":2630,"enrollment":6123,"conditions":6182,"interventions":6183},[92],[6125],[6110,6127,6128,6129],{"trials":6185,"activeCount":103},[],{"trials":6187,"activeCount":103},[],{"trials":6189,"activeCount":103},[],{"intervention":5472,"totalTrials":323,"cells":6191},{"EARLY_PHASE1":6192,"PHASE1":6194,"PHASE2":6196,"PHASE3":6202,"PHASE4":6204,"NA":6206},{"trials":6193,"activeCount":103},[],{"trials":6195,"activeCount":103},[],{"trials":6197,"activeCount":103},[6198],{"nctId":5464,"briefTitle":5465,"status":257,"phases":6199,"primaryCompletion":1108,"completion":5467,"start":5468,"enrollment":103,"conditions":6200,"interventions":6201},[92],[5470],[5472,5455],{"trials":6203,"activeCount":103},[],{"trials":6205,"activeCount":103},[],{"trials":6207,"activeCount":103},[],{"intervention":6209,"totalTrials":323,"cells":6210},"ATD Group",{"EARLY_PHASE1":6211,"PHASE1":6213,"PHASE2":6215,"PHASE3":6225,"PHASE4":6227,"NA":6229},{"trials":6212,"activeCount":103},[],{"trials":6214,"activeCount":103},[],{"trials":6216,"activeCount":103},[6217],{"nctId":6218,"briefTitle":6219,"status":115,"phases":6220,"primaryCompletion":3530,"completion":3530,"start":6221,"enrollment":37,"conditions":6222,"interventions":6224},"NCT01269749","Radioactive Iodide Therapy for Pediatric Graves' Disease",[92],"2010-10",[6223],"Graves' Disease",[6209],{"trials":6226,"activeCount":103},[],{"trials":6228,"activeCount":103},[],{"trials":6230,"activeCount":103},[],{"intervention":6232,"totalTrials":323,"cells":6233},"GTS-21",{"EARLY_PHASE1":6234,"PHASE1":6236,"PHASE2":6238,"PHASE3":6250,"PHASE4":6252,"NA":6254},{"trials":6235,"activeCount":103},[],{"trials":6237,"activeCount":103},[],{"trials":6239,"activeCount":103},[6240],{"nctId":6241,"briefTitle":6242,"status":257,"phases":6243,"primaryCompletion":6244,"completion":6245,"start":6246,"enrollment":103,"conditions":6247,"interventions":6249},"NCT02432066","Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions",[92],"2018-12-29","2020-12-29","2018-09-29",[6248],"Tobacco Use Disorder",[6232],{"trials":6251,"activeCount":103},[],{"trials":6253,"activeCount":103},[],{"trials":6255,"activeCount":103},[],{"intervention":6257,"totalTrials":323,"cells":6258},"Iodine I -01 Tositumomab",{"EARLY_PHASE1":6259,"PHASE1":6261,"PHASE2":6263,"PHASE3":6274,"PHASE4":6276,"NA":6278},{"trials":6260,"activeCount":103},[],{"trials":6262,"activeCount":103},[],{"trials":6264,"activeCount":103},[6265],{"nctId":6266,"briefTitle":6267,"status":1053,"phases":6268,"primaryCompletion":5007,"completion":5007,"start":6269,"enrollment":210,"conditions":6270,"interventions":6273},"NCT00475332","Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar",[92],"2007-09",[6271,6272],"Non-Hodgkin's Lymphoma","Follicular Lymphoma",[6257],{"trials":6275,"activeCount":103},[],{"trials":6277,"activeCount":103},[],{"trials":6279,"activeCount":103},[],{"intervention":6281,"totalTrials":323,"cells":6282},"Minocycline 50mg\u002Fd",{"EARLY_PHASE1":6283,"PHASE1":6285,"PHASE2":6287,"PHASE3":6296,"PHASE4":6298,"NA":6300},{"trials":6284,"activeCount":103},[],{"trials":6286,"activeCount":103},[],{"trials":6288,"activeCount":103},[6289],{"nctId":6290,"briefTitle":6291,"status":115,"phases":6292,"primaryCompletion":5383,"completion":5383,"start":734,"enrollment":19,"conditions":6293,"interventions":6294},"NCT02133872","Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients",[92],[27],[6281,6295],"Minocycline 100mg\u002Fd",{"trials":6297,"activeCount":103},[],{"trials":6299,"activeCount":103},[],{"trials":6301,"activeCount":103},[],{"intervention":6295,"totalTrials":323,"cells":6303},{"EARLY_PHASE1":6304,"PHASE1":6306,"PHASE2":6308,"PHASE3":6314,"PHASE4":6316,"NA":6318},{"trials":6305,"activeCount":103},[],{"trials":6307,"activeCount":103},[],{"trials":6309,"activeCount":103},[6310],{"nctId":6290,"briefTitle":6291,"status":115,"phases":6311,"primaryCompletion":5383,"completion":5383,"start":734,"enrollment":19,"conditions":6312,"interventions":6313},[92],[27],[6281,6295],{"trials":6315,"activeCount":103},[],{"trials":6317,"activeCount":103},[],{"trials":6319,"activeCount":103},[],{"intervention":6321,"totalTrials":323,"cells":6322},"L. johnsonii N6.2",{"EARLY_PHASE1":6323,"PHASE1":6325,"PHASE2":6327,"PHASE3":6336,"PHASE4":6338,"NA":6340},{"trials":6324,"activeCount":103},[],{"trials":6326,"activeCount":103},[],{"trials":6328,"activeCount":103},[6329],{"nctId":6330,"briefTitle":6331,"status":115,"phases":6332,"primaryCompletion":3079,"completion":3079,"start":733,"enrollment":6333,"conditions":6334,"interventions":6335},"NCT02349360","Safety, Tolerability and Host Response to Lactobacillus Johnsonii",[91,92],42,[15],[6321],{"trials":6337,"activeCount":103},[],{"trials":6339,"activeCount":103},[],{"trials":6341,"activeCount":103},[],{"intervention":6343,"totalTrials":323,"cells":6344},"CV9103",{"EARLY_PHASE1":6345,"PHASE1":6347,"PHASE2":6349,"PHASE3":6359,"PHASE4":6361,"NA":6363},{"trials":6346,"activeCount":103},[],{"trials":6348,"activeCount":103},[],{"trials":6350,"activeCount":103},[6351],{"nctId":6352,"briefTitle":6353,"status":1053,"phases":6354,"primaryCompletion":2841,"completion":2841,"start":6355,"enrollment":2714,"conditions":6356,"interventions":6358},"NCT00906243","RNActive®-Derived Therapeutic Vaccine",[91,92],"2009-05",[6357],"Hormone Refractory Prostate Cancer",[6343],{"trials":6360,"activeCount":103},[],{"trials":6362,"activeCount":103},[],{"trials":6364,"activeCount":103},[],{"intervention":6366,"totalTrials":323,"cells":6367},"Lanifibranor",{"EARLY_PHASE1":6368,"PHASE1":6370,"PHASE2":6372,"PHASE3":6385,"PHASE4":6387,"NA":6389},{"trials":6369,"activeCount":103},[],{"trials":6371,"activeCount":103},[],{"trials":6373,"activeCount":103},[6374],{"nctId":6375,"briefTitle":6376,"status":115,"phases":6377,"primaryCompletion":6378,"completion":3698,"start":6379,"enrollment":6380,"conditions":6381,"interventions":6384},"NCT03459079","Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease",[92],"2023-04-18","2018-08-14",128,[6382,6383],"Nonalcoholic Fatty Liver Disease (NAFLD)","Type 2 Diabetes (T2DM)",[6366],{"trials":6386,"activeCount":103},[],{"trials":6388,"activeCount":103},[],{"trials":6390,"activeCount":103},[],{"intervention":6392,"totalTrials":323,"cells":6393},"Plerixafor",{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6409,"PHASE4":6411,"NA":6413},{"trials":6395,"activeCount":103},[],{"trials":6397,"activeCount":103},[],{"trials":6399,"activeCount":103},[6400],{"nctId":6401,"briefTitle":6402,"status":115,"phases":6403,"primaryCompletion":6404,"completion":6404,"start":6405,"enrollment":3196,"conditions":6406,"interventions":6407},"NCT01339572","Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation",[92],"2015-11","2011-04",[6271,2694],[6392,6408],"Filgrastim",{"trials":6410,"activeCount":103},[],{"trials":6412,"activeCount":103},[],{"trials":6414,"activeCount":103},[],{"intervention":6408,"totalTrials":323,"cells":6416},{"EARLY_PHASE1":6417,"PHASE1":6419,"PHASE2":6421,"PHASE3":6427,"PHASE4":6429,"NA":6431},{"trials":6418,"activeCount":103},[],{"trials":6420,"activeCount":103},[],{"trials":6422,"activeCount":103},[6423],{"nctId":6401,"briefTitle":6402,"status":115,"phases":6424,"primaryCompletion":6404,"completion":6404,"start":6405,"enrollment":3196,"conditions":6425,"interventions":6426},[92],[6271,2694],[6392,6408],{"trials":6428,"activeCount":103},[],{"trials":6430,"activeCount":103},[],{"trials":6432,"activeCount":103},[],{"intervention":6434,"totalTrials":323,"cells":6435},"Healthy adults who receive capsaicin",{"EARLY_PHASE1":6436,"PHASE1":6438,"PHASE2":6440,"PHASE3":6449,"PHASE4":6451,"NA":6453},{"trials":6437,"activeCount":103},[],{"trials":6439,"activeCount":103},[],{"trials":6441,"activeCount":103},[6442],{"nctId":6443,"briefTitle":6444,"status":115,"phases":6445,"primaryCompletion":4449,"completion":4449,"start":5359,"enrollment":814,"conditions":6446,"interventions":6448},"NCT01854268","Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults",[91,92],[6447],"Cough",[6434],{"trials":6450,"activeCount":103},[],{"trials":6452,"activeCount":103},[],{"trials":6454,"activeCount":103},[],{"intervention":6456,"totalTrials":323,"cells":6457},"Sargramostim",{"EARLY_PHASE1":6458,"PHASE1":6460,"PHASE2":6462,"PHASE3":6474,"PHASE4":6476,"NA":6478},{"trials":6459,"activeCount":103},[],{"trials":6461,"activeCount":103},[],{"trials":6463,"activeCount":103},[6464],{"nctId":6465,"briefTitle":6466,"status":1053,"phases":6467,"primaryCompletion":6468,"completion":6468,"start":6469,"enrollment":328,"conditions":6470,"interventions":6472},"NCT03063242","Sargramostim for Myeloid Dendritic Cell Deficiency",[92],"2018-09-17","2017-02-23",[6471,2933],"Kidney Diseases",[6456,6473],"Blood samples",{"trials":6475,"activeCount":103},[],{"trials":6477,"activeCount":103},[],{"trials":6479,"activeCount":103},[],{"intervention":6473,"totalTrials":323,"cells":6481},{"EARLY_PHASE1":6482,"PHASE1":6484,"PHASE2":6486,"PHASE3":6492,"PHASE4":6494,"NA":6496},{"trials":6483,"activeCount":103},[],{"trials":6485,"activeCount":103},[],{"trials":6487,"activeCount":103},[6488],{"nctId":6465,"briefTitle":6466,"status":1053,"phases":6489,"primaryCompletion":6468,"completion":6468,"start":6469,"enrollment":328,"conditions":6490,"interventions":6491},[92],[6471,2933],[6456,6473],{"trials":6493,"activeCount":103},[],{"trials":6495,"activeCount":103},[],{"trials":6497,"activeCount":103},[],{"intervention":6499,"totalTrials":323,"cells":6500},"Anti-Thymocyte Globin",{"EARLY_PHASE1":6501,"PHASE1":6503,"PHASE2":6505,"PHASE3":6516,"PHASE4":6518,"NA":6520},{"trials":6502,"activeCount":103},[],{"trials":6504,"activeCount":103},[],{"trials":6506,"activeCount":103},[6507],{"nctId":6508,"briefTitle":6509,"status":115,"phases":6510,"primaryCompletion":4034,"completion":6511,"start":1952,"enrollment":814,"conditions":6512,"interventions":6514},"NCT01106157","Reversing Type 1 Diabetes After it is Established",[91,92],"2019-07-16",[6513],"Diabetes Mellitus, Type 1",[6499,6515],"Pegylated GCSF",{"trials":6517,"activeCount":103},[],{"trials":6519,"activeCount":103},[],{"trials":6521,"activeCount":103},[],{"intervention":6515,"totalTrials":323,"cells":6523},{"EARLY_PHASE1":6524,"PHASE1":6526,"PHASE2":6528,"PHASE3":6534,"PHASE4":6536,"NA":6538},{"trials":6525,"activeCount":103},[],{"trials":6527,"activeCount":103},[],{"trials":6529,"activeCount":103},[6530],{"nctId":6508,"briefTitle":6509,"status":115,"phases":6531,"primaryCompletion":4034,"completion":6511,"start":1952,"enrollment":814,"conditions":6532,"interventions":6533},[91,92],[6513],[6499,6515],{"trials":6535,"activeCount":103},[],{"trials":6537,"activeCount":103},[],{"trials":6539,"activeCount":103},[],{"intervention":6541,"totalTrials":323,"cells":6542},"Sirolimus",{"EARLY_PHASE1":6543,"PHASE1":6545,"PHASE2":6547,"PHASE3":6557,"PHASE4":6559,"NA":6561},{"trials":6544,"activeCount":103},[],{"trials":6546,"activeCount":103},[],{"trials":6548,"activeCount":103},[6549],{"nctId":6550,"briefTitle":6551,"status":1053,"phases":6552,"primaryCompletion":780,"completion":780,"start":6553,"enrollment":323,"conditions":6554,"interventions":6556},"NCT01764607","Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma",[92],"2013-04",[6555],"Squamous Cell Skin Carcinoma",[6541],{"trials":6558,"activeCount":103},[],{"trials":6560,"activeCount":103},[],{"trials":6562,"activeCount":103},[],{"intervention":6564,"totalTrials":323,"cells":6565},"Vigabatrin Only Product",{"EARLY_PHASE1":6566,"PHASE1":6568,"PHASE2":6570,"PHASE3":6583,"PHASE4":6585,"NA":6587},{"trials":6567,"activeCount":103},[],{"trials":6569,"activeCount":103},[],{"trials":6571,"activeCount":103},[6572],{"nctId":6573,"briefTitle":6574,"status":115,"phases":6575,"primaryCompletion":6576,"completion":6577,"start":6578,"enrollment":2714,"conditions":6579,"interventions":6582},"NCT04772547","VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa",[92],"2023-06-07","2024-01-23","2021-09-22",[6580,6581],"Status Epilepticus, Electrographic","Coma",[6564],{"trials":6584,"activeCount":103},[],{"trials":6586,"activeCount":103},[],{"trials":6588,"activeCount":103},[],{"intervention":6590,"totalTrials":323,"cells":6591},"Thiotepa--single daily dose",{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6596,"PHASE3":6624,"PHASE4":6626,"NA":6628},{"trials":6593,"activeCount":103},[],{"trials":6595,"activeCount":103},[],{"trials":6597,"activeCount":103},[6598],{"nctId":6599,"briefTitle":6600,"status":115,"phases":6601,"primaryCompletion":6602,"completion":6603,"start":6604,"enrollment":2714,"conditions":6605,"interventions":6622},"NCT03513328","Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation",[91,92],"2022-02-17","2023-02-19","2018-06-15",[6606,6607,6608,6609,6610,6611,6612,6613,6614,6615,6616,6617,6618,6619,6620,6621],"Bone Marrow Failure Syndrome","Thalassemia","Sickle Cell Disease","Diamond Blackfan Anemia","Acquired Neutropenia in Newborn","Acquired Anemia Hemolytic","Acquired Thrombocytopenia","Hemophagocytic Lymphohistiocytoses","Wiskott-Aldrich Syndrome","Chronic Granulomatous Disease","Common Variable Immunodeficiency","X-linked Lymphoproliferative Disease","Severe Combined Immunodeficiency","Hurler Syndrome","Mannosidosis","Adrenoleukodystrophy",[6590,6623],"Thiotepa--escalated dose",{"trials":6625,"activeCount":103},[],{"trials":6627,"activeCount":103},[],{"trials":6629,"activeCount":103},[],{"intervention":6623,"totalTrials":323,"cells":6631},{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6636,"PHASE3":6642,"PHASE4":6644,"NA":6646},{"trials":6633,"activeCount":103},[],{"trials":6635,"activeCount":103},[],{"trials":6637,"activeCount":103},[6638],{"nctId":6599,"briefTitle":6600,"status":115,"phases":6639,"primaryCompletion":6602,"completion":6603,"start":6604,"enrollment":2714,"conditions":6640,"interventions":6641},[91,92],[6606,6607,6608,6609,6610,6611,6612,6613,6614,6615,6616,6617,6618,6619,6620,6621],[6590,6623],{"trials":6643,"activeCount":103},[],{"trials":6645,"activeCount":103},[],{"trials":6647,"activeCount":103},[],{"intervention":282,"totalTrials":323,"cells":6649},{"EARLY_PHASE1":6650,"PHASE1":6652,"PHASE2":6654,"PHASE3":6660,"PHASE4":6662,"NA":6664},{"trials":6651,"activeCount":103},[],{"trials":6653,"activeCount":103},[],{"trials":6655,"activeCount":103},[6656],{"nctId":273,"briefTitle":274,"status":115,"phases":6657,"primaryCompletion":276,"completion":277,"start":278,"enrollment":130,"conditions":6658,"interventions":6659},[91,92],[280,33],[249,282],{"trials":6661,"activeCount":103},[],{"trials":6663,"activeCount":103},[],{"trials":6665,"activeCount":103},[],{"intervention":6667,"totalTrials":323,"cells":6668},"Bevacizumab",{"EARLY_PHASE1":6669,"PHASE1":6671,"PHASE2":6673,"PHASE3":6684,"PHASE4":6686,"NA":6688},{"trials":6670,"activeCount":103},[],{"trials":6672,"activeCount":103},[],{"trials":6674,"activeCount":103},[6675],{"nctId":6676,"briefTitle":6677,"status":1053,"phases":6678,"primaryCompletion":6679,"completion":6679,"start":6680,"enrollment":695,"conditions":6681,"interventions":6683},"NCT02663271","TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma",[92],"2021-06-11","2016-12-19",[1812,964,2114,6682],"GBM",[6667],{"trials":6685,"activeCount":103},[],{"trials":6687,"activeCount":103},[],{"trials":6689,"activeCount":103},[],{"intervention":6691,"totalTrials":323,"cells":6692},"Lactated Ringers",{"EARLY_PHASE1":6693,"PHASE1":6695,"PHASE2":6697,"PHASE3":6708,"PHASE4":6710,"NA":6712},{"trials":6694,"activeCount":103},[],{"trials":6696,"activeCount":103},[],{"trials":6698,"activeCount":103},[6699],{"nctId":6700,"briefTitle":6701,"status":115,"phases":6702,"primaryCompletion":6703,"completion":6703,"start":6704,"enrollment":2043,"conditions":6705,"interventions":6706},"NCT01770912","Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management",[92],"2019-01-24","2013-03",[33],[6691,6707],"Triamcinolone hexacetonide",{"trials":6709,"activeCount":103},[],{"trials":6711,"activeCount":103},[],{"trials":6713,"activeCount":103},[],{"intervention":6707,"totalTrials":323,"cells":6715},{"EARLY_PHASE1":6716,"PHASE1":6718,"PHASE2":6720,"PHASE3":6726,"PHASE4":6728,"NA":6730},{"trials":6717,"activeCount":103},[],{"trials":6719,"activeCount":103},[],{"trials":6721,"activeCount":103},[6722],{"nctId":6700,"briefTitle":6701,"status":115,"phases":6723,"primaryCompletion":6703,"completion":6703,"start":6704,"enrollment":2043,"conditions":6724,"interventions":6725},[92],[33],[6691,6707],{"trials":6727,"activeCount":103},[],{"trials":6729,"activeCount":103},[],{"trials":6731,"activeCount":103},[],{"intervention":6733,"totalTrials":323,"cells":6734},"Niraparib",{"EARLY_PHASE1":6735,"PHASE1":6737,"PHASE2":6739,"PHASE3":6754,"PHASE4":6756,"NA":6758},{"trials":6736,"activeCount":103},[],{"trials":6738,"activeCount":103},[],{"trials":6740,"activeCount":103},[6741],{"nctId":6742,"briefTitle":6743,"status":115,"phases":6744,"primaryCompletion":6745,"completion":6745,"start":6746,"enrollment":6747,"conditions":6748,"interventions":6753},"NCT03207347","A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)",[92],"2022-08-30","2018-08-13",37,[6749,6750,6751,6752],"Mesothelioma","Uveal Melanoma","Renal Cell Carcinoma","Cholangiocarcinoma",[6733],{"trials":6755,"activeCount":103},[],{"trials":6757,"activeCount":103},[],{"trials":6759,"activeCount":103},[],{"intervention":6761,"totalTrials":323,"cells":6762},"Influenza Vaccine",{"EARLY_PHASE1":6763,"PHASE1":6765,"PHASE2":6767,"PHASE3":6778,"PHASE4":6780,"NA":6782},{"trials":6764,"activeCount":103},[],{"trials":6766,"activeCount":103},[],{"trials":6768,"activeCount":103},[6769],{"nctId":6770,"briefTitle":6771,"status":115,"phases":6772,"primaryCompletion":433,"completion":6773,"start":6774,"enrollment":459,"conditions":6775,"interventions":6777},"NCT05074303","Beta-glucan and Immune Response to Influenza Vaccine",[92],"2024-08-28","2022-07-18",[6776],"Healthy Aging",[6761],{"trials":6779,"activeCount":103},[],{"trials":6781,"activeCount":103},[],{"trials":6783,"activeCount":103},[],{"intervention":423,"totalTrials":323,"cells":6785},{"EARLY_PHASE1":6786,"PHASE1":6788,"PHASE2":6790,"PHASE3":6796,"PHASE4":6798,"NA":6800},{"trials":6787,"activeCount":103},[],{"trials":6789,"activeCount":103},[],{"trials":6791,"activeCount":103},[6792],{"nctId":414,"briefTitle":415,"status":115,"phases":6793,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":6794,"interventions":6795},[92],[421],[405,423],{"trials":6797,"activeCount":103},[],{"trials":6799,"activeCount":103},[],{"trials":6801,"activeCount":103},[],{"intervention":6803,"totalTrials":323,"cells":6804},"Methotrexate + Folic Acid",{"EARLY_PHASE1":6805,"PHASE1":6807,"PHASE2":6809,"PHASE3":6818,"PHASE4":6820,"NA":6822},{"trials":6806,"activeCount":103},[],{"trials":6808,"activeCount":103},[],{"trials":6810,"activeCount":103},[6811],{"nctId":6812,"briefTitle":6813,"status":257,"phases":6814,"primaryCompletion":3044,"completion":3044,"start":6815,"enrollment":103,"conditions":6816,"interventions":6817},"NCT02079948","Inflammation Control For Elders: ICE Study",[92],"2014-02",[3062,21],[6803],{"trials":6819,"activeCount":103},[],{"trials":6821,"activeCount":103},[],{"trials":6823,"activeCount":103},[],{"intervention":6825,"totalTrials":323,"cells":6826},"Resveratrol",{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6840,"PHASE4":6842,"NA":6844},{"trials":6828,"activeCount":103},[],{"trials":6830,"activeCount":103},[],{"trials":6832,"activeCount":103},[6833],{"nctId":6834,"briefTitle":6835,"status":115,"phases":6836,"primaryCompletion":743,"completion":6837,"start":3530,"enrollment":1260,"conditions":6838,"interventions":6839},"NCT02523274","Resveratrol and Exercise to Treat Functional Limitations in Late Life",[92],"2019-07-17",[21],[6825],{"trials":6841,"activeCount":103},[],{"trials":6843,"activeCount":103},[],{"trials":6845,"activeCount":103},[],{"intervention":6847,"totalTrials":323,"cells":6848},"Conivaptan",{"EARLY_PHASE1":6849,"PHASE1":6851,"PHASE2":6853,"PHASE3":6863,"PHASE4":6865,"NA":6867},{"trials":6850,"activeCount":103},[],{"trials":6852,"activeCount":103},[],{"trials":6854,"activeCount":103},[6855],{"nctId":6856,"briefTitle":6857,"status":257,"phases":6858,"primaryCompletion":4624,"completion":4624,"start":4624,"enrollment":103,"conditions":6859,"interventions":6860},"NCT01954290","Study of Stroke Related Edema Treatments",[92],[5527,5528],[6847,6861,6862],"Hypertonic saline","Mannitol",{"trials":6864,"activeCount":103},[],{"trials":6866,"activeCount":103},[],{"trials":6868,"activeCount":103},[],{"intervention":6861,"totalTrials":323,"cells":6870},{"EARLY_PHASE1":6871,"PHASE1":6873,"PHASE2":6875,"PHASE3":6881,"PHASE4":6883,"NA":6885},{"trials":6872,"activeCount":103},[],{"trials":6874,"activeCount":103},[],{"trials":6876,"activeCount":103},[6877],{"nctId":6856,"briefTitle":6857,"status":257,"phases":6878,"primaryCompletion":4624,"completion":4624,"start":4624,"enrollment":103,"conditions":6879,"interventions":6880},[92],[5527,5528],[6847,6861,6862],{"trials":6882,"activeCount":103},[],{"trials":6884,"activeCount":103},[],{"trials":6886,"activeCount":103},[],{"intervention":6862,"totalTrials":323,"cells":6888},{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6893,"PHASE3":6899,"PHASE4":6901,"NA":6903},{"trials":6890,"activeCount":103},[],{"trials":6892,"activeCount":103},[],{"trials":6894,"activeCount":103},[6895],{"nctId":6856,"briefTitle":6857,"status":257,"phases":6896,"primaryCompletion":4624,"completion":4624,"start":4624,"enrollment":103,"conditions":6897,"interventions":6898},[92],[5527,5528],[6847,6861,6862],{"trials":6900,"activeCount":103},[],{"trials":6902,"activeCount":103},[],{"trials":6904,"activeCount":103},[],{"intervention":5733,"totalTrials":323,"cells":6906},{"EARLY_PHASE1":6907,"PHASE1":6909,"PHASE2":6911,"PHASE3":6917,"PHASE4":6919,"NA":6921},{"trials":6908,"activeCount":103},[],{"trials":6910,"activeCount":103},[],{"trials":6912,"activeCount":103},[6913],{"nctId":5724,"briefTitle":5725,"status":115,"phases":6914,"primaryCompletion":5727,"completion":5728,"start":5729,"enrollment":3401,"conditions":6915,"interventions":6916},[92],[5731],[5707,5733],{"trials":6918,"activeCount":103},[],{"trials":6920,"activeCount":103},[],{"trials":6922,"activeCount":103},[],{"intervention":5488,"totalTrials":323,"cells":6924},{"EARLY_PHASE1":6925,"PHASE1":6927,"PHASE2":6929,"PHASE3":6935,"PHASE4":6937,"NA":6939},{"trials":6926,"activeCount":103},[],{"trials":6928,"activeCount":103},[],{"trials":6930,"activeCount":103},[6931],{"nctId":5482,"briefTitle":5483,"status":257,"phases":6932,"primaryCompletion":2061,"completion":2041,"start":944,"enrollment":103,"conditions":6933,"interventions":6934},[92],[5470,5486],[5488,5455,5489,5490,5491],{"trials":6936,"activeCount":103},[],{"trials":6938,"activeCount":103},[],{"trials":6940,"activeCount":103},[],{"intervention":5490,"totalTrials":323,"cells":6942},{"EARLY_PHASE1":6943,"PHASE1":6945,"PHASE2":6947,"PHASE3":6953,"PHASE4":6955,"NA":6957},{"trials":6944,"activeCount":103},[],{"trials":6946,"activeCount":103},[],{"trials":6948,"activeCount":103},[6949],{"nctId":5482,"briefTitle":5483,"status":257,"phases":6950,"primaryCompletion":2061,"completion":2041,"start":944,"enrollment":103,"conditions":6951,"interventions":6952},[92],[5470,5486],[5488,5455,5489,5490,5491],{"trials":6954,"activeCount":103},[],{"trials":6956,"activeCount":103},[],{"trials":6958,"activeCount":103},[],{"intervention":5491,"totalTrials":323,"cells":6960},{"EARLY_PHASE1":6961,"PHASE1":6963,"PHASE2":6965,"PHASE3":6971,"PHASE4":6973,"NA":6975},{"trials":6962,"activeCount":103},[],{"trials":6964,"activeCount":103},[],{"trials":6966,"activeCount":103},[6967],{"nctId":5482,"briefTitle":5483,"status":257,"phases":6968,"primaryCompletion":2061,"completion":2041,"start":944,"enrollment":103,"conditions":6969,"interventions":6970},[92],[5470,5486],[5488,5455,5489,5490,5491],{"trials":6972,"activeCount":103},[],{"trials":6974,"activeCount":103},[],{"trials":6976,"activeCount":103},[],{"intervention":6978,"totalTrials":323,"cells":6979},"Inhaled Treprostinil",{"EARLY_PHASE1":6980,"PHASE1":6982,"PHASE2":6984,"PHASE3":6996,"PHASE4":6998,"NA":7000},{"trials":6981,"activeCount":103},[],{"trials":6983,"activeCount":103},[],{"trials":6985,"activeCount":103},[6986],{"nctId":6987,"briefTitle":6988,"status":115,"phases":6989,"primaryCompletion":77,"completion":77,"start":6990,"enrollment":250,"conditions":6991,"interventions":6995},"NCT03814317","Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension",[92],"2020-01-30",[6992,6993,6994],"Sarcoidosis","Precapillary Pulmonary Hypertension","Interstitial Lung Disease",[6978],{"trials":6997,"activeCount":103},[],{"trials":6999,"activeCount":103},[],{"trials":7001,"activeCount":103},[],{"intervention":7003,"totalTrials":323,"cells":7004},"Pemetrexed",{"EARLY_PHASE1":7005,"PHASE1":7007,"PHASE2":7009,"PHASE3":7018,"PHASE4":7020,"NA":7022},{"trials":7006,"activeCount":103},[],{"trials":7008,"activeCount":103},[],{"trials":7010,"activeCount":103},[7011],{"nctId":7012,"briefTitle":7013,"status":257,"phases":7014,"primaryCompletion":3000,"completion":3000,"start":4648,"enrollment":103,"conditions":7015,"interventions":7017},"NCT00712062","Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma",[92],[7016],"Primary Central Nervous System Lymphoma",[7003],{"trials":7019,"activeCount":103},[],{"trials":7021,"activeCount":103},[],{"trials":7023,"activeCount":103},[],{"intervention":7025,"totalTrials":323,"cells":7026},"Losartan",{"EARLY_PHASE1":7027,"PHASE1":7029,"PHASE2":7031,"PHASE3":7042,"PHASE4":7044,"NA":7046},{"trials":7028,"activeCount":103},[],{"trials":7030,"activeCount":103},[],{"trials":7032,"activeCount":103},[7033],{"nctId":7034,"briefTitle":7035,"status":115,"phases":7036,"primaryCompletion":7037,"completion":7037,"start":7038,"enrollment":7039,"conditions":7040,"interventions":7041},"NCT02676466","The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study",[92],"2018-06-22","2016-04-26",289,[3062],[7025],{"trials":7043,"activeCount":103},[],{"trials":7045,"activeCount":103},[],{"trials":7047,"activeCount":103},[],{"intervention":7049,"totalTrials":323,"cells":7050},"Fenofibrate IDD-P",{"EARLY_PHASE1":7051,"PHASE1":7053,"PHASE2":7055,"PHASE3":7065,"PHASE4":7067,"NA":7069},{"trials":7052,"activeCount":103},[],{"trials":7054,"activeCount":103},[],{"trials":7056,"activeCount":103},[7057],{"nctId":7058,"briefTitle":7059,"status":115,"phases":7060,"primaryCompletion":1982,"completion":722,"start":7061,"enrollment":34,"conditions":7062,"interventions":7064},"NCT00575042","Use of Fenofibrate for Primary Biliary Cirrhosis",[92],"2007-08",[7063],"Primary Biliary Cirrhosis",[7049],{"trials":7066,"activeCount":103},[],{"trials":7068,"activeCount":103},[],{"trials":7070,"activeCount":103},[],{"intervention":7072,"totalTrials":323,"cells":7073},"PD0332991",{"EARLY_PHASE1":7074,"PHASE1":7076,"PHASE2":7078,"PHASE3":7088,"PHASE4":7090,"NA":7092},{"trials":7075,"activeCount":103},[],{"trials":7077,"activeCount":103},[],{"trials":7079,"activeCount":103},[7080],{"nctId":7081,"briefTitle":7082,"status":115,"phases":7083,"primaryCompletion":6815,"completion":7084,"start":4689,"enrollment":37,"conditions":7085,"interventions":7087},"NCT01291017","Cyclin Dependent Kinase (CDK)4\u002F6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.",[92],"2015-02",[7086],"Non-small Cell Lung Cancer",[7072],{"trials":7089,"activeCount":103},[],{"trials":7091,"activeCount":103},[],{"trials":7093,"activeCount":103},[],{"intervention":7095,"totalTrials":323,"cells":7096},"Capecitabine",{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7101,"PHASE3":7110,"PHASE4":7112,"NA":7114},{"trials":7098,"activeCount":103},[],{"trials":7100,"activeCount":103},[],{"trials":7102,"activeCount":103},[7103],{"nctId":7104,"briefTitle":7105,"status":115,"phases":7106,"primaryCompletion":4035,"completion":5359,"start":7107,"enrollment":1272,"conditions":7108,"interventions":7109},"NCT00717197","Study of Capecitabine to Treat Recurrent High Grade Gliomas",[92],"2008-07",[2114],[7095],{"trials":7111,"activeCount":103},[],{"trials":7113,"activeCount":103},[],{"trials":7115,"activeCount":103},[],{"intervention":7117,"totalTrials":323,"cells":7118},"TTFields with adjuvant temozolomide",{"EARLY_PHASE1":7119,"PHASE1":7121,"PHASE2":7123,"PHASE3":7135,"PHASE4":7137,"NA":7139},{"trials":7120,"activeCount":103},[],{"trials":7122,"activeCount":103},[],{"trials":7124,"activeCount":103},[7125],{"nctId":7126,"briefTitle":7127,"status":1053,"phases":7128,"primaryCompletion":7129,"completion":7129,"start":7130,"enrollment":323,"conditions":7131,"interventions":7134},"NCT03906448","FORWARD Optune and Adjuvant TMZ in Grade II\u002FIII Astrocytoma",[92],"2020-06-08","2019-05-20",[7132,7133],"Astrocytoma, Grade II","Astrocytoma, Grade III",[7117],{"trials":7136,"activeCount":103},[],{"trials":7138,"activeCount":103},[],{"trials":7140,"activeCount":103},[],{"intervention":7142,"totalTrials":323,"cells":7143},"Measures performed on all subjects",{"EARLY_PHASE1":7144,"PHASE1":7146,"PHASE2":7148,"PHASE3":7157,"PHASE4":7159,"NA":7161},{"trials":7145,"activeCount":103},[],{"trials":7147,"activeCount":103},[],{"trials":7149,"activeCount":103},[7150],{"nctId":7151,"briefTitle":7152,"status":115,"phases":7153,"primaryCompletion":6122,"completion":6122,"start":1174,"enrollment":759,"conditions":7154,"interventions":7156},"NCT01907321","Cough and Swallow Rehab Following Stroke",[91,92],[7155],"Ischemic Stroke",[7142],{"trials":7158,"activeCount":103},[],{"trials":7160,"activeCount":103},[],{"trials":7162,"activeCount":103},[],{"intervention":2658,"totalTrials":323,"cells":7164},{"EARLY_PHASE1":7165,"PHASE1":7167,"PHASE2":7169,"PHASE3":7175,"PHASE4":7177,"NA":7179},{"trials":7166,"activeCount":103},[],{"trials":7168,"activeCount":103},[],{"trials":7170,"activeCount":103},[7171],{"nctId":2651,"briefTitle":2652,"status":115,"phases":7172,"primaryCompletion":2654,"completion":2655,"start":1087,"enrollment":695,"conditions":7173,"interventions":7174},[92],[1089],[2642,2658],{"trials":7176,"activeCount":103},[],{"trials":7178,"activeCount":103},[],{"trials":7180,"activeCount":103},[],{"intervention":7182,"totalTrials":323,"cells":7183},"Resveratrol 1000 mg\u002Fday",{"EARLY_PHASE1":7184,"PHASE1":7186,"PHASE2":7188,"PHASE3":7199,"PHASE4":7201,"NA":7203},{"trials":7185,"activeCount":103},[],{"trials":7187,"activeCount":103},[],{"trials":7189,"activeCount":103},[7190],{"nctId":7191,"briefTitle":7192,"status":115,"phases":7193,"primaryCompletion":7194,"completion":7194,"start":4624,"enrollment":1260,"conditions":7195,"interventions":7197},"NCT02123121","Resveratrol to Enhance Vitality and Vigor in Elders",[92],"2019-05-02",[7196,5163],"Mitochondrial Function",[7182,7198],"Resveratrol 1500 mg\u002Fday",{"trials":7200,"activeCount":103},[],{"trials":7202,"activeCount":103},[],{"trials":7204,"activeCount":103},[],{"intervention":7198,"totalTrials":323,"cells":7206},{"EARLY_PHASE1":7207,"PHASE1":7209,"PHASE2":7211,"PHASE3":7217,"PHASE4":7219,"NA":7221},{"trials":7208,"activeCount":103},[],{"trials":7210,"activeCount":103},[],{"trials":7212,"activeCount":103},[7213],{"nctId":7191,"briefTitle":7192,"status":115,"phases":7214,"primaryCompletion":7194,"completion":7194,"start":4624,"enrollment":1260,"conditions":7215,"interventions":7216},[92],[7196,5163],[7182,7198],{"trials":7218,"activeCount":103},[],{"trials":7220,"activeCount":103},[],{"trials":7222,"activeCount":103},[],{"intervention":7224,"totalTrials":323,"cells":7225},"Acetazolamide",{"EARLY_PHASE1":7226,"PHASE1":7228,"PHASE2":7230,"PHASE3":7240,"PHASE4":7242,"NA":7244},{"trials":7227,"activeCount":103},[],{"trials":7229,"activeCount":103},[],{"trials":7231,"activeCount":103},[7232],{"nctId":7233,"briefTitle":7234,"status":257,"phases":7235,"primaryCompletion":4624,"completion":4624,"start":4624,"enrollment":103,"conditions":7236,"interventions":7238},"NCT02165644","Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage",[92],[5527,7237],"Vasospasm",[7224,7239],"Nimodipine",{"trials":7241,"activeCount":103},[],{"trials":7243,"activeCount":103},[],{"trials":7245,"activeCount":103},[],{"intervention":7239,"totalTrials":323,"cells":7247},{"EARLY_PHASE1":7248,"PHASE1":7250,"PHASE2":7252,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7249,"activeCount":103},[],{"trials":7251,"activeCount":103},[],{"trials":7253,"activeCount":103},[7254],{"nctId":7233,"briefTitle":7234,"status":257,"phases":7255,"primaryCompletion":4624,"completion":4624,"start":4624,"enrollment":103,"conditions":7256,"interventions":7257},[92],[5527,7237],[7224,7239],{"trials":7259,"activeCount":103},[],{"trials":7261,"activeCount":103},[],{"trials":7263,"activeCount":103},[],{"intervention":7265,"totalTrials":323,"cells":7266},"rAAV1-CMV-GAA (study agent) Administration",{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7271,"PHASE3":7280,"PHASE4":7282,"NA":7284},{"trials":7268,"activeCount":103},[],{"trials":7270,"activeCount":103},[],{"trials":7272,"activeCount":103},[7273],{"nctId":7274,"briefTitle":7275,"status":115,"phases":7276,"primaryCompletion":7277,"completion":7277,"start":2630,"enrollment":2429,"conditions":7278,"interventions":7279},"NCT00976352","Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease",[91,92],"2015-12",[5512],[7265],{"trials":7281,"activeCount":103},[],{"trials":7283,"activeCount":103},[],{"trials":7285,"activeCount":103},[],{"intervention":7287,"totalTrials":323,"cells":7288},"hTERT mRNA DC",{"EARLY_PHASE1":7289,"PHASE1":7291,"PHASE2":7293,"PHASE3":7302,"PHASE4":7304,"NA":7306},{"trials":7290,"activeCount":103},[],{"trials":7292,"activeCount":103},[],{"trials":7294,"activeCount":103},[7295],{"nctId":7296,"briefTitle":7297,"status":257,"phases":7298,"primaryCompletion":2999,"completion":2841,"start":3001,"enrollment":103,"conditions":7299,"interventions":7301},"NCT01153113","Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines",[91,92],[7300],"Metastatic Prostate Cancer",[7287,7287],{"trials":7303,"activeCount":103},[],{"trials":7305,"activeCount":103},[],{"trials":7307,"activeCount":103},[],{"intervention":7309,"totalTrials":323,"cells":7310},"Atezolizumab",{"EARLY_PHASE1":7311,"PHASE1":7313,"PHASE2":7315,"PHASE3":7333,"PHASE4":7335,"NA":7337},{"trials":7312,"activeCount":103},[],{"trials":7314,"activeCount":103},[],{"trials":7316,"activeCount":103},[7317],{"nctId":7318,"briefTitle":7319,"status":940,"phases":7320,"primaryCompletion":1118,"completion":7321,"start":7322,"enrollment":945,"conditions":7323,"interventions":7331},"NCT05000294","Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types",[91,92],"2027-06","2021-12-07",[7324,7325,36,7326,7327,1293,7328,7329,7330],"Bile Duct Cancer","Gall Bladder Cancer","Neuroendocrine Tumors","Ovarian Cancer","Soft Tissue Sarcoma","Vulvar Cancer","Prostate Cancer",[7309,7332],"Tivozanib",{"trials":7334,"activeCount":103},[],{"trials":7336,"activeCount":103},[],{"trials":7338,"activeCount":103},[],{"intervention":7332,"totalTrials":323,"cells":7340},{"EARLY_PHASE1":7341,"PHASE1":7343,"PHASE2":7345,"PHASE3":7351,"PHASE4":7353,"NA":7355},{"trials":7342,"activeCount":103},[],{"trials":7344,"activeCount":103},[],{"trials":7346,"activeCount":103},[7347],{"nctId":7318,"briefTitle":7319,"status":940,"phases":7348,"primaryCompletion":1118,"completion":7321,"start":7322,"enrollment":945,"conditions":7349,"interventions":7350},[91,92],[7324,7325,36,7326,7327,1293,7328,7329,7330],[7309,7332],{"trials":7352,"activeCount":103},[],{"trials":7354,"activeCount":103},[],{"trials":7356,"activeCount":103},[],{"intervention":7358,"totalTrials":323,"cells":7359},"D-Cycloserine",{"EARLY_PHASE1":7360,"PHASE1":7362,"PHASE2":7364,"PHASE3":7374,"PHASE4":7376,"NA":7378},{"trials":7361,"activeCount":103},[],{"trials":7363,"activeCount":103},[],{"trials":7365,"activeCount":103},[7366],{"nctId":7367,"briefTitle":7368,"status":257,"phases":7369,"start":7370,"enrollment":103,"conditions":7371,"interventions":7373},"NCT00257361","D-Cycloserine Augmentation of Exposure and Response Prevention Treatment for Obsessive-Compulsive Disorder",[92],"2005-07",[7372],"Obsessive Compulsive Disorder",[7358],{"trials":7375,"activeCount":103},[],{"trials":7377,"activeCount":103},[],{"trials":7379,"activeCount":103},[],{"intervention":7381,"totalTrials":323,"cells":7382},"Sorafenib Plus Capecitabine",{"EARLY_PHASE1":7383,"PHASE1":7385,"PHASE2":7387,"PHASE3":7399,"PHASE4":7401,"NA":7403},{"trials":7384,"activeCount":103},[],{"trials":7386,"activeCount":103},[],{"trials":7388,"activeCount":103},[7389],{"nctId":7390,"briefTitle":7391,"status":115,"phases":7392,"primaryCompletion":7393,"completion":7394,"start":7395,"enrollment":6123,"conditions":7396,"interventions":7398},"NCT01471353","Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer",[92],"2015-10","2017-05","2011-11",[7397],"Colorectal Cancer Metastatic",[7381],{"trials":7400,"activeCount":103},[],{"trials":7402,"activeCount":103},[],{"trials":7404,"activeCount":103},[],{"intervention":7406,"totalTrials":323,"cells":7407},"Orca-Q",{"EARLY_PHASE1":7408,"PHASE1":7410,"PHASE2":7412,"PHASE3":7427,"PHASE4":7429,"NA":7431},{"trials":7409,"activeCount":103},[],{"trials":7411,"activeCount":103},[],{"trials":7413,"activeCount":103},[7414],{"nctId":7415,"briefTitle":7416,"status":940,"phases":7417,"primaryCompletion":902,"completion":344,"start":7418,"enrollment":146,"conditions":7419,"interventions":7426},"NCT05322850","Phase I\u002FII Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)",[91,92],"2022-08-16",[5470,7420,7421,7422,7423,7424,7425],"Acute Lymphoid Leukemia","Mixed Phenotype Acute Leukemia","Acute Undifferentiated Leukemia","Chronic Myeloid Leukemia in Myeloid Blast Crisis","Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)","Chronic Myeloid Leukemia - Accelerated Phase",[7406],{"trials":7428,"activeCount":103},[],{"trials":7430,"activeCount":103},[],{"trials":7432,"activeCount":103},[],{"intervention":7434,"totalTrials":323,"cells":7435},"Adenosine",{"EARLY_PHASE1":7436,"PHASE1":7438,"PHASE2":7440,"PHASE3":7450,"PHASE4":7452,"NA":7454},{"trials":7437,"activeCount":103},[],{"trials":7439,"activeCount":103},[],{"trials":7441,"activeCount":103},[7442],{"nctId":7443,"briefTitle":7444,"status":257,"phases":7445,"primaryCompletion":67,"completion":67,"start":7446,"enrollment":103,"conditions":7447,"interventions":7449},"NCT04588441","The ARCTIC Trial: Aerosolized Inhaled Adenosine Treatment in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by COVID-19",[92],"2023-12",[7448],"Acute Respiratory Distress",[7434],{"trials":7451,"activeCount":103},[],{"trials":7453,"activeCount":103},[],{"trials":7455,"activeCount":103},[],{"intervention":5562,"totalTrials":323,"cells":7457},{"EARLY_PHASE1":7458,"PHASE1":7460,"PHASE2":7462,"PHASE3":7468,"PHASE4":7470,"NA":7472},{"trials":7459,"activeCount":103},[],{"trials":7461,"activeCount":103},[],{"trials":7463,"activeCount":103},[7464],{"nctId":5552,"briefTitle":5553,"status":1053,"phases":7465,"primaryCompletion":5555,"completion":5556,"start":5557,"enrollment":2099,"conditions":7466,"interventions":7467},[91,92],[5559,5560,5470],[5562,5563,5564,5565],{"trials":7469,"activeCount":103},[],{"trials":7471,"activeCount":103},[],{"trials":7473,"activeCount":103},[],{"intervention":5564,"totalTrials":323,"cells":7475},{"EARLY_PHASE1":7476,"PHASE1":7478,"PHASE2":7480,"PHASE3":7486,"PHASE4":7488,"NA":7490},{"trials":7477,"activeCount":103},[],{"trials":7479,"activeCount":103},[],{"trials":7481,"activeCount":103},[7482],{"nctId":5552,"briefTitle":5553,"status":1053,"phases":7483,"primaryCompletion":5555,"completion":5556,"start":5557,"enrollment":2099,"conditions":7484,"interventions":7485},[91,92],[5559,5560,5470],[5562,5563,5564,5565],{"trials":7487,"activeCount":103},[],{"trials":7489,"activeCount":103},[],{"trials":7491,"activeCount":103},[],{"intervention":5565,"totalTrials":323,"cells":7493},{"EARLY_PHASE1":7494,"PHASE1":7496,"PHASE2":7498,"PHASE3":7504,"PHASE4":7506,"NA":7508},{"trials":7495,"activeCount":103},[],{"trials":7497,"activeCount":103},[],{"trials":7499,"activeCount":103},[7500],{"nctId":5552,"briefTitle":5553,"status":1053,"phases":7501,"primaryCompletion":5555,"completion":5556,"start":5557,"enrollment":2099,"conditions":7502,"interventions":7503},[91,92],[5559,5560,5470],[5562,5563,5564,5565],{"trials":7505,"activeCount":103},[],{"trials":7507,"activeCount":103},[],{"trials":7509,"activeCount":103},[],{"intervention":7511,"totalTrials":323,"cells":7512},"Dichloroacetate environmental dose",{"EARLY_PHASE1":7513,"PHASE1":7515,"PHASE2":7517,"PHASE3":7528,"PHASE4":7530,"NA":7532},{"trials":7514,"activeCount":103},[],{"trials":7516,"activeCount":103},[],{"trials":7518,"activeCount":103},[7519],{"nctId":7520,"briefTitle":1979,"status":115,"phases":7521,"primaryCompletion":7522,"completion":7522,"start":1952,"enrollment":25,"conditions":7523,"interventions":7524},"NCT01128270",[91,92],"2012-10",[15],[7511,7525,7526,7527],"Chloral Hydrate environmental dose","Dichloroacetate therapeutic dose","Chloral Hydrate therapeutic dose",{"trials":7529,"activeCount":103},[],{"trials":7531,"activeCount":103},[],{"trials":7533,"activeCount":103},[],{"intervention":7525,"totalTrials":323,"cells":7535},{"EARLY_PHASE1":7536,"PHASE1":7538,"PHASE2":7540,"PHASE3":7546,"PHASE4":7548,"NA":7550},{"trials":7537,"activeCount":103},[],{"trials":7539,"activeCount":103},[],{"trials":7541,"activeCount":103},[7542],{"nctId":7520,"briefTitle":1979,"status":115,"phases":7543,"primaryCompletion":7522,"completion":7522,"start":1952,"enrollment":25,"conditions":7544,"interventions":7545},[91,92],[15],[7511,7525,7526,7527],{"trials":7547,"activeCount":103},[],{"trials":7549,"activeCount":103},[],{"trials":7551,"activeCount":103},[],{"intervention":7526,"totalTrials":323,"cells":7553},{"EARLY_PHASE1":7554,"PHASE1":7556,"PHASE2":7558,"PHASE3":7564,"PHASE4":7566,"NA":7568},{"trials":7555,"activeCount":103},[],{"trials":7557,"activeCount":103},[],{"trials":7559,"activeCount":103},[7560],{"nctId":7520,"briefTitle":1979,"status":115,"phases":7561,"primaryCompletion":7522,"completion":7522,"start":1952,"enrollment":25,"conditions":7562,"interventions":7563},[91,92],[15],[7511,7525,7526,7527],{"trials":7565,"activeCount":103},[],{"trials":7567,"activeCount":103},[],{"trials":7569,"activeCount":103},[],{"intervention":7527,"totalTrials":323,"cells":7571},{"EARLY_PHASE1":7572,"PHASE1":7574,"PHASE2":7576,"PHASE3":7582,"PHASE4":7584,"NA":7586},{"trials":7573,"activeCount":103},[],{"trials":7575,"activeCount":103},[],{"trials":7577,"activeCount":103},[7578],{"nctId":7520,"briefTitle":1979,"status":115,"phases":7579,"primaryCompletion":7522,"completion":7522,"start":1952,"enrollment":25,"conditions":7580,"interventions":7581},[91,92],[15],[7511,7525,7526,7527],{"trials":7583,"activeCount":103},[],{"trials":7585,"activeCount":103},[],{"trials":7587,"activeCount":103},[],{"intervention":7589,"totalTrials":323,"cells":7590},"Nesiritide",{"EARLY_PHASE1":7591,"PHASE1":7593,"PHASE2":7595,"PHASE3":7605,"PHASE4":7607,"NA":7609},{"trials":7592,"activeCount":103},[],{"trials":7594,"activeCount":103},[],{"trials":7596,"activeCount":103},[7597],{"nctId":7598,"briefTitle":7599,"status":115,"phases":7600,"primaryCompletion":7601,"completion":7601,"start":1952,"enrollment":6747,"conditions":7602,"interventions":7604},"NCT01440881","Does Nesiritide Provide Renal Protection",[92],"2012-12",[7603],"Renal Failure",[7589],{"trials":7606,"activeCount":103},[],{"trials":7608,"activeCount":103},[],{"trials":7610,"activeCount":103},[],{"intervention":7612,"totalTrials":323,"cells":7613},"Krill oil",{"EARLY_PHASE1":7614,"PHASE1":7616,"PHASE2":7618,"PHASE3":7629,"PHASE4":7631,"NA":7633},{"trials":7615,"activeCount":103},[],{"trials":7617,"activeCount":103},[],{"trials":7619,"activeCount":103},[7620],{"nctId":7621,"briefTitle":7622,"status":115,"phases":7623,"primaryCompletion":7624,"completion":7624,"start":7625,"enrollment":146,"conditions":7626,"interventions":7628},"NCT06580912","Krill Oil for Pain in Elders",[92],"2025-12-17","2025-01-17",[7627],"Chronic Musculoskeletal Pain",[7612],{"trials":7630,"activeCount":103},[],{"trials":7632,"activeCount":103},[],{"trials":7634,"activeCount":103},[],{"intervention":7636,"totalTrials":323,"cells":7637},"pp65-shLAMP DC with GM-CSF",{"EARLY_PHASE1":7638,"PHASE1":7640,"PHASE2":7642,"PHASE3":7658,"PHASE4":7660,"NA":7662},{"trials":7639,"activeCount":103},[],{"trials":7641,"activeCount":103},[],{"trials":7643,"activeCount":103},[7644],{"nctId":7645,"briefTitle":7646,"status":115,"phases":7647,"primaryCompletion":7648,"completion":7648,"start":7649,"enrollment":7650,"conditions":7651,"interventions":7653},"NCT02465268","Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme",[92],"2023-11-30","2016-08-09",175,[1812,964,2114,7652,6682],"Astrocytoma, Grade IV",[7636,7654,7655,7656,7657],"unpulsed PBMC and saline","Td","Saline","pp65-flLAMP DC with GM-CSF",{"trials":7659,"activeCount":103},[],{"trials":7661,"activeCount":103},[],{"trials":7663,"activeCount":103},[],{"intervention":7654,"totalTrials":323,"cells":7665},{"EARLY_PHASE1":7666,"PHASE1":7668,"PHASE2":7670,"PHASE3":7676,"PHASE4":7678,"NA":7680},{"trials":7667,"activeCount":103},[],{"trials":7669,"activeCount":103},[],{"trials":7671,"activeCount":103},[7672],{"nctId":7645,"briefTitle":7646,"status":115,"phases":7673,"primaryCompletion":7648,"completion":7648,"start":7649,"enrollment":7650,"conditions":7674,"interventions":7675},[92],[1812,964,2114,7652,6682],[7636,7654,7655,7656,7657],{"trials":7677,"activeCount":103},[],{"trials":7679,"activeCount":103},[],{"trials":7681,"activeCount":103},[],{"intervention":7655,"totalTrials":323,"cells":7683},{"EARLY_PHASE1":7684,"PHASE1":7686,"PHASE2":7688,"PHASE3":7694,"PHASE4":7696,"NA":7698},{"trials":7685,"activeCount":103},[],{"trials":7687,"activeCount":103},[],{"trials":7689,"activeCount":103},[7690],{"nctId":7645,"briefTitle":7646,"status":115,"phases":7691,"primaryCompletion":7648,"completion":7648,"start":7649,"enrollment":7650,"conditions":7692,"interventions":7693},[92],[1812,964,2114,7652,6682],[7636,7654,7655,7656,7657],{"trials":7695,"activeCount":103},[],{"trials":7697,"activeCount":103},[],{"trials":7699,"activeCount":103},[],{"intervention":7656,"totalTrials":323,"cells":7701},{"EARLY_PHASE1":7702,"PHASE1":7704,"PHASE2":7706,"PHASE3":7712,"PHASE4":7714,"NA":7716},{"trials":7703,"activeCount":103},[],{"trials":7705,"activeCount":103},[],{"trials":7707,"activeCount":103},[7708],{"nctId":7645,"briefTitle":7646,"status":115,"phases":7709,"primaryCompletion":7648,"completion":7648,"start":7649,"enrollment":7650,"conditions":7710,"interventions":7711},[92],[1812,964,2114,7652,6682],[7636,7654,7655,7656,7657],{"trials":7713,"activeCount":103},[],{"trials":7715,"activeCount":103},[],{"trials":7717,"activeCount":103},[],{"intervention":7657,"totalTrials":323,"cells":7719},{"EARLY_PHASE1":7720,"PHASE1":7722,"PHASE2":7724,"PHASE3":7730,"PHASE4":7732,"NA":7734},{"trials":7721,"activeCount":103},[],{"trials":7723,"activeCount":103},[],{"trials":7725,"activeCount":103},[7726],{"nctId":7645,"briefTitle":7646,"status":115,"phases":7727,"primaryCompletion":7648,"completion":7648,"start":7649,"enrollment":7650,"conditions":7728,"interventions":7729},[92],[1812,964,2114,7652,6682],[7636,7654,7655,7656,7657],{"trials":7731,"activeCount":103},[],{"trials":7733,"activeCount":103},[],{"trials":7735,"activeCount":103},[],{"intervention":7737,"totalTrials":323,"cells":7738},"Mitomycin c",{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7743,"PHASE3":7755,"PHASE4":7757,"NA":7759},{"trials":7740,"activeCount":103},[],{"trials":7742,"activeCount":103},[],{"trials":7744,"activeCount":103},[7745],{"nctId":7746,"briefTitle":7747,"status":115,"phases":7748,"primaryCompletion":7749,"completion":7750,"start":7751,"enrollment":945,"conditions":7752,"interventions":7754},"NCT03658304","Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma",[92],"2021-11-10","2023-10-17","2018-12-05",[7753],"Urothelial Carcinoma",[7737],{"trials":7756,"activeCount":103},[],{"trials":7758,"activeCount":103},[],{"trials":7760,"activeCount":103},[],{"intervention":7762,"totalTrials":323,"cells":7763},"Naltrexone, 50mg, once per day for 4 months",{"EARLY_PHASE1":7764,"PHASE1":7766,"PHASE2":7768,"PHASE3":7779,"PHASE4":7781,"NA":7783},{"trials":7765,"activeCount":103},[],{"trials":7767,"activeCount":103},[],{"trials":7769,"activeCount":103},[7770],{"nctId":7771,"briefTitle":7772,"status":115,"phases":7773,"primaryCompletion":7522,"completion":7522,"start":7774,"enrollment":37,"conditions":7775,"interventions":7778},"NCT01245647","Will Having Alcohol Treatment Improve Functioning?",[92],"2010-11",[7776,7777],"HIV","Alcoholism",[7762],{"trials":7780,"activeCount":103},[],{"trials":7782,"activeCount":103},[],{"trials":7784,"activeCount":103},[],{"intervention":7786,"totalTrials":323,"cells":7787},"Antibiotics",{"EARLY_PHASE1":7788,"PHASE1":7790,"PHASE2":7792,"PHASE3":7811,"PHASE4":7813,"NA":7815},{"trials":7789,"activeCount":103},[],{"trials":7791,"activeCount":103},[],{"trials":7793,"activeCount":103},[7794],{"nctId":7795,"briefTitle":7796,"status":115,"phases":7797,"primaryCompletion":7798,"completion":7798,"start":7799,"enrollment":7800,"conditions":7801,"interventions":7809},"NCT02784821","Antibiotic \"Dysbiosis\" in Preterm Infants",[92],"2019-09-11","2017-01-16",98,[7802,7803,7804,7805,7806,7807,7808],"Enterocolitis, Necrotizing","Bacteremia","Bronchopulmonary Dysplasia","Intraventricular Hemorrhage","Periventricular Leukomalacia","Chronic Lung Disease","Ileal Perforation",[7810,7786],"Antibiotic",{"trials":7812,"activeCount":103},[],{"trials":7814,"activeCount":103},[],{"trials":7816,"activeCount":103},[],{"intervention":7818,"totalTrials":323,"cells":7819},"oral cannabinoid",{"EARLY_PHASE1":7820,"PHASE1":7822,"PHASE2":7824,"PHASE3":7838,"PHASE4":7840,"NA":7842},{"trials":7821,"activeCount":103},[],{"trials":7823,"activeCount":103},[],{"trials":7825,"activeCount":103},[7826],{"nctId":7827,"briefTitle":7828,"status":115,"phases":7829,"primaryCompletion":7830,"completion":7830,"start":7831,"enrollment":3856,"conditions":7832,"interventions":7836},"NCT05477875","Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control",[92],"2025-01-22","2024-02-01",[7833,7834,7835],"Photorefractive Keratectomy","Myopia","Hyperopia",[7818,7837],"oral codeine\u002Facetaminophen",{"trials":7839,"activeCount":103},[],{"trials":7841,"activeCount":103},[],{"trials":7843,"activeCount":103},[],{"intervention":7837,"totalTrials":323,"cells":7845},{"EARLY_PHASE1":7846,"PHASE1":7848,"PHASE2":7850,"PHASE3":7856,"PHASE4":7858,"NA":7860},{"trials":7847,"activeCount":103},[],{"trials":7849,"activeCount":103},[],{"trials":7851,"activeCount":103},[7852],{"nctId":7827,"briefTitle":7828,"status":115,"phases":7853,"primaryCompletion":7830,"completion":7830,"start":7831,"enrollment":3856,"conditions":7854,"interventions":7855},[92],[7833,7834,7835],[7818,7837],{"trials":7857,"activeCount":103},[],{"trials":7859,"activeCount":103},[],{"trials":7861,"activeCount":103},[],{"intervention":7863,"totalTrials":323,"cells":7864},"Rasburicase",{"EARLY_PHASE1":7865,"PHASE1":7867,"PHASE2":7869,"PHASE3":7880,"PHASE4":7882,"NA":7884},{"trials":7866,"activeCount":103},[],{"trials":7868,"activeCount":103},[],{"trials":7870,"activeCount":103},[7871],{"nctId":7872,"briefTitle":7873,"status":115,"phases":7874,"primaryCompletion":7875,"completion":2001,"start":7876,"enrollment":9,"conditions":7877,"interventions":7879},"NCT00756964","Lowering Serum Uric Acid to Prevent Acute Kidney Injury",[92],"2011-07","2008-10",[7878],"Hyperuricemia",[7863],{"trials":7881,"activeCount":103},[],{"trials":7883,"activeCount":103},[],{"trials":7885,"activeCount":103},[],{"intervention":7887,"totalTrials":323,"cells":7888},"Chemoradiotherapy Temozolomide",{"EARLY_PHASE1":7889,"PHASE1":7891,"PHASE2":7893,"PHASE3":7902,"PHASE4":7904,"NA":7906},{"trials":7890,"activeCount":103},[],{"trials":7892,"activeCount":103},[],{"trials":7894,"activeCount":103},[7895],{"nctId":7896,"briefTitle":7897,"status":257,"phases":7898,"primaryCompletion":1981,"completion":1981,"start":4648,"enrollment":103,"conditions":7899,"interventions":7901},"NCT00881595","Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas",[92],[7900],"Soft Tissue Sarcomas",[7887],{"trials":7903,"activeCount":103},[],{"trials":7905,"activeCount":103},[],{"trials":7907,"activeCount":103},[],{"intervention":7909,"totalTrials":323,"cells":7910},"Minocycline",{"EARLY_PHASE1":7911,"PHASE1":7913,"PHASE2":7915,"PHASE3":7924,"PHASE4":7926,"NA":7928},{"trials":7912,"activeCount":103},[],{"trials":7914,"activeCount":103},[],{"trials":7916,"activeCount":103},[7917],{"nctId":7918,"briefTitle":7919,"status":115,"phases":7920,"primaryCompletion":5383,"completion":5383,"start":7921,"enrollment":250,"conditions":7922,"interventions":7923},"NCT02213575","Study 3: Minocycline Decreases Microglia Activation",[92],"2016-03-05",[27],[7909],{"trials":7925,"activeCount":103},[],{"trials":7927,"activeCount":103},[],{"trials":7929,"activeCount":103},[],{"intervention":7931,"totalTrials":323,"cells":7932},"Erythromycin",{"EARLY_PHASE1":7933,"PHASE1":7935,"PHASE2":7937,"PHASE3":7947,"PHASE4":7949,"NA":7951},{"trials":7934,"activeCount":103},[],{"trials":7936,"activeCount":103},[],{"trials":7938,"activeCount":103},[7939],{"nctId":7940,"briefTitle":7941,"status":1053,"phases":7942,"primaryCompletion":7601,"completion":7601,"start":4648,"enrollment":9,"conditions":7943,"interventions":7945},"NCT01323582","Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis",[92],[7944],"Gastroparesis",[7931,7946],"Azithromycin",{"trials":7948,"activeCount":103},[],{"trials":7950,"activeCount":103},[],{"trials":7952,"activeCount":103},[],{"intervention":7946,"totalTrials":323,"cells":7954},{"EARLY_PHASE1":7955,"PHASE1":7957,"PHASE2":7959,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7956,"activeCount":103},[],{"trials":7958,"activeCount":103},[],{"trials":7960,"activeCount":103},[7961],{"nctId":7940,"briefTitle":7941,"status":1053,"phases":7962,"primaryCompletion":7601,"completion":7601,"start":4648,"enrollment":9,"conditions":7963,"interventions":7964},[92],[7944],[7931,7946],{"trials":7966,"activeCount":103},[],{"trials":7968,"activeCount":103},[],{"trials":7970,"activeCount":103},[],{"intervention":3114,"totalTrials":323,"cells":7972},{"EARLY_PHASE1":7973,"PHASE1":7975,"PHASE2":7977,"PHASE3":7983,"PHASE4":7985,"NA":7987},{"trials":7974,"activeCount":103},[],{"trials":7976,"activeCount":103},[],{"trials":7978,"activeCount":103},[7979],{"nctId":3105,"briefTitle":3106,"status":115,"phases":7980,"primaryCompletion":3108,"completion":3109,"start":3110,"enrollment":31,"conditions":7981,"interventions":7982},[92],[3112],[2720,3114],{"trials":7984,"activeCount":103},[],{"trials":7986,"activeCount":103},[],{"trials":7988,"activeCount":103},[],{"intervention":7990,"totalTrials":323,"cells":7991},"Zofran",{"EARLY_PHASE1":7992,"PHASE1":7994,"PHASE2":7996,"PHASE3":8007,"PHASE4":8009,"NA":8011},{"trials":7993,"activeCount":103},[],{"trials":7995,"activeCount":103},[],{"trials":7997,"activeCount":103},[7998],{"nctId":7999,"briefTitle":8000,"status":257,"phases":8001,"primaryCompletion":6704,"completion":6704,"start":8002,"enrollment":103,"conditions":8003,"interventions":8006},"NCT01719042","Improving Tolerance of Treatment of Pulmonary MAC Infections",[92],"2013-01",[8004,8005],"Mycobacterium Avium Complex","Adverse Effects",[7990],{"trials":8008,"activeCount":103},[],{"trials":8010,"activeCount":103},[],{"trials":8012,"activeCount":103},[],{"intervention":2131,"totalTrials":323,"cells":8014},{"EARLY_PHASE1":8015,"PHASE1":8017,"PHASE2":8019,"PHASE3":8025,"PHASE4":8027,"NA":8029},{"trials":8016,"activeCount":103},[],{"trials":8018,"activeCount":103},[],{"trials":8020,"activeCount":103},[8021],{"nctId":2121,"briefTitle":2122,"status":115,"phases":8022,"primaryCompletion":2124,"completion":2125,"start":2126,"enrollment":9,"conditions":8023,"interventions":8024},[92],[2128,2129],[932,2131],{"trials":8026,"activeCount":103},[],{"trials":8028,"activeCount":103},[],{"trials":8030,"activeCount":103},[],{"intervention":8032,"totalTrials":323,"cells":8033},"Standard dosing of methadone",{"EARLY_PHASE1":8034,"PHASE1":8036,"PHASE2":8038,"PHASE3":8049,"PHASE4":8051,"NA":8053},{"trials":8035,"activeCount":103},[],{"trials":8037,"activeCount":103},[],{"trials":8039,"activeCount":103},[8040],{"nctId":8041,"briefTitle":8042,"status":1053,"phases":8043,"primaryCompletion":8044,"completion":8044,"start":8045,"enrollment":1424,"conditions":8046,"interventions":8047},"NCT03605901","Dosing of Methadone for Spine Surgery",[92],"2025-05-09","2019-03-19",[265],[8032,8048],"Aliquots of methadone titrated to apnea",{"trials":8050,"activeCount":103},[],{"trials":8052,"activeCount":103},[],{"trials":8054,"activeCount":103},[],{"intervention":8048,"totalTrials":323,"cells":8056},{"EARLY_PHASE1":8057,"PHASE1":8059,"PHASE2":8061,"PHASE3":8067,"PHASE4":8069,"NA":8071},{"trials":8058,"activeCount":103},[],{"trials":8060,"activeCount":103},[],{"trials":8062,"activeCount":103},[8063],{"nctId":8041,"briefTitle":8042,"status":1053,"phases":8064,"primaryCompletion":8044,"completion":8044,"start":8045,"enrollment":1424,"conditions":8065,"interventions":8066},[92],[265],[8032,8048],{"trials":8068,"activeCount":103},[],{"trials":8070,"activeCount":103},[],{"trials":8072,"activeCount":103},[],{"intervention":8074,"totalTrials":323,"cells":8075},"Active CBD",{"EARLY_PHASE1":8076,"PHASE1":8078,"PHASE2":8080,"PHASE3":8094,"PHASE4":8096,"NA":8098},{"trials":8077,"activeCount":103},[],{"trials":8079,"activeCount":103},[],{"trials":8081,"activeCount":103},[8082],{"nctId":8083,"briefTitle":8084,"status":115,"phases":8085,"primaryCompletion":8086,"completion":8086,"start":8087,"enrollment":19,"conditions":8088,"interventions":8092},"NCT04586712","Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury",[92],"2024-03-21","2021-03-01",[8089,8090,8091],"Muscle Injury","Recovery","Pain Relief",[8074,8093],"Vehicle Control",{"trials":8095,"activeCount":103},[],{"trials":8097,"activeCount":103},[],{"trials":8099,"activeCount":103},[],{"intervention":8093,"totalTrials":323,"cells":8101},{"EARLY_PHASE1":8102,"PHASE1":8104,"PHASE2":8106,"PHASE3":8112,"PHASE4":8114,"NA":8116},{"trials":8103,"activeCount":103},[],{"trials":8105,"activeCount":103},[],{"trials":8107,"activeCount":103},[8108],{"nctId":8083,"briefTitle":8084,"status":115,"phases":8109,"primaryCompletion":8086,"completion":8086,"start":8087,"enrollment":19,"conditions":8110,"interventions":8111},[92],[8089,8090,8091],[8074,8093],{"trials":8113,"activeCount":103},[],{"trials":8115,"activeCount":103},[],{"trials":8117,"activeCount":103},[],{"intervention":8119,"totalTrials":323,"cells":8120},"4-PBA",{"EARLY_PHASE1":8121,"PHASE1":8123,"PHASE2":8125,"PHASE3":8136,"PHASE4":8138,"NA":8140},{"trials":8122,"activeCount":103},[],{"trials":8124,"activeCount":103},[],{"trials":8126,"activeCount":103},[8127],{"nctId":8128,"briefTitle":8129,"status":115,"phases":8130,"primaryCompletion":8131,"completion":8131,"start":8132,"enrollment":926,"conditions":8133,"interventions":8135},"NCT00067756","4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?",[92],"2003-10","2001-11",[8134],"Alpha 1-Antitrypsin Deficiency",[8119],{"trials":8137,"activeCount":103},[],{"trials":8139,"activeCount":103},[],{"trials":8141,"activeCount":103},[],{"intervention":8143,"totalTrials":323,"cells":8144},"pre-specified sequence of FDA-approved drugs and drug combinations",{"EARLY_PHASE1":8145,"PHASE1":8147,"PHASE2":8149,"PHASE3":8160,"PHASE4":8162,"NA":8164},{"trials":8146,"activeCount":103},[],{"trials":8148,"activeCount":103},[],{"trials":8150,"activeCount":103},[8151],{"nctId":8152,"briefTitle":8153,"status":1053,"phases":8154,"primaryCompletion":8155,"completion":8155,"start":8156,"enrollment":2714,"conditions":8157,"interventions":8159},"NCT04786600","A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial",[92],"2024-03-19","2022-03-14",[8158],"Metastatic Colorectal Cancer",[8143],{"trials":8161,"activeCount":103},[],{"trials":8163,"activeCount":103},[],{"trials":8165,"activeCount":103},[],{"intervention":8167,"totalTrials":323,"cells":8168},"Lavandula angustifolia, Aura Cacia",{"EARLY_PHASE1":8169,"PHASE1":8171,"PHASE2":8173,"PHASE3":8183,"PHASE4":8185,"NA":8187},{"trials":8170,"activeCount":103},[],{"trials":8172,"activeCount":103},[],{"trials":8174,"activeCount":103},[8175],{"nctId":8176,"briefTitle":8177,"status":115,"phases":8178,"primaryCompletion":3787,"completion":3787,"start":8179,"enrollment":356,"conditions":8180,"interventions":8182},"NCT06316934","Lavender Aromatherapy to Decrease Anxiety\u002FPain Perception During Office Hysteroscopy",[92],"2024-06-01",[1922,8181],"Pain, Procedural",[8167],{"trials":8184,"activeCount":103},[],{"trials":8186,"activeCount":103},[],{"trials":8188,"activeCount":103},[],{"intervention":8190,"totalTrials":323,"cells":8191},"Omacetaxine",{"EARLY_PHASE1":8192,"PHASE1":8194,"PHASE2":8196,"PHASE3":8206,"PHASE4":8208,"NA":8210},{"trials":8193,"activeCount":103},[],{"trials":8195,"activeCount":103},[],{"trials":8197,"activeCount":103},[8198],{"nctId":8199,"briefTitle":8200,"status":257,"phases":8201,"primaryCompletion":127,"completion":127,"start":4838,"enrollment":103,"conditions":8202,"interventions":8203},"NCT02835794","A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)",[91,92],[5486],[8190,8204,8205],"Azacitidine","G-CSF",{"trials":8207,"activeCount":103},[],{"trials":8209,"activeCount":103},[],{"trials":8211,"activeCount":103},[],{"intervention":8204,"totalTrials":323,"cells":8213},{"EARLY_PHASE1":8214,"PHASE1":8216,"PHASE2":8218,"PHASE3":8224,"PHASE4":8226,"NA":8228},{"trials":8215,"activeCount":103},[],{"trials":8217,"activeCount":103},[],{"trials":8219,"activeCount":103},[8220],{"nctId":8199,"briefTitle":8200,"status":257,"phases":8221,"primaryCompletion":127,"completion":127,"start":4838,"enrollment":103,"conditions":8222,"interventions":8223},[91,92],[5486],[8190,8204,8205],{"trials":8225,"activeCount":103},[],{"trials":8227,"activeCount":103},[],{"trials":8229,"activeCount":103},[],{"intervention":8205,"totalTrials":323,"cells":8231},{"EARLY_PHASE1":8232,"PHASE1":8234,"PHASE2":8236,"PHASE3":8242,"PHASE4":8244,"NA":8246},{"trials":8233,"activeCount":103},[],{"trials":8235,"activeCount":103},[],{"trials":8237,"activeCount":103},[8238],{"nctId":8199,"briefTitle":8200,"status":257,"phases":8239,"primaryCompletion":127,"completion":127,"start":4838,"enrollment":103,"conditions":8240,"interventions":8241},[91,92],[5486],[8190,8204,8205],{"trials":8243,"activeCount":103},[],{"trials":8245,"activeCount":103},[],{"trials":8247,"activeCount":103},[],{"intervention":8249,"totalTrials":323,"cells":8250},"Ticagrelor 270mg",{"EARLY_PHASE1":8251,"PHASE1":8253,"PHASE2":8255,"PHASE3":8266,"PHASE4":8268,"NA":8270},{"trials":8252,"activeCount":103},[],{"trials":8254,"activeCount":103},[],{"trials":8256,"activeCount":103},[8257],{"nctId":8258,"briefTitle":8259,"status":115,"phases":8260,"primaryCompletion":780,"completion":780,"start":8261,"enrollment":735,"conditions":8262,"interventions":8263},"NCT01898442","High Ticagrelor Loading Dose in STEMI",[92],"2013-09",[18],[8264,8249,8265],"Ticagrelor 180mg","Ticagrelor 360mg",{"trials":8267,"activeCount":103},[],{"trials":8269,"activeCount":103},[],{"trials":8271,"activeCount":103},[],{"intervention":8265,"totalTrials":323,"cells":8273},{"EARLY_PHASE1":8274,"PHASE1":8276,"PHASE2":8278,"PHASE3":8284,"PHASE4":8286,"NA":8288},{"trials":8275,"activeCount":103},[],{"trials":8277,"activeCount":103},[],{"trials":8279,"activeCount":103},[8280],{"nctId":8258,"briefTitle":8259,"status":115,"phases":8281,"primaryCompletion":780,"completion":780,"start":8261,"enrollment":735,"conditions":8282,"interventions":8283},[92],[18],[8264,8249,8265],{"trials":8285,"activeCount":103},[],{"trials":8287,"activeCount":103},[],{"trials":8289,"activeCount":103},[],{"intervention":8291,"totalTrials":323,"cells":8292},"Nicardipine hydrochloride",{"EARLY_PHASE1":8293,"PHASE1":8295,"PHASE2":8297,"PHASE3":8307,"PHASE4":8309,"NA":8311},{"trials":8294,"activeCount":103},[],{"trials":8296,"activeCount":103},[],{"trials":8298,"activeCount":103},[8299],{"nctId":8300,"briefTitle":8301,"status":1053,"phases":8302,"primaryCompletion":2654,"completion":2654,"start":3399,"enrollment":210,"conditions":8303,"interventions":8305},"NCT01810302","Safety Study of Nicardipine to Treat Cerebral Vasospasm",[92],[8304],"Cerebral Vasospasm",[8291,8306],"Preservative-free normal saline",{"trials":8308,"activeCount":103},[],{"trials":8310,"activeCount":103},[],{"trials":8312,"activeCount":103},[],{"intervention":8306,"totalTrials":323,"cells":8314},{"EARLY_PHASE1":8315,"PHASE1":8317,"PHASE2":8319,"PHASE3":8325,"PHASE4":8327,"NA":8329},{"trials":8316,"activeCount":103},[],{"trials":8318,"activeCount":103},[],{"trials":8320,"activeCount":103},[8321],{"nctId":8300,"briefTitle":8301,"status":1053,"phases":8322,"primaryCompletion":2654,"completion":2654,"start":3399,"enrollment":210,"conditions":8323,"interventions":8324},[92],[8304],[8291,8306],{"trials":8326,"activeCount":103},[],{"trials":8328,"activeCount":103},[],{"trials":8330,"activeCount":103},[],{"intervention":8332,"totalTrials":323,"cells":8333},"Minocycline Group",{"EARLY_PHASE1":8334,"PHASE1":8336,"PHASE2":8338,"PHASE3":8348,"PHASE4":8350,"NA":8352},{"trials":8335,"activeCount":103},[],{"trials":8337,"activeCount":103},[],{"trials":8339,"activeCount":103},[8340],{"nctId":8341,"briefTitle":8342,"status":257,"phases":8343,"primaryCompletion":8344,"completion":8344,"start":8345,"enrollment":103,"conditions":8346,"interventions":8347},"NCT02133885","Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients",[91,92],"2024-03","2023-01-30",[27],[8332],{"trials":8349,"activeCount":103},[],{"trials":8351,"activeCount":103},[],{"trials":8353,"activeCount":103},[],{"intervention":5754,"totalTrials":210,"cells":8355},{"EARLY_PHASE1":8356,"PHASE1":8358,"PHASE2":8375,"PHASE3":8377,"PHASE4":8379,"NA":8381},{"trials":8357,"activeCount":103},[],{"trials":8359,"activeCount":103},[8360,8364],{"nctId":5748,"briefTitle":5749,"status":115,"phases":8361,"primaryCompletion":3079,"completion":3079,"start":734,"enrollment":1272,"conditions":8362,"interventions":8363},[91],[5752,21],[5741,5754],{"nctId":8365,"briefTitle":8366,"status":115,"phases":8367,"primaryCompletion":8368,"completion":8368,"start":721,"enrollment":210,"conditions":8369,"interventions":8372},"NCT01433757","Ampicillin for DYT-1 Dystonia Motor Symptoms",[91],"2017-06",[8370,8371],"DYT-1","Dystonia",[8373,8374],"Ampicillin","Sugar pill",{"trials":8376,"activeCount":103},[],{"trials":8378,"activeCount":103},[],{"trials":8380,"activeCount":103},[],{"trials":8382,"activeCount":103},[],{"intervention":2105,"totalTrials":210,"cells":8384},{"EARLY_PHASE1":8385,"PHASE1":8387,"PHASE2":8397,"PHASE3":8399,"PHASE4":8401,"NA":8403},{"trials":8386,"activeCount":103},[],{"trials":8388,"activeCount":103},[8389,8393],{"nctId":2094,"briefTitle":2095,"status":1053,"phases":8390,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":8391,"interventions":8392},[91],[2101,2102],[931,932,2104,2105,933,2106],{"nctId":2108,"briefTitle":2109,"status":1053,"phases":8394,"primaryCompletion":2097,"completion":2097,"start":2111,"enrollment":2112,"conditions":8395,"interventions":8396},[91],[2114,2115],[931,2117,2088,932,933],{"trials":8398,"activeCount":103},[],{"trials":8400,"activeCount":103},[],{"trials":8402,"activeCount":103},[],{"trials":8404,"activeCount":103},[],{"intervention":5514,"totalTrials":323,"cells":8406},{"EARLY_PHASE1":8407,"PHASE1":8409,"PHASE2":8415,"PHASE3":8417,"PHASE4":8419,"NA":8421},{"trials":8408,"activeCount":103},[],{"trials":8410,"activeCount":103},[8411],{"nctId":5506,"briefTitle":5507,"status":115,"phases":8412,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":210,"conditions":8413,"interventions":8414},[91],[5512],[5514,5515,5516,5499,5517,5518,5519],{"trials":8416,"activeCount":103},[],{"trials":8418,"activeCount":103},[],{"trials":8420,"activeCount":103},[],{"trials":8422,"activeCount":103},[],{"intervention":5515,"totalTrials":323,"cells":8424},{"EARLY_PHASE1":8425,"PHASE1":8427,"PHASE2":8433,"PHASE3":8435,"PHASE4":8437,"NA":8439},{"trials":8426,"activeCount":103},[],{"trials":8428,"activeCount":103},[8429],{"nctId":5506,"briefTitle":5507,"status":115,"phases":8430,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":210,"conditions":8431,"interventions":8432},[91],[5512],[5514,5515,5516,5499,5517,5518,5519],{"trials":8434,"activeCount":103},[],{"trials":8436,"activeCount":103},[],{"trials":8438,"activeCount":103},[],{"trials":8440,"activeCount":103},[],{"intervention":5516,"totalTrials":323,"cells":8442},{"EARLY_PHASE1":8443,"PHASE1":8445,"PHASE2":8451,"PHASE3":8453,"PHASE4":8455,"NA":8457},{"trials":8444,"activeCount":103},[],{"trials":8446,"activeCount":103},[8447],{"nctId":5506,"briefTitle":5507,"status":115,"phases":8448,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":210,"conditions":8449,"interventions":8450},[91],[5512],[5514,5515,5516,5499,5517,5518,5519],{"trials":8452,"activeCount":103},[],{"trials":8454,"activeCount":103},[],{"trials":8456,"activeCount":103},[],{"trials":8458,"activeCount":103},[],{"intervention":5519,"totalTrials":323,"cells":8460},{"EARLY_PHASE1":8461,"PHASE1":8463,"PHASE2":8469,"PHASE3":8471,"PHASE4":8473,"NA":8475},{"trials":8462,"activeCount":103},[],{"trials":8464,"activeCount":103},[8465],{"nctId":5506,"briefTitle":5507,"status":115,"phases":8466,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":210,"conditions":8467,"interventions":8468},[91],[5512],[5514,5515,5516,5499,5517,5518,5519],{"trials":8470,"activeCount":103},[],{"trials":8472,"activeCount":103},[],{"trials":8474,"activeCount":103},[],{"trials":8476,"activeCount":103},[],{"intervention":8478,"totalTrials":323,"cells":8479},"Lenalidomide",{"EARLY_PHASE1":8480,"PHASE1":8482,"PHASE2":8493,"PHASE3":8495,"PHASE4":8497,"NA":8499},{"trials":8481,"activeCount":103},[],{"trials":8483,"activeCount":103},[8484],{"nctId":8485,"briefTitle":8486,"status":1053,"phases":8487,"primaryCompletion":8488,"completion":8488,"start":8489,"enrollment":2099,"conditions":8490,"interventions":8492},"NCT02370888","Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease",[91],"2019-05-31","2016-05-16",[8491,5486],"Leukemia, Myeloid",[8478],{"trials":8494,"activeCount":103},[],{"trials":8496,"activeCount":103},[],{"trials":8498,"activeCount":103},[],{"trials":8500,"activeCount":103},[],{"intervention":8502,"totalTrials":323,"cells":8503},"100% Oxygen",{"EARLY_PHASE1":8504,"PHASE1":8506,"PHASE2":8519,"PHASE3":8521,"PHASE4":8523,"NA":8525},{"trials":8505,"activeCount":103},[],{"trials":8507,"activeCount":103},[8508],{"nctId":8509,"briefTitle":8510,"status":115,"phases":8511,"primaryCompletion":8512,"completion":8512,"start":8513,"enrollment":5160,"conditions":8514,"interventions":8518},"NCT03386136","Therapeutic Oxygen for Gastrointestinal Atony (TOGA)",[91],"2019-10-17","2018-01-25",[8515,8516,8517],"Ileus","Ogilvie Syndrome","Small Bowel Obstruction",[8502],{"trials":8520,"activeCount":103},[],{"trials":8522,"activeCount":103},[],{"trials":8524,"activeCount":103},[],{"trials":8526,"activeCount":103},[],{"intervention":8528,"totalTrials":323,"cells":8529},"Myfortic",{"EARLY_PHASE1":8530,"PHASE1":8532,"PHASE2":8544,"PHASE3":8546,"PHASE4":8548,"NA":8550},{"trials":8531,"activeCount":103},[],{"trials":8533,"activeCount":103},[8534],{"nctId":8535,"briefTitle":8536,"status":115,"phases":8537,"primaryCompletion":8538,"completion":3059,"start":8539,"enrollment":2429,"conditions":8540,"interventions":8543},"NCT00298883","Desensitization of Renal Transplant Candidates",[91],"2008-08","2006-02",[8541,8542],"End Stage Renal Disease","Kidney Transplantation",[8528],{"trials":8545,"activeCount":103},[],{"trials":8547,"activeCount":103},[],{"trials":8549,"activeCount":103},[],{"trials":8551,"activeCount":103},[],{"intervention":8553,"totalTrials":323,"cells":8554},"Mometasone furoate drug formulation (MFF) 1",{"EARLY_PHASE1":8555,"PHASE1":8557,"PHASE2":8569,"PHASE3":8571,"PHASE4":8573,"NA":8575},{"trials":8556,"activeCount":103},[],{"trials":8558,"activeCount":103},[8559],{"nctId":8560,"briefTitle":8561,"status":115,"phases":8562,"primaryCompletion":8563,"completion":8564,"start":2929,"enrollment":469,"conditions":8565,"interventions":8567},"NCT02588326","Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays",[91],"2020-07-08","2021-04-16",[8566],"Hypersensitivity",[8553,8568],"Mometasone furoate drug formulation (MFF) 2",{"trials":8570,"activeCount":103},[],{"trials":8572,"activeCount":103},[],{"trials":8574,"activeCount":103},[],{"trials":8576,"activeCount":103},[],{"intervention":8568,"totalTrials":323,"cells":8578},{"EARLY_PHASE1":8579,"PHASE1":8581,"PHASE2":8587,"PHASE3":8589,"PHASE4":8591,"NA":8593},{"trials":8580,"activeCount":103},[],{"trials":8582,"activeCount":103},[8583],{"nctId":8560,"briefTitle":8561,"status":115,"phases":8584,"primaryCompletion":8563,"completion":8564,"start":2929,"enrollment":469,"conditions":8585,"interventions":8586},[91],[8566],[8553,8568],{"trials":8588,"activeCount":103},[],{"trials":8590,"activeCount":103},[],{"trials":8592,"activeCount":103},[],{"trials":8594,"activeCount":103},[],{"intervention":8596,"totalTrials":323,"cells":8597},"LITT + Pembrolizumab",{"EARLY_PHASE1":8598,"PHASE1":8600,"PHASE2":8621,"PHASE3":8623,"PHASE4":8625,"NA":8627},{"trials":8599,"activeCount":103},[],{"trials":8601,"activeCount":103},[8602],{"nctId":8603,"briefTitle":8604,"status":1053,"phases":8605,"primaryCompletion":8606,"completion":8606,"start":1724,"enrollment":695,"conditions":8607,"interventions":8620},"NCT04187872","LITT and Pembrolizumab in Recurrent Brain Metastasis",[91],"2023-12-01",[8608,8609,8610,8611,8612,8613,8614,7753,8615,8616,2666,8617,1263,8618,8619],"Melanoma","Non-small Cell Lung Carcinoma (NSCLC)","Renal Cell Carcinoma (RCC)","Small-cell Lung Cancer","Head and Neck Squamous Cell Cancer","Classical Hodgkin Lymphoma","Primary Mediastinal Large B-Cell Lymphoma","Microsatellite Instability-High Cancer","Gastric Cancer","Cervical Cancer","Merkel Cell Carcinoma","Brain Metastases, Adult",[8596],{"trials":8622,"activeCount":103},[],{"trials":8624,"activeCount":103},[],{"trials":8626,"activeCount":103},[],{"trials":8628,"activeCount":103},[],{"intervention":8630,"totalTrials":323,"cells":8631},"13C-Pyruvate 13C-lactate and dichloroacetate",{"EARLY_PHASE1":8632,"PHASE1":8634,"PHASE2":8643,"PHASE3":8645,"PHASE4":8647,"NA":8649},{"trials":8633,"activeCount":103},[],{"trials":8635,"activeCount":103},[8636],{"nctId":8637,"briefTitle":8638,"status":115,"phases":8639,"primaryCompletion":8640,"completion":8640,"start":6704,"enrollment":250,"conditions":8641,"interventions":8642},"NCT01807702","13C-Pyruvate Breath Test",[91],"2013-07",[15],[8630],{"trials":8644,"activeCount":103},[],{"trials":8646,"activeCount":103},[],{"trials":8648,"activeCount":103},[],{"trials":8650,"activeCount":103},[],{"intervention":5720,"totalTrials":323,"cells":8652},{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8661,"PHASE3":8663,"PHASE4":8665,"NA":8667},{"trials":8654,"activeCount":103},[],{"trials":8656,"activeCount":103},[8657],{"nctId":5714,"briefTitle":5715,"status":257,"phases":8658,"primaryCompletion":734,"completion":734,"start":3044,"enrollment":103,"conditions":8659,"interventions":8660},[91],[5718],[5707,5720],{"trials":8662,"activeCount":103},[],{"trials":8664,"activeCount":103},[],{"trials":8666,"activeCount":103},[],{"trials":8668,"activeCount":103},[],{"intervention":8670,"totalTrials":323,"cells":8671},"OXi4503",{"EARLY_PHASE1":8672,"PHASE1":8674,"PHASE2":8684,"PHASE3":8686,"PHASE4":8688,"NA":8690},{"trials":8673,"activeCount":103},[],{"trials":8675,"activeCount":103},[8676],{"nctId":8677,"briefTitle":8678,"status":1053,"phases":8679,"primaryCompletion":8680,"completion":8680,"start":4689,"enrollment":2112,"conditions":8681,"interventions":8683},"NCT01085656","A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS",[91],"2016-01",[8682,5486],"Leukemia, Myelogenous, Acute",[8670],{"trials":8685,"activeCount":103},[],{"trials":8687,"activeCount":103},[],{"trials":8689,"activeCount":103},[],{"trials":8691,"activeCount":103},[],{"intervention":8693,"totalTrials":323,"cells":8694},"PEP-CMV",{"EARLY_PHASE1":8695,"PHASE1":8697,"PHASE2":8705,"PHASE3":8707,"PHASE4":8709,"NA":8711},{"trials":8696,"activeCount":103},[],{"trials":8698,"activeCount":103},[8699],{"nctId":8700,"briefTitle":8701,"status":257,"phases":8702,"primaryCompletion":2654,"completion":2654,"start":2654,"enrollment":103,"conditions":8703,"interventions":8704},"NCT01854099","Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens",[91],[964],[8693,8693,8693],{"trials":8706,"activeCount":103},[],{"trials":8708,"activeCount":103},[],{"trials":8710,"activeCount":103},[],{"trials":8712,"activeCount":103},[],{"intervention":8714,"totalTrials":323,"cells":8715},"Zavesca® Prescription",{"EARLY_PHASE1":8716,"PHASE1":8718,"PHASE2":8728,"PHASE3":8730,"PHASE4":8732,"NA":8734},{"trials":8717,"activeCount":103},[],{"trials":8719,"activeCount":103},[8720],{"nctId":8721,"briefTitle":8722,"status":1053,"phases":8723,"primaryCompletion":8724,"completion":8724,"start":5781,"enrollment":210,"conditions":8725,"interventions":8727},"NCT02185651","A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction",[91],"2018-07",[5512,8726],"Hypersensitivity Reaction",[8714],{"trials":8729,"activeCount":103},[],{"trials":8731,"activeCount":103},[],{"trials":8733,"activeCount":103},[],{"trials":8735,"activeCount":103},[],{"intervention":8737,"totalTrials":323,"cells":8738},"NP-101",{"EARLY_PHASE1":8739,"PHASE1":8741,"PHASE2":8751,"PHASE3":8753,"PHASE4":8755,"NA":8757},{"trials":8740,"activeCount":103},[],{"trials":8742,"activeCount":103},[8743],{"nctId":8744,"briefTitle":8745,"status":257,"phases":8746,"primaryCompletion":531,"completion":8747,"start":8748,"enrollment":103,"conditions":8749,"interventions":8750},"NCT06217094","Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment",[91],"2030-09","2026-02",[1263],[8737,8737,8737],{"trials":8752,"activeCount":103},[],{"trials":8754,"activeCount":103},[],{"trials":8756,"activeCount":103},[],{"trials":8758,"activeCount":103},[],{"intervention":8760,"totalTrials":323,"cells":8761},"Epoetin Alfa group",{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8773,"PHASE3":8775,"PHASE4":8777,"NA":8779},{"trials":8763,"activeCount":103},[],{"trials":8765,"activeCount":103},[8766],{"nctId":8767,"briefTitle":8768,"status":115,"phases":8769,"primaryCompletion":3059,"completion":3059,"start":8539,"enrollment":146,"conditions":8770,"interventions":8772},"NCT00294203","Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer",[91],[8771],"Anemia",[8760],{"trials":8774,"activeCount":103},[],{"trials":8776,"activeCount":103},[],{"trials":8778,"activeCount":103},[],{"trials":8780,"activeCount":103},[],{"intervention":8782,"totalTrials":323,"cells":8783},"Intranasal oxytocin",{"EARLY_PHASE1":8784,"PHASE1":8786,"PHASE2":8795,"PHASE3":8797,"PHASE4":8799,"NA":8801},{"trials":8785,"activeCount":103},[],{"trials":8787,"activeCount":103},[8788],{"nctId":8789,"briefTitle":8790,"status":115,"phases":8791,"primaryCompletion":733,"completion":733,"start":1055,"enrollment":2043,"conditions":8792,"interventions":8794},"NCT02013258","Oxytocin Trial in Prader-Willi Syndrome",[91],[8793],"Prader Willi Syndrome",[8782],{"trials":8796,"activeCount":103},[],{"trials":8798,"activeCount":103},[],{"trials":8800,"activeCount":103},[],{"trials":8802,"activeCount":103},[],{"intervention":8804,"totalTrials":323,"cells":8805},"Capsaicin vapor",{"EARLY_PHASE1":8806,"PHASE1":8808,"PHASE2":8819,"PHASE3":8821,"PHASE4":8823,"NA":8825},{"trials":8807,"activeCount":103},[],{"trials":8809,"activeCount":103},[8810],{"nctId":8811,"briefTitle":8812,"status":115,"phases":8813,"primaryCompletion":8814,"completion":8815,"start":6122,"enrollment":8816,"conditions":8817,"interventions":8818},"NCT02390089","Cough According to Stimulus Type in PD",[91],"2017-02-10","2019-02-13",158,[2987],[8804],{"trials":8820,"activeCount":103},[],{"trials":8822,"activeCount":103},[],{"trials":8824,"activeCount":103},[],{"trials":8826,"activeCount":103},[],{"intervention":8828,"totalTrials":323,"cells":8829},"armodafinil",{"EARLY_PHASE1":8830,"PHASE1":8832,"PHASE2":8842,"PHASE3":8844,"PHASE4":8846,"NA":8848},{"trials":8831,"activeCount":103},[],{"trials":8833,"activeCount":103},[8834],{"nctId":8835,"briefTitle":8836,"status":115,"phases":8837,"primaryCompletion":8838,"completion":8838,"start":8839,"enrollment":926,"conditions":8840,"interventions":8841},"NCT02468856","Effect of Armodafinil on Simulated Driving",[91],"2017-11-30","2017-05-21",[5718],[8828],{"trials":8843,"activeCount":103},[],{"trials":8845,"activeCount":103},[],{"trials":8847,"activeCount":103},[],{"trials":8849,"activeCount":103},[],{"intervention":8851,"totalTrials":323,"cells":8852},"Low dose Resveratrol",{"EARLY_PHASE1":8853,"PHASE1":8855,"PHASE2":8865,"PHASE3":8867,"PHASE4":8869,"NA":8871},{"trials":8854,"activeCount":103},[],{"trials":8856,"activeCount":103},[8857],{"nctId":8858,"briefTitle":8859,"status":115,"phases":8860,"primaryCompletion":7601,"completion":7601,"start":2832,"enrollment":2772,"conditions":8861,"interventions":8863},"NCT01126229","Resveratrol for Improved Performance in the Elderly",[91],[8862],"Memory",[8851,8864],"High dose Resveratrol",{"trials":8866,"activeCount":103},[],{"trials":8868,"activeCount":103},[],{"trials":8870,"activeCount":103},[],{"trials":8872,"activeCount":103},[],{"intervention":8864,"totalTrials":323,"cells":8874},{"EARLY_PHASE1":8875,"PHASE1":8877,"PHASE2":8883,"PHASE3":8885,"PHASE4":8887,"NA":8889},{"trials":8876,"activeCount":103},[],{"trials":8878,"activeCount":103},[8879],{"nctId":8858,"briefTitle":8859,"status":115,"phases":8880,"primaryCompletion":7601,"completion":7601,"start":2832,"enrollment":2772,"conditions":8881,"interventions":8882},[91],[8862],[8851,8864],{"trials":8884,"activeCount":103},[],{"trials":8886,"activeCount":103},[],{"trials":8888,"activeCount":103},[],{"trials":8890,"activeCount":103},[],{"intervention":8892,"totalTrials":323,"cells":8893},"Autologous total tumor mRNA loaded DOTAP liposome vaccine",{"EARLY_PHASE1":8894,"PHASE1":8896,"PHASE2":8905,"PHASE3":8907,"PHASE4":8909,"NA":8911},{"trials":8895,"activeCount":103},[],{"trials":8897,"activeCount":103},[8898],{"nctId":8899,"briefTitle":8900,"status":940,"phases":8901,"primaryCompletion":1118,"completion":1118,"start":8902,"enrollment":2112,"conditions":8903,"interventions":8904},"NCT05264974","Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization",[91],"2026-03-17",[8608,7328],[8892],{"trials":8906,"activeCount":103},[],{"trials":8908,"activeCount":103},[],{"trials":8910,"activeCount":103},[],{"trials":8912,"activeCount":103},[],{"intervention":8373,"totalTrials":323,"cells":8914},{"EARLY_PHASE1":8915,"PHASE1":8917,"PHASE2":8923,"PHASE3":8925,"PHASE4":8927,"NA":8929},{"trials":8916,"activeCount":103},[],{"trials":8918,"activeCount":103},[8919],{"nctId":8365,"briefTitle":8366,"status":115,"phases":8920,"primaryCompletion":8368,"completion":8368,"start":721,"enrollment":210,"conditions":8921,"interventions":8922},[91],[8370,8371],[8373,8374],{"trials":8924,"activeCount":103},[],{"trials":8926,"activeCount":103},[],{"trials":8928,"activeCount":103},[],{"trials":8930,"activeCount":103},[],{"intervention":8932,"totalTrials":323,"cells":8933},"ibuprofen",{"EARLY_PHASE1":8934,"PHASE1":8936,"PHASE2":8947,"PHASE3":8949,"PHASE4":8951,"NA":8953},{"trials":8935,"activeCount":103},[],{"trials":8937,"activeCount":103},[8938],{"nctId":8939,"briefTitle":8940,"status":115,"phases":8941,"primaryCompletion":8942,"completion":8942,"start":8943,"enrollment":34,"conditions":8944,"interventions":8946},"NCT03103022","Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus",[91],"2019-04-30","2017-06-12",[5839,8945],"Neonate",[5517,8932],{"trials":8948,"activeCount":103},[],{"trials":8950,"activeCount":103},[],{"trials":8952,"activeCount":103},[],{"trials":8954,"activeCount":103},[],{"intervention":8956,"totalTrials":323,"cells":8957},"Autologous UCB",{"EARLY_PHASE1":8958,"PHASE1":8960,"PHASE2":8969,"PHASE3":8971,"PHASE4":8973,"NA":8975},{"trials":8959,"activeCount":103},[],{"trials":8961,"activeCount":103},[8962],{"nctId":8963,"briefTitle":8964,"status":115,"phases":8965,"primaryCompletion":4035,"completion":7522,"start":8966,"enrollment":1953,"conditions":8967,"interventions":8968},"NCT00873925","Cord Blood Plus Vitamin D and Omega 3s in T1D",[91],"2009-03",[1495],[8956],{"trials":8970,"activeCount":103},[],{"trials":8972,"activeCount":103},[],{"trials":8974,"activeCount":103},[],{"trials":8976,"activeCount":103},[],{"intervention":8978,"totalTrials":323,"cells":8979},"timolol maleate and dorzolamide hydrochloride",{"EARLY_PHASE1":8980,"PHASE1":8982,"PHASE2":8993,"PHASE3":8995,"PHASE4":8997,"NA":8999},{"trials":8981,"activeCount":103},[],{"trials":8983,"activeCount":103},[8984],{"nctId":8985,"briefTitle":8986,"status":115,"phases":8987,"primaryCompletion":8988,"completion":8988,"start":8989,"enrollment":210,"conditions":8990,"interventions":8992},"NCT02852057","Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses",[91],"2021-08-10","2018-01-18",[8991],"Glaucoma",[8978],{"trials":8994,"activeCount":103},[],{"trials":8996,"activeCount":103},[],{"trials":8998,"activeCount":103},[],{"trials":9000,"activeCount":103},[],{"intervention":9002,"totalTrials":323,"cells":9003},"Milnacipran",{"EARLY_PHASE1":9004,"PHASE1":9006,"PHASE2":9016,"PHASE3":9018,"PHASE4":9020,"NA":9022},{"trials":9005,"activeCount":103},[],{"trials":9007,"activeCount":103},[9008],{"nctId":9009,"briefTitle":9010,"status":115,"phases":9011,"primaryCompletion":2808,"completion":2808,"start":2832,"enrollment":9012,"conditions":9013,"interventions":9015},"NCT01294059","Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients",[91],51,[9014],"Fibromyalgia",[9002],{"trials":9017,"activeCount":103},[],{"trials":9019,"activeCount":103},[],{"trials":9021,"activeCount":103},[],{"trials":9023,"activeCount":103},[],{"intervention":9025,"totalTrials":323,"cells":9026},"Autologous DCs derived from PBMC loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF",{"EARLY_PHASE1":9027,"PHASE1":9029,"PHASE2":9039,"PHASE3":9041,"PHASE4":9043,"NA":9045},{"trials":9028,"activeCount":103},[],{"trials":9030,"activeCount":103},[9031],{"nctId":9032,"briefTitle":9033,"status":1053,"phases":9034,"primaryCompletion":9035,"completion":9035,"start":9036,"enrollment":2714,"conditions":9037,"interventions":9038},"NCT04963413","RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.",[91],"2023-09-28","2022-01-13",[964],[9025],{"trials":9040,"activeCount":103},[],{"trials":9042,"activeCount":103},[],{"trials":9044,"activeCount":103},[],{"trials":9046,"activeCount":103},[],{"intervention":9048,"totalTrials":323,"cells":9049},"Fluticasone Propionate Formulation 1",{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9064,"PHASE3":9066,"PHASE4":9068,"NA":9070},{"trials":9051,"activeCount":103},[],{"trials":9053,"activeCount":103},[9054],{"nctId":9055,"briefTitle":9056,"status":115,"phases":9057,"primaryCompletion":9058,"completion":9058,"start":2528,"enrollment":2043,"conditions":9059,"interventions":9060},"NCT01966692","Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution",[91],"2018-01-20",[2716],[9048,9061,9062,9063],"Fluticasone Propionate Formulation 2","Fluticasone Propionate Formulation 3","Fluticasone Propionate Formulation 3*",{"trials":9065,"activeCount":103},[],{"trials":9067,"activeCount":103},[],{"trials":9069,"activeCount":103},[],{"trials":9071,"activeCount":103},[],{"intervention":9061,"totalTrials":323,"cells":9073},{"EARLY_PHASE1":9074,"PHASE1":9076,"PHASE2":9082,"PHASE3":9084,"PHASE4":9086,"NA":9088},{"trials":9075,"activeCount":103},[],{"trials":9077,"activeCount":103},[9078],{"nctId":9055,"briefTitle":9056,"status":115,"phases":9079,"primaryCompletion":9058,"completion":9058,"start":2528,"enrollment":2043,"conditions":9080,"interventions":9081},[91],[2716],[9048,9061,9062,9063],{"trials":9083,"activeCount":103},[],{"trials":9085,"activeCount":103},[],{"trials":9087,"activeCount":103},[],{"trials":9089,"activeCount":103},[],{"intervention":9062,"totalTrials":323,"cells":9091},{"EARLY_PHASE1":9092,"PHASE1":9094,"PHASE2":9100,"PHASE3":9102,"PHASE4":9104,"NA":9106},{"trials":9093,"activeCount":103},[],{"trials":9095,"activeCount":103},[9096],{"nctId":9055,"briefTitle":9056,"status":115,"phases":9097,"primaryCompletion":9058,"completion":9058,"start":2528,"enrollment":2043,"conditions":9098,"interventions":9099},[91],[2716],[9048,9061,9062,9063],{"trials":9101,"activeCount":103},[],{"trials":9103,"activeCount":103},[],{"trials":9105,"activeCount":103},[],{"trials":9107,"activeCount":103},[],{"intervention":9063,"totalTrials":323,"cells":9109},{"EARLY_PHASE1":9110,"PHASE1":9112,"PHASE2":9118,"PHASE3":9120,"PHASE4":9122,"NA":9124},{"trials":9111,"activeCount":103},[],{"trials":9113,"activeCount":103},[9114],{"nctId":9055,"briefTitle":9056,"status":115,"phases":9115,"primaryCompletion":9058,"completion":9058,"start":2528,"enrollment":2043,"conditions":9116,"interventions":9117},[91],[2716],[9048,9061,9062,9063],{"trials":9119,"activeCount":103},[],{"trials":9121,"activeCount":103},[],{"trials":9123,"activeCount":103},[],{"trials":9125,"activeCount":103},[],{"intervention":9127,"totalTrials":323,"cells":9128},"Next Science OTC Oral Rinse with Essential Oils",{"EARLY_PHASE1":9129,"PHASE1":9131,"PHASE2":9146,"PHASE3":9148,"PHASE4":9150,"NA":9152},{"trials":9130,"activeCount":103},[],{"trials":9132,"activeCount":103},[9133],{"nctId":9134,"briefTitle":9135,"status":115,"phases":9136,"primaryCompletion":9137,"completion":9138,"start":9139,"enrollment":9140,"conditions":9141,"interventions":9144},"NCT03154021","Next Science Antimicrobial Mouth Rinse Study",[91],"2018-03-08","2018-05-15","2017-08-28",118,[9142,9143],"Gingivitis","Dental Plaque",[9127,9145],"OTC Oral Rinse Control",{"trials":9147,"activeCount":103},[],{"trials":9149,"activeCount":103},[],{"trials":9151,"activeCount":103},[],{"trials":9153,"activeCount":103},[],{"intervention":9145,"totalTrials":323,"cells":9155},{"EARLY_PHASE1":9156,"PHASE1":9158,"PHASE2":9164,"PHASE3":9166,"PHASE4":9168,"NA":9170},{"trials":9157,"activeCount":103},[],{"trials":9159,"activeCount":103},[9160],{"nctId":9134,"briefTitle":9135,"status":115,"phases":9161,"primaryCompletion":9137,"completion":9138,"start":9139,"enrollment":9140,"conditions":9162,"interventions":9163},[91],[9142,9143],[9127,9145],{"trials":9165,"activeCount":103},[],{"trials":9167,"activeCount":103},[],{"trials":9169,"activeCount":103},[],{"trials":9171,"activeCount":103},[],{"intervention":9173,"totalTrials":323,"cells":9174},"Nicotinamide Riboside",{"EARLY_PHASE1":9175,"PHASE1":9177,"PHASE2":9188,"PHASE3":9190,"PHASE4":9192,"NA":9194},{"trials":9176,"activeCount":103},[],{"trials":9178,"activeCount":103},[9179],{"nctId":9180,"briefTitle":9181,"status":115,"phases":9182,"primaryCompletion":9183,"completion":9183,"start":9184,"enrollment":9185,"conditions":9186,"interventions":9187},"NCT04112043","Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)",[91],"2023-05-26","2020-07-28",147,[27],[9173],{"trials":9189,"activeCount":103},[],{"trials":9191,"activeCount":103},[],{"trials":9193,"activeCount":103},[],{"trials":9195,"activeCount":103},[],{"intervention":2104,"totalTrials":323,"cells":9197},{"EARLY_PHASE1":9198,"PHASE1":9200,"PHASE2":9206,"PHASE3":9208,"PHASE4":9210,"NA":9212},{"trials":9199,"activeCount":103},[],{"trials":9201,"activeCount":103},[9202],{"nctId":2094,"briefTitle":2095,"status":1053,"phases":9203,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":9204,"interventions":9205},[91],[2101,2102],[931,932,2104,2105,933,2106],{"trials":9207,"activeCount":103},[],{"trials":9209,"activeCount":103},[],{"trials":9211,"activeCount":103},[],{"trials":9213,"activeCount":103},[],{"intervention":9215,"totalTrials":323,"cells":9216},"Nexium",{"EARLY_PHASE1":9217,"PHASE1":9219,"PHASE2":9230,"PHASE3":9232,"PHASE4":9234,"NA":9236},{"trials":9218,"activeCount":103},[],{"trials":9220,"activeCount":103},[9221],{"nctId":9222,"briefTitle":9223,"status":1053,"phases":9224,"primaryCompletion":1056,"completion":4035,"start":4648,"enrollment":926,"conditions":9225,"interventions":9227},"NCT01142128","Viokase 16, Viokase16 Plus Nexium and Nexium Alone",[91],[9226],"Chronic Pancreatitis",[9215,9228,9229],"Viokase 16 (pancrelipase) + Nexium","Viokase 16 + placebo to Nexium",{"trials":9231,"activeCount":103},[],{"trials":9233,"activeCount":103},[],{"trials":9235,"activeCount":103},[],{"trials":9237,"activeCount":103},[],{"intervention":9228,"totalTrials":323,"cells":9239},{"EARLY_PHASE1":9240,"PHASE1":9242,"PHASE2":9248,"PHASE3":9250,"PHASE4":9252,"NA":9254},{"trials":9241,"activeCount":103},[],{"trials":9243,"activeCount":103},[9244],{"nctId":9222,"briefTitle":9223,"status":1053,"phases":9245,"primaryCompletion":1056,"completion":4035,"start":4648,"enrollment":926,"conditions":9246,"interventions":9247},[91],[9226],[9215,9228,9229],{"trials":9249,"activeCount":103},[],{"trials":9251,"activeCount":103},[],{"trials":9253,"activeCount":103},[],{"trials":9255,"activeCount":103},[],{"intervention":9229,"totalTrials":323,"cells":9257},{"EARLY_PHASE1":9258,"PHASE1":9260,"PHASE2":9266,"PHASE3":9268,"PHASE4":9270,"NA":9272},{"trials":9259,"activeCount":103},[],{"trials":9261,"activeCount":103},[9262],{"nctId":9222,"briefTitle":9223,"status":1053,"phases":9263,"primaryCompletion":1056,"completion":4035,"start":4648,"enrollment":926,"conditions":9264,"interventions":9265},[91],[9226],[9215,9228,9229],{"trials":9267,"activeCount":103},[],{"trials":9269,"activeCount":103},[],{"trials":9271,"activeCount":103},[],{"trials":9273,"activeCount":103},[],{"intervention":9275,"totalTrials":323,"cells":9276},"Intranasal Oxytocin spray",{"EARLY_PHASE1":9277,"PHASE1":9279,"PHASE2":9289,"PHASE3":9291,"PHASE4":9293,"NA":9295},{"trials":9278,"activeCount":103},[],{"trials":9280,"activeCount":103},[9281],{"nctId":9282,"briefTitle":9283,"status":1053,"phases":9284,"primaryCompletion":9285,"completion":9285,"start":745,"enrollment":9286,"conditions":9287,"interventions":9288},"NCT02069431","Oxytocin Aging Study",[91],"2020-05",153,[3062],[9275],{"trials":9290,"activeCount":103},[],{"trials":9292,"activeCount":103},[],{"trials":9294,"activeCount":103},[],{"trials":9296,"activeCount":103},[],{"intervention":9298,"totalTrials":323,"cells":9299},"Vitamin D",{"EARLY_PHASE1":9300,"PHASE1":9302,"PHASE2":9310,"PHASE3":9312,"PHASE4":9314,"NA":9316},{"trials":9301,"activeCount":103},[],{"trials":9303,"activeCount":103},[9304],{"nctId":9305,"briefTitle":9306,"status":115,"phases":9307,"primaryCompletion":1055,"completion":1055,"start":722,"enrollment":1004,"conditions":9308,"interventions":9309},"NCT01855321","Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes",[91],[3359],[9298],{"trials":9311,"activeCount":103},[],{"trials":9313,"activeCount":103},[],{"trials":9315,"activeCount":103},[],{"trials":9317,"activeCount":103},[],{"intervention":9319,"totalTrials":323,"cells":9320},"omeprazole and pantoprazole",{"EARLY_PHASE1":9321,"PHASE1":9323,"PHASE2":9331,"PHASE3":9333,"PHASE4":9335,"NA":9337},{"trials":9322,"activeCount":103},[],{"trials":9324,"activeCount":103},[9325],{"nctId":9326,"briefTitle":9327,"status":115,"phases":9328,"primaryCompletion":722,"completion":722,"start":8966,"enrollment":34,"conditions":9329,"interventions":9330},"NCT01170533","PPI and Clopidogrel Response",[91],[3929],[9319],{"trials":9332,"activeCount":103},[],{"trials":9334,"activeCount":103},[],{"trials":9336,"activeCount":103},[],{"trials":9338,"activeCount":103},[],{"intervention":9340,"totalTrials":323,"cells":9341},"Neulasta",{"EARLY_PHASE1":9342,"PHASE1":9344,"PHASE2":9352,"PHASE3":9354,"PHASE4":9356,"NA":9358},{"trials":9343,"activeCount":103},[],{"trials":9345,"activeCount":103},[9346],{"nctId":9347,"briefTitle":9348,"status":115,"phases":9349,"primaryCompletion":712,"completion":712,"start":3027,"enrollment":31,"conditions":9350,"interventions":9351},"NCT00662519","Neulasta in Type 1 Diabetes",[91],[1495],[9340],{"trials":9353,"activeCount":103},[],{"trials":9355,"activeCount":103},[],{"trials":9357,"activeCount":103},[],{"trials":9359,"activeCount":103},[],{"intervention":2696,"totalTrials":323,"cells":9361},{"EARLY_PHASE1":9362,"PHASE1":9364,"PHASE2":9370,"PHASE3":9372,"PHASE4":9374,"NA":9376},{"trials":9363,"activeCount":103},[],{"trials":9365,"activeCount":103},[9366],{"nctId":2690,"briefTitle":2691,"status":257,"phases":9367,"primaryCompletion":773,"completion":773,"start":773,"enrollment":103,"conditions":9368,"interventions":9369},[91],[2694],[2696,2697,296],{"trials":9371,"activeCount":103},[],{"trials":9373,"activeCount":103},[],{"trials":9375,"activeCount":103},[],{"trials":9377,"activeCount":103},[],{"intervention":2697,"totalTrials":323,"cells":9379},{"EARLY_PHASE1":9380,"PHASE1":9382,"PHASE2":9388,"PHASE3":9390,"PHASE4":9392,"NA":9394},{"trials":9381,"activeCount":103},[],{"trials":9383,"activeCount":103},[9384],{"nctId":2690,"briefTitle":2691,"status":257,"phases":9385,"primaryCompletion":773,"completion":773,"start":773,"enrollment":103,"conditions":9386,"interventions":9387},[91],[2694],[2696,2697,296],{"trials":9389,"activeCount":103},[],{"trials":9391,"activeCount":103},[],{"trials":9393,"activeCount":103},[],{"trials":9395,"activeCount":103},[],{"intervention":9397,"totalTrials":323,"cells":9398},"Pyridostigmine Bromide",{"EARLY_PHASE1":9399,"PHASE1":9408,"PHASE2":9410,"PHASE3":9412,"PHASE4":9414,"NA":9416},{"trials":9400,"activeCount":103},[9401],{"nctId":9402,"briefTitle":9403,"status":1053,"phases":9404,"primaryCompletion":9405,"completion":9405,"start":733,"enrollment":210,"conditions":9406,"interventions":9407},"NCT02357225","A Pilot Study of Pyridostigmine in Pompe Disease",[90],"2018-01-01",[5512],[9397],{"trials":9409,"activeCount":103},[],{"trials":9411,"activeCount":103},[],{"trials":9413,"activeCount":103},[],{"trials":9415,"activeCount":103},[],{"trials":9417,"activeCount":103},[],{"intervention":9419,"totalTrials":323,"cells":9420},"Probiotic Strains",{"EARLY_PHASE1":9421,"PHASE1":9431,"PHASE2":9433,"PHASE3":9435,"PHASE4":9437,"NA":9439},{"trials":9422,"activeCount":103},[9423],{"nctId":9424,"briefTitle":9425,"status":115,"phases":9426,"primaryCompletion":5585,"completion":9427,"start":9428,"enrollment":1139,"conditions":9429,"interventions":9430},"NCT04065503","Probiotic Detection and Persistence Study",[90],"2020-12-31","2019-12-06",[15],[9419],{"trials":9432,"activeCount":103},[],{"trials":9434,"activeCount":103},[],{"trials":9436,"activeCount":103},[],{"trials":9438,"activeCount":103},[],{"trials":9440,"activeCount":103},[],{"intervention":9442,"totalTrials":323,"cells":9443},"Intra-articular corticosteroid",{"EARLY_PHASE1":9444,"PHASE1":9455,"PHASE2":9457,"PHASE3":9459,"PHASE4":9461,"NA":9463},{"trials":9445,"activeCount":103},[9446],{"nctId":9447,"briefTitle":9448,"status":115,"phases":9449,"primaryCompletion":9450,"completion":9450,"start":6221,"enrollment":2212,"conditions":9451,"interventions":9453},"NCT01382771","Intraarticular Lumbar Joint Corticosteroid Injection(s) as a Treatment of Chronic Low Back Pain in a Selected Population",[90],"2012-09",[9452],"Low Back Pain",[9442,9454],"Intra-articular saline",{"trials":9456,"activeCount":103},[],{"trials":9458,"activeCount":103},[],{"trials":9460,"activeCount":103},[],{"trials":9462,"activeCount":103},[],{"trials":9464,"activeCount":103},[],{"intervention":9454,"totalTrials":323,"cells":9466},{"EARLY_PHASE1":9467,"PHASE1":9473,"PHASE2":9475,"PHASE3":9477,"PHASE4":9479,"NA":9481},{"trials":9468,"activeCount":103},[9469],{"nctId":9447,"briefTitle":9448,"status":115,"phases":9470,"primaryCompletion":9450,"completion":9450,"start":6221,"enrollment":2212,"conditions":9471,"interventions":9472},[90],[9452],[9442,9454],{"trials":9474,"activeCount":103},[],{"trials":9476,"activeCount":103},[],{"trials":9478,"activeCount":103},[],{"trials":9480,"activeCount":103},[],{"trials":9482,"activeCount":103},[],{"intervention":9484,"totalTrials":323,"cells":9485},"Capsaicin cough sensitivity testing",{"EARLY_PHASE1":9486,"PHASE1":9497,"PHASE2":9499,"PHASE3":9501,"PHASE4":9503,"NA":9505},{"trials":9487,"activeCount":103},[9488],{"nctId":9489,"briefTitle":9490,"status":115,"phases":9491,"primaryCompletion":9492,"completion":9492,"start":6704,"enrollment":328,"conditions":9493,"interventions":9496},"NCT02240329","Assessment of Dystussia in Traumatic Brain Injury",[90],"2015-06",[9494,9495],"TBI","Brain Injury",[9484],{"trials":9498,"activeCount":103},[],{"trials":9500,"activeCount":103},[],{"trials":9502,"activeCount":103},[],{"trials":9504,"activeCount":103},[],{"trials":9506,"activeCount":103},[],{"intervention":9508,"totalTrials":323,"cells":9509},"Mycophenolate Mofetil",{"EARLY_PHASE1":9510,"PHASE1":9521,"PHASE2":9523,"PHASE3":9525,"PHASE4":9527,"NA":9529},{"trials":9511,"activeCount":103},[9512],{"nctId":9513,"briefTitle":9514,"status":115,"phases":9515,"primaryCompletion":9516,"completion":9516,"start":2863,"enrollment":356,"conditions":9517,"interventions":9520},"NCT00187941","MPA PK Monitoring Strategy With MMF\u002FFK Based Immunosuppression",[90],"2006-11",[9518,9519],"Transplantation, Renal","Immunosuppression",[9508],{"trials":9522,"activeCount":103},[],{"trials":9524,"activeCount":103},[],{"trials":9526,"activeCount":103},[],{"trials":9528,"activeCount":103},[],{"trials":9530,"activeCount":103},[],{"intervention":9532,"totalTrials":323,"cells":9533},"Alcohol",{"EARLY_PHASE1":9534,"PHASE1":9547,"PHASE2":9549,"PHASE3":9551,"PHASE4":9553,"NA":9555},{"trials":9535,"activeCount":103},[9536],{"nctId":9537,"briefTitle":9538,"status":1053,"phases":9539,"primaryCompletion":9540,"completion":9541,"start":9542,"enrollment":2043,"conditions":9543,"interventions":9546},"NCT03736343","Impulsivity and Alcohol Response",[90],"2020-05-31","2022-10-17","2019-05-01",[9544,9545],"Alcohol Use Disorder (AUD)","Subjective Response to Alcohol (SR)",[9532],{"trials":9548,"activeCount":103},[],{"trials":9550,"activeCount":103},[],{"trials":9552,"activeCount":103},[],{"trials":9554,"activeCount":103},[],{"trials":9556,"activeCount":103},[],{"intervention":9558,"totalTrials":323,"cells":9559},"Intravenous Infusion of UCLSCs",{"EARLY_PHASE1":9560,"PHASE1":9571,"PHASE2":9573,"PHASE3":9575,"PHASE4":9577,"NA":9579},{"trials":9561,"activeCount":103},[9562],{"nctId":9563,"briefTitle":9564,"status":115,"phases":9565,"primaryCompletion":9566,"completion":9566,"start":9567,"enrollment":2429,"conditions":9568,"interventions":9570},"NCT04811261","u-STOP LVAD Bleed: Utilization of Umbilical Cord Lining Stem Cells (ULSCs) To Prevent Left Ventricular Assist Device (LVAD) Associated Angiodysplastic Bleeding",[90],"2023-07-27","2021-11-01",[9569],"Angiodysplastic Bleeding",[9558],{"trials":9572,"activeCount":103},[],{"trials":9574,"activeCount":103},[],{"trials":9576,"activeCount":103},[],{"trials":9578,"activeCount":103},[],{"trials":9580,"activeCount":103},[],{"intervention":9582,"totalTrials":323,"cells":9583},"Receive ICBN with ropivacaine",{"EARLY_PHASE1":9584,"PHASE1":9595,"PHASE2":9597,"PHASE3":9599,"PHASE4":9601,"NA":9603},{"trials":9585,"activeCount":103},[9586],{"nctId":9587,"briefTitle":9588,"status":115,"phases":9589,"primaryCompletion":9590,"completion":2211,"start":9591,"enrollment":5689,"conditions":9592,"interventions":9594},"NCT03797924","Intercostobrachial Nerve Block (ICBN) for Tourniquet Pain: Is it Necessary?",[90],"2020-12-20","2019-04-25",[9593,33],"Nerve Block",[9582],{"trials":9596,"activeCount":103},[],{"trials":9598,"activeCount":103},[],{"trials":9600,"activeCount":103},[],{"trials":9602,"activeCount":103},[],{"trials":9604,"activeCount":103},[],{"intervention":9606,"totalTrials":323,"cells":9607},"Umbilical Cord Lining Stem Cells",{"EARLY_PHASE1":9608,"PHASE1":9621,"PHASE2":9623,"PHASE3":9625,"PHASE4":9627,"NA":9629},{"trials":9609,"activeCount":103},[9610],{"nctId":9611,"briefTitle":9612,"status":115,"phases":9613,"primaryCompletion":9614,"completion":9615,"start":9616,"enrollment":695,"conditions":9617,"interventions":9620},"NCT04723303","Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)",[90],"2023-12-12","2024-03-08","2021-10-06",[9618,9619],"Polymyositis","Dermatomyositis",[9606],{"trials":9622,"activeCount":103},[],{"trials":9624,"activeCount":103},[],{"trials":9626,"activeCount":103},[],{"trials":9628,"activeCount":103},[],{"trials":9630,"activeCount":103},[],{"intervention":9632,"totalTrials":323,"cells":9633},"Satralizumab",{"EARLY_PHASE1":9634,"PHASE1":9644,"PHASE2":9646,"PHASE3":9648,"PHASE4":9650,"NA":9652},{"trials":9635,"activeCount":103},[9636],{"nctId":9637,"briefTitle":9638,"status":257,"phases":9639,"primaryCompletion":9640,"completion":9640,"start":9641,"enrollment":103,"conditions":9642,"interventions":9643},"NCT05727657","Satralizumab in Aneurysmal Subarachnoid Hemorrhage",[90],"2024-06-24","2024-06",[2276,2277],[9632],{"trials":9645,"activeCount":103},[],{"trials":9647,"activeCount":103},[],{"trials":9649,"activeCount":103},[],{"trials":9651,"activeCount":103},[],{"trials":9653,"activeCount":103},[],{"intervention":9655,"totalTrials":323,"cells":9656},"Reference, Patch location thigh, batch 1",{"EARLY_PHASE1":9657,"PHASE1":9668,"PHASE2":9670,"PHASE3":9672,"PHASE4":9674,"NA":9676},{"trials":9658,"activeCount":103},[9659],{"nctId":9660,"briefTitle":9661,"status":115,"phases":9662,"primaryCompletion":1981,"completion":1981,"start":9663,"enrollment":2714,"conditions":9664,"interventions":9666},"NCT01592019","Clinical Study to Evaluate the Role of Microdialysis for the Comparison of Topical Products",[90],"2012-04",[9665],"Bioequivalence",[9655,9667],"Reference, Patch location abdomen, batch 1",{"trials":9669,"activeCount":103},[],{"trials":9671,"activeCount":103},[],{"trials":9673,"activeCount":103},[],{"trials":9675,"activeCount":103},[],{"trials":9677,"activeCount":103},[],{"intervention":9667,"totalTrials":323,"cells":9679},{"EARLY_PHASE1":9680,"PHASE1":9686,"PHASE2":9688,"PHASE3":9690,"PHASE4":9692,"NA":9694},{"trials":9681,"activeCount":103},[9682],{"nctId":9660,"briefTitle":9661,"status":115,"phases":9683,"primaryCompletion":1981,"completion":1981,"start":9663,"enrollment":2714,"conditions":9684,"interventions":9685},[90],[9665],[9655,9667],{"trials":9687,"activeCount":103},[],{"trials":9689,"activeCount":103},[],{"trials":9691,"activeCount":103},[],{"trials":9693,"activeCount":103},[],{"trials":9695,"activeCount":103},[],{"intervention":162,"totalTrials":695,"cells":9697},{"EARLY_PHASE1":9698,"PHASE1":9700,"PHASE2":9702,"PHASE3":9704,"PHASE4":9706,"NA":9745},{"trials":9699,"activeCount":103},[],{"trials":9701,"activeCount":103},[],{"trials":9703,"activeCount":103},[],{"trials":9705,"activeCount":103},[],{"trials":9707,"activeCount":103},[9708,9712,9721,9725,9729,9733,9737,9741],{"nctId":708,"briefTitle":709,"status":115,"phases":9709,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":9710,"interventions":9711},[94],[18],[151,162],{"nctId":9713,"briefTitle":9714,"status":115,"phases":9715,"primaryCompletion":9716,"completion":9717,"start":745,"enrollment":9718,"conditions":9719,"interventions":9720},"NCT02539160","Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease",[94],"2019-11-14","2020-06-17",101,[18,133],[193],{"nctId":153,"briefTitle":154,"status":115,"phases":9722,"primaryCompletion":156,"completion":157,"start":158,"enrollment":146,"conditions":9723,"interventions":9724},[94],[160,18],[162,98],{"nctId":4192,"briefTitle":4193,"status":115,"phases":9726,"primaryCompletion":4195,"completion":4195,"start":733,"enrollment":1272,"conditions":9727,"interventions":9728},[94],[18],[4179,4198,162],{"nctId":740,"briefTitle":741,"status":115,"phases":9730,"primaryCompletion":743,"completion":744,"start":745,"enrollment":746,"conditions":9731,"interventions":9732},[94],[132],[151,136,137,162],{"nctId":164,"briefTitle":165,"status":115,"phases":9734,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":9735,"interventions":9736},[94],[18],[98,162],{"nctId":754,"briefTitle":755,"status":115,"phases":9738,"primaryCompletion":757,"completion":757,"start":758,"enrollment":759,"conditions":9739,"interventions":9740},[94],[18],[151,162],{"nctId":184,"briefTitle":185,"status":115,"phases":9742,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":9743,"interventions":9744},[94],[18],[98,151,193,194,195],{"trials":9746,"activeCount":103},[9747,9751],{"nctId":769,"briefTitle":770,"status":115,"phases":9748,"primaryCompletion":772,"completion":733,"start":773,"enrollment":180,"conditions":9749,"interventions":9750},[95],[133,18],[151,162],{"nctId":777,"briefTitle":778,"status":115,"phases":9752,"primaryCompletion":780,"completion":781,"start":782,"enrollment":783,"conditions":9753,"interventions":9754},[95],[18],[151,162],{"intervention":5517,"totalTrials":250,"cells":9756},{"EARLY_PHASE1":9757,"PHASE1":9759,"PHASE2":9769,"PHASE3":9771,"PHASE4":9773,"NA":9775},{"trials":9758,"activeCount":103},[],{"trials":9760,"activeCount":103},[9761,9765],{"nctId":5506,"briefTitle":5507,"status":115,"phases":9762,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":210,"conditions":9763,"interventions":9764},[91],[5512],[5514,5515,5516,5499,5517,5518,5519],{"nctId":8939,"briefTitle":8940,"status":115,"phases":9766,"primaryCompletion":8942,"completion":8942,"start":8943,"enrollment":34,"conditions":9767,"interventions":9768},[91],[5839,8945],[5517,8932],{"trials":9770,"activeCount":103},[],{"trials":9772,"activeCount":103},[],{"trials":9774,"activeCount":103},[],{"trials":9776,"activeCount":103},[9777,9786,9801],{"nctId":9778,"briefTitle":9779,"status":257,"phases":9780,"primaryCompletion":9781,"completion":8724,"start":9782,"enrollment":103,"conditions":9783,"interventions":9784},"NCT02815111","Evaluation of Ketamine and Multi-modal Analgesics",[],"2018-01","2016-07",[33],[4388,5518,5517,9785],"Neurontin",{"nctId":9787,"briefTitle":9788,"status":115,"phases":9789,"primaryCompletion":9790,"completion":9790,"start":9791,"enrollment":9792,"conditions":9793,"interventions":9795},"NCT01810458","Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)",[],"2019-09","2013-10",109,[9794,2601,2602,2603],"Liver Fibrosis",[9796,9797,5518,5517,9798,9799,9800],"Midazolam","Fentanyl","Lorazepam","Oxycodone\u002FAcetaminophen","Ondansetron",{"nctId":9802,"briefTitle":9803,"status":115,"phases":9804,"primaryCompletion":9805,"completion":5727,"start":9806,"enrollment":328,"conditions":9807,"interventions":9809},"NCT02719834","Behavioral Expressions in Alzheimer's Disease",[],"2017-02-09","2016-04",[9808],"Alzheimer's Disease",[5517],{"intervention":9811,"totalTrials":250,"cells":9812},"Capsaicin",{"EARLY_PHASE1":9813,"PHASE1":9829,"PHASE2":9831,"PHASE3":9848,"PHASE4":9850,"NA":9852},{"trials":9814,"activeCount":103},[9815,9822],{"nctId":9816,"briefTitle":9817,"status":115,"phases":9818,"primaryCompletion":9819,"completion":9819,"start":9806,"enrollment":31,"conditions":9820,"interventions":9821},"NCT02710162","Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)",[90],"2017-12-19",[6056],[9811],{"nctId":9823,"briefTitle":9824,"status":115,"phases":9825,"primaryCompletion":8838,"completion":9826,"start":9806,"enrollment":180,"conditions":9827,"interventions":9828},"NCT02710110","Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)",[90],"2019-02-07",[6056],[9811],{"trials":9830,"activeCount":103},[],{"trials":9832,"activeCount":103},[9833,9839],{"nctId":9834,"briefTitle":9835,"status":115,"phases":9836,"primaryCompletion":733,"completion":733,"start":734,"enrollment":3401,"conditions":9837,"interventions":9838},"NCT02183519","Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease",[91,92],[6447,2987],[9811],{"nctId":9840,"briefTitle":9841,"status":115,"phases":9842,"primaryCompletion":9843,"completion":9843,"start":9844,"enrollment":9845,"conditions":9846,"interventions":9847},"NCT03122145","Normal Breathing and Swallowing in Healthy Volunteers",[91,92],"2019-02-28","2017-05-23",49,[15],[9811],{"trials":9849,"activeCount":103},[],{"trials":9851,"activeCount":103},[],{"trials":9853,"activeCount":103},[9854],{"nctId":9855,"briefTitle":9856,"status":115,"phases":9857,"primaryCompletion":9858,"completion":9859,"start":9860,"enrollment":9861,"conditions":9862,"interventions":9863},"NCT03321019","Airway Protective Mechanisms in PD (R01)",[],"2023-07-29","2023-09-29","2017-12-12",119,[30],[9811],{"intervention":5518,"totalTrials":328,"cells":9865},{"EARLY_PHASE1":9866,"PHASE1":9868,"PHASE2":9874,"PHASE3":9876,"PHASE4":9878,"NA":9887},{"trials":9867,"activeCount":103},[],{"trials":9869,"activeCount":103},[9870],{"nctId":5506,"briefTitle":5507,"status":115,"phases":9871,"primaryCompletion":5509,"completion":5509,"start":5510,"enrollment":210,"conditions":9872,"interventions":9873},[91],[5512],[5514,5515,5516,5499,5517,5518,5519],{"trials":9875,"activeCount":103},[],{"trials":9877,"activeCount":103},[],{"trials":9879,"activeCount":103},[9880],{"nctId":9881,"briefTitle":9882,"status":115,"phases":9883,"primaryCompletion":9884,"completion":9884,"start":3044,"enrollment":19,"conditions":9885,"interventions":9886},"NCT02229578","Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.",[94],"2017-11-14",[33],[5518],{"trials":9888,"activeCount":103},[9889,9893],{"nctId":9778,"briefTitle":9779,"status":257,"phases":9890,"primaryCompletion":9781,"completion":8724,"start":9782,"enrollment":103,"conditions":9891,"interventions":9892},[],[33],[4388,5518,5517,9785],{"nctId":9787,"briefTitle":9788,"status":115,"phases":9894,"primaryCompletion":9790,"completion":9790,"start":9791,"enrollment":9792,"conditions":9895,"interventions":9896},[],[9794,2601,2602,2603],[9796,9797,5518,5517,9798,9799,9800],{"intervention":8264,"totalTrials":328,"cells":9898},{"EARLY_PHASE1":9899,"PHASE1":9901,"PHASE2":9903,"PHASE3":9909,"PHASE4":9911,"NA":9913},{"trials":9900,"activeCount":103},[],{"trials":9902,"activeCount":103},[],{"trials":9904,"activeCount":103},[9905],{"nctId":8258,"briefTitle":8259,"status":115,"phases":9906,"primaryCompletion":780,"completion":780,"start":8261,"enrollment":735,"conditions":9907,"interventions":9908},[92],[18],[8264,8249,8265],{"trials":9910,"activeCount":103},[],{"trials":9912,"activeCount":103},[],{"trials":9914,"activeCount":103},[9915,9924,9930],{"nctId":9916,"briefTitle":9917,"status":115,"phases":9918,"primaryCompletion":7393,"completion":7393,"start":712,"enrollment":9919,"conditions":9920,"interventions":9921},"NCT02016170","Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor",[95],82,[18,368],[8264,9922,9923],"Prasugrel 10mg","Ticagrelor 90mg",{"nctId":9925,"briefTitle":9926,"status":115,"phases":9927,"primaryCompletion":780,"completion":780,"start":8002,"enrollment":1260,"conditions":9928,"interventions":9929},"NCT01731041","Impact of Ticagrelor Re-load on Pharmacodynamic Profiles",[95],[18],[8264,9923],{"nctId":9931,"briefTitle":9932,"status":115,"phases":9933,"primaryCompletion":7393,"completion":7393,"start":2808,"enrollment":1260,"conditions":9934,"interventions":9935},"NCT02081443","In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients",[95],[18],[8264,9923],{"intervention":9923,"totalTrials":1016,"cells":9937},{"EARLY_PHASE1":9938,"PHASE1":9940,"PHASE2":9942,"PHASE3":9944,"PHASE4":9946,"NA":9948},{"trials":9939,"activeCount":103},[],{"trials":9941,"activeCount":103},[],{"trials":9943,"activeCount":103},[],{"trials":9945,"activeCount":103},[],{"trials":9947,"activeCount":103},[],{"trials":9949,"activeCount":103},[9950,9954,9958],{"nctId":9916,"briefTitle":9917,"status":115,"phases":9951,"primaryCompletion":7393,"completion":7393,"start":712,"enrollment":9919,"conditions":9952,"interventions":9953},[95],[18,368],[8264,9922,9923],{"nctId":9925,"briefTitle":9926,"status":115,"phases":9955,"primaryCompletion":780,"completion":780,"start":8002,"enrollment":1260,"conditions":9956,"interventions":9957},[95],[18],[8264,9923],{"nctId":9931,"briefTitle":9932,"status":115,"phases":9959,"primaryCompletion":7393,"completion":7393,"start":2808,"enrollment":1260,"conditions":9960,"interventions":9961},[95],[18],[8264,9923],{"intervention":9963,"totalTrials":210,"cells":9964},"Naltrexone",{"EARLY_PHASE1":9965,"PHASE1":9967,"PHASE2":9969,"PHASE3":9971,"PHASE4":9981,"NA":9983},{"trials":9966,"activeCount":103},[],{"trials":9968,"activeCount":103},[],{"trials":9970,"activeCount":103},[],{"trials":9972,"activeCount":103},[9973],{"nctId":9974,"briefTitle":9975,"status":115,"phases":9976,"primaryCompletion":9782,"completion":9782,"start":7601,"enrollment":9977,"conditions":9978,"interventions":9980},"NCT01625091","Clinical Trial to Reduce Drinking in Women With HIV",[93],194,[9979],"HIV Infection",[9963],{"trials":9982,"activeCount":103},[],{"trials":9984,"activeCount":103},[9985],{"nctId":9986,"briefTitle":9987,"status":257,"phases":9988,"primaryCompletion":5729,"completion":5729,"start":1056,"enrollment":103,"conditions":9989,"interventions":9992},"NCT01327326","Role of the Endogenous Opioid System Underlying Modulation of Experimental Pain",[95],[9990,9991],"Temporomandibular Disorder","Facial Pain",[9963],{"intervention":4388,"totalTrials":210,"cells":9994},{"EARLY_PHASE1":9995,"PHASE1":9997,"PHASE2":9999,"PHASE3":10001,"PHASE4":10003,"NA":10009},{"trials":9996,"activeCount":103},[],{"trials":9998,"activeCount":103},[],{"trials":10000,"activeCount":103},[],{"trials":10002,"activeCount":103},[],{"trials":10004,"activeCount":103},[10005],{"nctId":4379,"briefTitle":4380,"status":115,"phases":10006,"primaryCompletion":4382,"completion":4382,"start":4383,"enrollment":4384,"conditions":10007,"interventions":10008},[94],[4386,24,265],[4388,4366],{"trials":10010,"activeCount":103},[10011],{"nctId":9778,"briefTitle":9779,"status":257,"phases":10012,"primaryCompletion":9781,"completion":8724,"start":9782,"enrollment":103,"conditions":10013,"interventions":10014},[],[33],[4388,5518,5517,9785],{"intervention":10016,"totalTrials":210,"cells":10017},"Blood volume collected specifically for this study",{"EARLY_PHASE1":10018,"PHASE1":10020,"PHASE2":10022,"PHASE3":10024,"PHASE4":10026,"NA":10028},{"trials":10019,"activeCount":103},[],{"trials":10021,"activeCount":103},[],{"trials":10023,"activeCount":103},[],{"trials":10025,"activeCount":103},[],{"trials":10027,"activeCount":103},[],{"trials":10029,"activeCount":103},[10030,10038],{"nctId":10031,"briefTitle":10032,"status":115,"phases":10033,"primaryCompletion":5688,"completion":5688,"start":10034,"enrollment":210,"conditions":10035,"interventions":10037},"NCT03144492","Microgravity Effects on Co-cultured Vascular Cells Types",[],"2017-05-26",[10036],"Microgravity Exposed Endothelial Cells",[10016],{"nctId":10039,"briefTitle":10040,"status":115,"phases":10041,"primaryCompletion":10042,"completion":10042,"start":10034,"enrollment":328,"conditions":10043,"interventions":10044},"NCT03156257","The Role of the Space Environment on Vascular Endothelial and Smooth Muscle Cell Processes",[],"2020-01-06",[2866],[10016],{"intervention":10046,"totalTrials":210,"cells":10047},"Iodohippurate",{"EARLY_PHASE1":10048,"PHASE1":10050,"PHASE2":10052,"PHASE3":10054,"PHASE4":10056,"NA":10058},{"trials":10049,"activeCount":103},[],{"trials":10051,"activeCount":103},[],{"trials":10053,"activeCount":103},[],{"trials":10055,"activeCount":103},[],{"trials":10057,"activeCount":103},[],{"trials":10059,"activeCount":103},[10060,10069],{"nctId":10061,"briefTitle":10062,"status":257,"phases":10063,"primaryCompletion":5688,"completion":5688,"start":7277,"enrollment":103,"conditions":10064,"interventions":10067},"NCT02599844","Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults",[],[10065,10066,27],"Acute Kidney Injury","Chronic Kidney Disease",[10046,10068],"Gadolinium",{"nctId":10070,"briefTitle":10071,"status":257,"phases":10072,"primaryCompletion":10073,"completion":10073,"start":2655,"enrollment":103,"conditions":10074,"interventions":10075},"NCT02598674","Severe Sepsis in Children - IMPRESS-C",[],"2021-09",[10065,10066,27],[10046,10068],{"intervention":10068,"totalTrials":210,"cells":10077},{"EARLY_PHASE1":10078,"PHASE1":10080,"PHASE2":10082,"PHASE3":10084,"PHASE4":10086,"NA":10088},{"trials":10079,"activeCount":103},[],{"trials":10081,"activeCount":103},[],{"trials":10083,"activeCount":103},[],{"trials":10085,"activeCount":103},[],{"trials":10087,"activeCount":103},[],{"trials":10089,"activeCount":103},[10090,10094],{"nctId":10061,"briefTitle":10062,"status":257,"phases":10091,"primaryCompletion":5688,"completion":5688,"start":7277,"enrollment":103,"conditions":10092,"interventions":10093},[],[10065,10066,27],[10046,10068],{"nctId":10070,"briefTitle":10071,"status":257,"phases":10095,"primaryCompletion":10073,"completion":10073,"start":2655,"enrollment":103,"conditions":10096,"interventions":10097},[],[10065,10066,27],[10046,10068],{"intervention":3048,"totalTrials":210,"cells":10099},{"EARLY_PHASE1":10100,"PHASE1":10102,"PHASE2":10108,"PHASE3":10110,"PHASE4":10112,"NA":10114},{"trials":10101,"activeCount":103},[],{"trials":10103,"activeCount":103},[10104],{"nctId":3041,"briefTitle":3042,"status":115,"phases":10105,"primaryCompletion":3044,"completion":3044,"start":780,"enrollment":22,"conditions":10106,"interventions":10107},[91],[3046],[3034,3048],{"trials":10109,"activeCount":103},[],{"trials":10111,"activeCount":103},[],{"trials":10113,"activeCount":103},[],{"trials":10115,"activeCount":103},[10116],{"nctId":10117,"briefTitle":10118,"status":115,"phases":10119,"primaryCompletion":10120,"completion":10121,"start":3079,"enrollment":180,"conditions":10122,"interventions":10123},"NCT02471014","Effect of Obesity on Immune Response to Pneumovax 23",[],"2019-03","2019-05-16",[24],[3048],{"intervention":10125,"totalTrials":210,"cells":10126},"Oxytocin Spray",{"EARLY_PHASE1":10127,"PHASE1":10129,"PHASE2":10131,"PHASE3":10133,"PHASE4":10144,"NA":10146},{"trials":10128,"activeCount":103},[],{"trials":10130,"activeCount":103},[],{"trials":10132,"activeCount":103},[],{"trials":10134,"activeCount":103},[10135],{"nctId":10136,"briefTitle":10137,"status":257,"phases":10138,"primaryCompletion":10139,"completion":10139,"start":10140,"enrollment":103,"conditions":10141,"interventions":10143},"NCT02409862","Faces: Choices Study",[92,93],"2019-08-30","2019-01-01",[10142],"Socioemotional Aging",[10125],{"trials":10145,"activeCount":103},[],{"trials":10147,"activeCount":103},[10148],{"nctId":10149,"briefTitle":10150,"status":115,"phases":10151,"primaryCompletion":3044,"completion":3044,"start":8640,"enrollment":10152,"conditions":10153,"interventions":10154},"NCT01823146","Oxytocin's Effect on Socioemotional Aging",[95],106,[21],[10155],"Oxytocin spray",{"intervention":9796,"totalTrials":210,"cells":10157},{"EARLY_PHASE1":10158,"PHASE1":10160,"PHASE2":10162,"PHASE3":10171,"PHASE4":10173,"NA":10175},{"trials":10159,"activeCount":103},[],{"trials":10161,"activeCount":103},[],{"trials":10163,"activeCount":103},[10164],{"nctId":10165,"briefTitle":10166,"status":1053,"phases":10167,"primaryCompletion":772,"completion":772,"start":1055,"enrollment":323,"conditions":10168,"interventions":10170},"NCT02367170","Project 4A: Inspiratory Muscle Training and Diaphragm Strength",[91,92],[10169],"Sepsis",[9796],{"trials":10172,"activeCount":103},[],{"trials":10174,"activeCount":103},[],{"trials":10176,"activeCount":103},[10177],{"nctId":9787,"briefTitle":9788,"status":115,"phases":10178,"primaryCompletion":9790,"completion":9790,"start":9791,"enrollment":9792,"conditions":10179,"interventions":10180},[],[9794,2601,2602,2603],[9796,9797,5518,5517,9798,9799,9800],{"intervention":7810,"totalTrials":210,"cells":10182},{"EARLY_PHASE1":10183,"PHASE1":10185,"PHASE2":10187,"PHASE3":10193,"PHASE4":10195,"NA":10197},{"trials":10184,"activeCount":103},[],{"trials":10186,"activeCount":103},[],{"trials":10188,"activeCount":103},[10189],{"nctId":7795,"briefTitle":7796,"status":115,"phases":10190,"primaryCompletion":7798,"completion":7798,"start":7799,"enrollment":7800,"conditions":10191,"interventions":10192},[92],[7802,7803,7804,7805,7806,7807,7808],[7810,7786],{"trials":10194,"activeCount":103},[],{"trials":10196,"activeCount":103},[],{"trials":10198,"activeCount":103},[10199],{"nctId":10200,"briefTitle":10201,"status":115,"phases":10202,"primaryCompletion":2832,"completion":2832,"start":10203,"enrollment":10204,"conditions":10205,"interventions":10207},"NCT00805545","Timing of Antibiotic Prophylaxis for Cesarean Deliveries",[95],"2008-11",400,[10206],"Infection",[7810,7810],{"intervention":10209,"totalTrials":210,"cells":10210},"Ethanol",{"EARLY_PHASE1":10211,"PHASE1":10213,"PHASE2":10215,"PHASE3":10217,"PHASE4":10219,"NA":10221},{"trials":10212,"activeCount":103},[],{"trials":10214,"activeCount":103},[],{"trials":10216,"activeCount":103},[],{"trials":10218,"activeCount":103},[],{"trials":10220,"activeCount":103},[],{"trials":10222,"activeCount":103},[10223,10231],{"nctId":10224,"briefTitle":10225,"status":115,"phases":10226,"primaryCompletion":3698,"completion":3698,"start":317,"enrollment":10227,"conditions":10228,"interventions":10230},"NCT04925076","Characterizing the Effects of Family History of Alcoholism on Alcohol Analgesia",[95],125,[10229],"Effects of Family History of Alcoholism and Sex on Alcohol Analgesia",[10209],{"nctId":10232,"briefTitle":10233,"status":115,"phases":10234,"primaryCompletion":10235,"completion":10235,"start":10236,"enrollment":16,"conditions":10237,"interventions":10239},"NCT04019093","Acute Effects of Alcohol Use on Chronic Orofacial Pain",[95],"2022-04-30","2019-11-05",[10238],"Temporomandibular Joint Disorders",[10209],{"intervention":10241,"totalTrials":323,"cells":10242},"Capsaicin Patch 8% or 0.1% Capsaicin Cream",{"EARLY_PHASE1":10243,"PHASE1":10245,"PHASE2":10247,"PHASE3":10249,"PHASE4":10251,"NA":10253},{"trials":10244,"activeCount":103},[],{"trials":10246,"activeCount":103},[],{"trials":10248,"activeCount":103},[],{"trials":10250,"activeCount":103},[],{"trials":10252,"activeCount":103},[],{"trials":10254,"activeCount":103},[10255],{"nctId":10256,"briefTitle":10257,"status":115,"phases":10258,"primaryCompletion":5595,"completion":10259,"start":10260,"enrollment":419,"conditions":10261,"interventions":10262},"NCT03464292","Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia",[],"2023-12-08","2018-07-05",[9014,33],[10241],{"intervention":10264,"totalTrials":323,"cells":10265},"CYP2D6",{"EARLY_PHASE1":10266,"PHASE1":10268,"PHASE2":10270,"PHASE3":10272,"PHASE4":10274,"NA":10276},{"trials":10267,"activeCount":103},[],{"trials":10269,"activeCount":103},[],{"trials":10271,"activeCount":103},[],{"trials":10273,"activeCount":103},[],{"trials":10275,"activeCount":103},[],{"trials":10277,"activeCount":103},[10278],{"nctId":10279,"briefTitle":10280,"status":115,"phases":10281,"primaryCompletion":10282,"completion":10282,"start":9806,"enrollment":10283,"conditions":10284,"interventions":10286},"NCT02664350","Precision Medicine Guided Treatment for Cancer Pain",[95],"2019-01-10",63,[33,10285],"CYP2D6 Polymorphism",[10264,10287],"OPRM1",{"intervention":10287,"totalTrials":323,"cells":10289},{"EARLY_PHASE1":10290,"PHASE1":10292,"PHASE2":10294,"PHASE3":10296,"PHASE4":10298,"NA":10300},{"trials":10291,"activeCount":103},[],{"trials":10293,"activeCount":103},[],{"trials":10295,"activeCount":103},[],{"trials":10297,"activeCount":103},[],{"trials":10299,"activeCount":103},[],{"trials":10301,"activeCount":103},[10302],{"nctId":10279,"briefTitle":10280,"status":115,"phases":10303,"primaryCompletion":10282,"completion":10282,"start":9806,"enrollment":10283,"conditions":10304,"interventions":10305},[95],[33,10285],[10264,10287],{"intervention":10307,"totalTrials":323,"cells":10308},"iPSC",{"EARLY_PHASE1":10309,"PHASE1":10311,"PHASE2":10313,"PHASE3":10315,"PHASE4":10317,"NA":10319},{"trials":10310,"activeCount":103},[],{"trials":10312,"activeCount":103},[],{"trials":10314,"activeCount":103},[],{"trials":10316,"activeCount":103},[],{"trials":10318,"activeCount":103},[],{"trials":10320,"activeCount":103},[10321],{"nctId":10322,"briefTitle":10323,"status":115,"phases":10324,"primaryCompletion":10325,"completion":10325,"start":3399,"enrollment":31,"conditions":10326,"interventions":10327},"NCT01943383","Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study",[],"2018-05",[27],[10307],{"intervention":10329,"totalTrials":323,"cells":10330},"Oral Glucose Gel",{"EARLY_PHASE1":10331,"PHASE1":10333,"PHASE2":10335,"PHASE3":10337,"PHASE4":10339,"NA":10341},{"trials":10332,"activeCount":103},[],{"trials":10334,"activeCount":103},[],{"trials":10336,"activeCount":103},[],{"trials":10338,"activeCount":103},[],{"trials":10340,"activeCount":103},[],{"trials":10342,"activeCount":103},[10343],{"nctId":10344,"briefTitle":10345,"status":257,"phases":10346,"primaryCompletion":127,"completion":127,"start":9781,"enrollment":103,"conditions":10347,"interventions":10350},"NCT02729870","Oral Glucose Intervention for Children With Gastroenteritis and Ketosis",[],[10348,10349],"Gastrointestinal Infections","Ketosis",[10329],{"intervention":10352,"totalTrials":323,"cells":10353},"cannabidiol",{"EARLY_PHASE1":10354,"PHASE1":10356,"PHASE2":10358,"PHASE3":10360,"PHASE4":10362,"NA":10364},{"trials":10355,"activeCount":103},[],{"trials":10357,"activeCount":103},[],{"trials":10359,"activeCount":103},[],{"trials":10361,"activeCount":103},[],{"trials":10363,"activeCount":103},[],{"trials":10365,"activeCount":103},[10366],{"nctId":10367,"briefTitle":10368,"status":1972,"phases":10369,"conditions":10370,"interventions":10372},"NCT02461706","Treatment of Drug Resistant Epilepsy",[],[10371],"Epilepsy",[10352],{"intervention":10374,"totalTrials":323,"cells":10375},"All Participants",{"EARLY_PHASE1":10376,"PHASE1":10378,"PHASE2":10380,"PHASE3":10382,"PHASE4":10384,"NA":10386},{"trials":10377,"activeCount":103},[],{"trials":10379,"activeCount":103},[],{"trials":10381,"activeCount":103},[],{"trials":10383,"activeCount":103},[],{"trials":10385,"activeCount":103},[],{"trials":10387,"activeCount":103},[10388],{"nctId":10389,"briefTitle":10390,"status":1027,"phases":10391,"primaryCompletion":10392,"completion":10392,"start":1952,"enrollment":10393,"conditions":10394,"interventions":10399},"NCT01060371","Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias",[],"2024-05-19",800,[10395,10396,10397,10398],"Spinocerebellar Ataxia Type 1","Spinocerebellar Ataxia Type 2","Spinocerebellar Ataxia Type 3","Spinocerebellar Ataxia Type 6",[10374],{"intervention":10401,"totalTrials":323,"cells":10402},"CYP2D6-guided opioid therapy",{"EARLY_PHASE1":10403,"PHASE1":10405,"PHASE2":10407,"PHASE3":10409,"PHASE4":10411,"NA":10413},{"trials":10404,"activeCount":103},[],{"trials":10406,"activeCount":103},[],{"trials":10408,"activeCount":103},[],{"trials":10410,"activeCount":103},[],{"trials":10412,"activeCount":103},[],{"trials":10414,"activeCount":103},[10415],{"nctId":10416,"briefTitle":10417,"status":115,"phases":10418,"primaryCompletion":10419,"completion":10419,"start":10420,"enrollment":10421,"conditions":10422,"interventions":10423},"NCT03534063","Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery",[95],"2020-04-29","2018-06-07",260,[265],[10401],{"intervention":10425,"totalTrials":323,"cells":10426},"Triclosan containing toothpaste",{"EARLY_PHASE1":10427,"PHASE1":10429,"PHASE2":10431,"PHASE3":10433,"PHASE4":10435,"NA":10437},{"trials":10428,"activeCount":103},[],{"trials":10430,"activeCount":103},[],{"trials":10432,"activeCount":103},[],{"trials":10434,"activeCount":103},[],{"trials":10436,"activeCount":103},[],{"trials":10438,"activeCount":103},[10439],{"nctId":10440,"briefTitle":10441,"status":115,"phases":10442,"primaryCompletion":7277,"completion":7277,"start":10443,"enrollment":1204,"conditions":10444,"interventions":10447},"NCT01881074","Periodontal Treatment Response in Type II Diabetic Patients",[],"2012-06",[10445,10446],"Type II Diabetes","Periodontal Disease",[10425,10448],"Non-triclosan containing toothpaste",{"intervention":10448,"totalTrials":323,"cells":10450},{"EARLY_PHASE1":10451,"PHASE1":10453,"PHASE2":10455,"PHASE3":10457,"PHASE4":10459,"NA":10461},{"trials":10452,"activeCount":103},[],{"trials":10454,"activeCount":103},[],{"trials":10456,"activeCount":103},[],{"trials":10458,"activeCount":103},[],{"trials":10460,"activeCount":103},[],{"trials":10462,"activeCount":103},[10463],{"nctId":10440,"briefTitle":10441,"status":115,"phases":10464,"primaryCompletion":7277,"completion":7277,"start":10443,"enrollment":1204,"conditions":10465,"interventions":10466},[],[10445,10446],[10425,10448],{"intervention":10468,"totalTrials":323,"cells":10469},"Mycophenolate mofetil + Tacrolimus",{"EARLY_PHASE1":10470,"PHASE1":10472,"PHASE2":10474,"PHASE3":10476,"PHASE4":10478,"NA":10480},{"trials":10471,"activeCount":103},[],{"trials":10473,"activeCount":103},[],{"trials":10475,"activeCount":103},[],{"trials":10477,"activeCount":103},[],{"trials":10479,"activeCount":103},[],{"trials":10481,"activeCount":103},[10482],{"nctId":10483,"briefTitle":10484,"status":115,"phases":10485,"primaryCompletion":10486,"completion":3291,"start":4103,"enrollment":2043,"conditions":10487,"interventions":10489},"NCT00187915","Pilot Trial for Implementation of a MPA PK Monitoring Strategy",[95],"2004-11",[10488],"Transplant, Kidney",[10468,10490],"Mycophenolate mofetil + Cyclosporin",{"intervention":10490,"totalTrials":323,"cells":10492},{"EARLY_PHASE1":10493,"PHASE1":10495,"PHASE2":10497,"PHASE3":10499,"PHASE4":10501,"NA":10503},{"trials":10494,"activeCount":103},[],{"trials":10496,"activeCount":103},[],{"trials":10498,"activeCount":103},[],{"trials":10500,"activeCount":103},[],{"trials":10502,"activeCount":103},[],{"trials":10504,"activeCount":103},[10505],{"nctId":10483,"briefTitle":10484,"status":115,"phases":10506,"primaryCompletion":10486,"completion":3291,"start":4103,"enrollment":2043,"conditions":10507,"interventions":10508},[95],[10488],[10468,10490],{"intervention":10510,"totalTrials":323,"cells":10511},"Molecular diagnostic testing",{"EARLY_PHASE1":10512,"PHASE1":10514,"PHASE2":10516,"PHASE3":10518,"PHASE4":10520,"NA":10522},{"trials":10513,"activeCount":103},[],{"trials":10515,"activeCount":103},[],{"trials":10517,"activeCount":103},[],{"trials":10519,"activeCount":103},[],{"trials":10521,"activeCount":103},[],{"trials":10523,"activeCount":103},[10524],{"nctId":10525,"briefTitle":10526,"status":1053,"phases":10527,"primaryCompletion":10528,"completion":10528,"start":10529,"enrollment":10530,"conditions":10531,"interventions":10534},"NCT02435550","iCare for Cancer Patients",[95],"2019-10-01","2015-06-26",136,[5486,5470,5560,7420,10532,2694,10533],"Leukemia, Acute Lymphoblastic","Myelofibrosis",[10510],{"intervention":9785,"totalTrials":323,"cells":10536},{"EARLY_PHASE1":10537,"PHASE1":10539,"PHASE2":10541,"PHASE3":10543,"PHASE4":10545,"NA":10547},{"trials":10538,"activeCount":103},[],{"trials":10540,"activeCount":103},[],{"trials":10542,"activeCount":103},[],{"trials":10544,"activeCount":103},[],{"trials":10546,"activeCount":103},[],{"trials":10548,"activeCount":103},[10549],{"nctId":9778,"briefTitle":9779,"status":257,"phases":10550,"primaryCompletion":9781,"completion":8724,"start":9782,"enrollment":103,"conditions":10551,"interventions":10552},[],[33],[4388,5518,5517,9785],{"intervention":10554,"totalTrials":323,"cells":10555},"FDA-approved drug or combination of drugs",{"EARLY_PHASE1":10556,"PHASE1":10558,"PHASE2":10560,"PHASE3":10562,"PHASE4":10564,"NA":10566},{"trials":10557,"activeCount":103},[],{"trials":10559,"activeCount":103},[],{"trials":10561,"activeCount":103},[],{"trials":10563,"activeCount":103},[],{"trials":10565,"activeCount":103},[],{"trials":10567,"activeCount":103},[10568],{"nctId":10569,"briefTitle":10570,"status":257,"phases":10571,"primaryCompletion":10572,"completion":10573,"start":743,"enrollment":103,"conditions":10574,"interventions":10575},"NCT03446638","iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes",[95],"2021-08","2022-09",[5486],[10554,10576,10577,10578],"FLAG induction","7 + 3 induction","Low-dose cytarabine",{"intervention":10576,"totalTrials":323,"cells":10580},{"EARLY_PHASE1":10581,"PHASE1":10583,"PHASE2":10585,"PHASE3":10587,"PHASE4":10589,"NA":10591},{"trials":10582,"activeCount":103},[],{"trials":10584,"activeCount":103},[],{"trials":10586,"activeCount":103},[],{"trials":10588,"activeCount":103},[],{"trials":10590,"activeCount":103},[],{"trials":10592,"activeCount":103},[10593],{"nctId":10569,"briefTitle":10570,"status":257,"phases":10594,"primaryCompletion":10572,"completion":10573,"start":743,"enrollment":103,"conditions":10595,"interventions":10596},[95],[5486],[10554,10576,10577,10578],{"intervention":10577,"totalTrials":323,"cells":10598},{"EARLY_PHASE1":10599,"PHASE1":10601,"PHASE2":10603,"PHASE3":10605,"PHASE4":10607,"NA":10609},{"trials":10600,"activeCount":103},[],{"trials":10602,"activeCount":103},[],{"trials":10604,"activeCount":103},[],{"trials":10606,"activeCount":103},[],{"trials":10608,"activeCount":103},[],{"trials":10610,"activeCount":103},[10611],{"nctId":10569,"briefTitle":10570,"status":257,"phases":10612,"primaryCompletion":10572,"completion":10573,"start":743,"enrollment":103,"conditions":10613,"interventions":10614},[95],[5486],[10554,10576,10577,10578],{"intervention":10578,"totalTrials":323,"cells":10616},{"EARLY_PHASE1":10617,"PHASE1":10619,"PHASE2":10621,"PHASE3":10623,"PHASE4":10625,"NA":10627},{"trials":10618,"activeCount":103},[],{"trials":10620,"activeCount":103},[],{"trials":10622,"activeCount":103},[],{"trials":10624,"activeCount":103},[],{"trials":10626,"activeCount":103},[],{"trials":10628,"activeCount":103},[10629],{"nctId":10569,"briefTitle":10570,"status":257,"phases":10630,"primaryCompletion":10572,"completion":10573,"start":743,"enrollment":103,"conditions":10631,"interventions":10632},[95],[5486],[10554,10576,10577,10578],{"intervention":1986,"totalTrials":323,"cells":10634},{"EARLY_PHASE1":10635,"PHASE1":10637,"PHASE2":10639,"PHASE3":10641,"PHASE4":10643,"NA":10645},{"trials":10636,"activeCount":103},[],{"trials":10638,"activeCount":103},[],{"trials":10640,"activeCount":103},[],{"trials":10642,"activeCount":103},[],{"trials":10644,"activeCount":103},[],{"trials":10646,"activeCount":103},[10647],{"nctId":1978,"briefTitle":1979,"status":115,"phases":10648,"primaryCompletion":1981,"completion":1981,"start":1982,"enrollment":31,"conditions":10649,"interventions":10650},[95],[1984],[1814,1986],{"intervention":10652,"totalTrials":323,"cells":10653},"Primary Cervical Dystonia",{"EARLY_PHASE1":10654,"PHASE1":10656,"PHASE2":10658,"PHASE3":10660,"PHASE4":10662,"NA":10664},{"trials":10655,"activeCount":103},[],{"trials":10657,"activeCount":103},[],{"trials":10659,"activeCount":103},[],{"trials":10661,"activeCount":103},[],{"trials":10663,"activeCount":103},[],{"trials":10665,"activeCount":103},[10666],{"nctId":10667,"briefTitle":10668,"status":115,"phases":10669,"primaryCompletion":7277,"completion":10670,"start":4449,"enrollment":34,"conditions":10671,"interventions":10673},"NCT02046447","Neuroimaging of Dystonia",[],"2017-12",[10652,10672],"DYT 1 Dystonia",[10652],{"intervention":10675,"totalTrials":323,"cells":10676},"Aripiprazole",{"EARLY_PHASE1":10677,"PHASE1":10679,"PHASE2":10681,"PHASE3":10683,"PHASE4":10685,"NA":10687},{"trials":10678,"activeCount":103},[],{"trials":10680,"activeCount":103},[],{"trials":10682,"activeCount":103},[],{"trials":10684,"activeCount":103},[],{"trials":10686,"activeCount":103},[],{"trials":10688,"activeCount":103},[10689],{"nctId":10690,"briefTitle":10691,"status":1053,"phases":10692,"primaryCompletion":10693,"completion":10693,"start":10694,"enrollment":146,"conditions":10695,"interventions":10697},"NCT00282139","Aripiprazole in the Treatment of Tourette's Syndrome",[95],"2006-10","2004-01",[10696],"Tourette's Syndrome",[10675],{"intervention":10699,"totalTrials":323,"cells":10700},"Capsaicin Challenge",{"EARLY_PHASE1":10701,"PHASE1":10703,"PHASE2":10705,"PHASE3":10707,"PHASE4":10709,"NA":10711},{"trials":10702,"activeCount":103},[],{"trials":10704,"activeCount":103},[],{"trials":10706,"activeCount":103},[],{"trials":10708,"activeCount":103},[],{"trials":10710,"activeCount":103},[],{"trials":10712,"activeCount":103},[10713],{"nctId":10714,"briefTitle":10715,"status":115,"phases":10716,"primaryCompletion":10717,"completion":10717,"start":10718,"enrollment":9792,"conditions":10719,"interventions":10720},"NCT02962050","Delineating Swallowing Impairment and Decline in ALS",[],"2023-02-16","2017-05-31",[6056],[10699],{"intervention":10722,"totalTrials":323,"cells":10723},"Apidra",{"EARLY_PHASE1":10724,"PHASE1":10726,"PHASE2":10728,"PHASE3":10730,"PHASE4":10732,"NA":10734},{"trials":10725,"activeCount":103},[],{"trials":10727,"activeCount":103},[],{"trials":10729,"activeCount":103},[],{"trials":10731,"activeCount":103},[],{"trials":10733,"activeCount":103},[],{"trials":10735,"activeCount":103},[10736],{"nctId":10737,"briefTitle":10738,"status":115,"phases":10739,"primaryCompletion":10740,"completion":10740,"start":1175,"enrollment":10741,"conditions":10742,"interventions":10743},"NCT01621776","Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia",[95],"2012-08",107,[1495],[10722,10744,10745],"Humalog","Novolog",{"intervention":10744,"totalTrials":323,"cells":10747},{"EARLY_PHASE1":10748,"PHASE1":10750,"PHASE2":10752,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10749,"activeCount":103},[],{"trials":10751,"activeCount":103},[],{"trials":10753,"activeCount":103},[],{"trials":10755,"activeCount":103},[],{"trials":10757,"activeCount":103},[],{"trials":10759,"activeCount":103},[10760],{"nctId":10737,"briefTitle":10738,"status":115,"phases":10761,"primaryCompletion":10740,"completion":10740,"start":1175,"enrollment":10741,"conditions":10762,"interventions":10763},[95],[1495],[10722,10744,10745],{"intervention":10745,"totalTrials":323,"cells":10765},{"EARLY_PHASE1":10766,"PHASE1":10768,"PHASE2":10770,"PHASE3":10772,"PHASE4":10774,"NA":10776},{"trials":10767,"activeCount":103},[],{"trials":10769,"activeCount":103},[],{"trials":10771,"activeCount":103},[],{"trials":10773,"activeCount":103},[],{"trials":10775,"activeCount":103},[],{"trials":10777,"activeCount":103},[10778],{"nctId":10737,"briefTitle":10738,"status":115,"phases":10779,"primaryCompletion":10740,"completion":10740,"start":1175,"enrollment":10741,"conditions":10780,"interventions":10781},[95],[1495],[10722,10744,10745],{"intervention":10783,"totalTrials":323,"cells":10784},"montelukast",{"EARLY_PHASE1":10785,"PHASE1":10787,"PHASE2":10789,"PHASE3":10791,"PHASE4":10793,"NA":10795},{"trials":10786,"activeCount":103},[],{"trials":10788,"activeCount":103},[],{"trials":10790,"activeCount":103},[],{"trials":10792,"activeCount":103},[],{"trials":10794,"activeCount":103},[],{"trials":10796,"activeCount":103},[10797],{"nctId":10798,"briefTitle":10799,"status":115,"phases":10800,"primaryCompletion":10801,"completion":1982,"start":3831,"enrollment":356,"conditions":10802,"interventions":10804},"NCT00379808","Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease",[95],"2009-07",[10803],"Coronary Heart Disease",[10783],{"intervention":9922,"totalTrials":323,"cells":10806},{"EARLY_PHASE1":10807,"PHASE1":10809,"PHASE2":10811,"PHASE3":10813,"PHASE4":10815,"NA":10817},{"trials":10808,"activeCount":103},[],{"trials":10810,"activeCount":103},[],{"trials":10812,"activeCount":103},[],{"trials":10814,"activeCount":103},[],{"trials":10816,"activeCount":103},[],{"trials":10818,"activeCount":103},[10819],{"nctId":9916,"briefTitle":9917,"status":115,"phases":10820,"primaryCompletion":7393,"completion":7393,"start":712,"enrollment":9919,"conditions":10821,"interventions":10822},[95],[18,368],[8264,9922,9923],{"intervention":10824,"totalTrials":323,"cells":10825},"Fenofibrate capsule daily for 4 weeks",{"EARLY_PHASE1":10826,"PHASE1":10828,"PHASE2":10830,"PHASE3":10832,"PHASE4":10834,"NA":10836},{"trials":10827,"activeCount":103},[],{"trials":10829,"activeCount":103},[],{"trials":10831,"activeCount":103},[],{"trials":10833,"activeCount":103},[],{"trials":10835,"activeCount":103},[],{"trials":10837,"activeCount":103},[10838],{"nctId":10839,"briefTitle":10840,"status":1053,"phases":10841,"primaryCompletion":1982,"completion":1982,"start":10842,"enrollment":2099,"conditions":10843,"interventions":10844},"NCT00644592","LXRA Gene Polymorphisms and Response to Fenofibrate",[95],"2008-03",[15],[10824,10845],"Fenofibrate",{"intervention":10845,"totalTrials":323,"cells":10847},{"EARLY_PHASE1":10848,"PHASE1":10850,"PHASE2":10852,"PHASE3":10854,"PHASE4":10856,"NA":10858},{"trials":10849,"activeCount":103},[],{"trials":10851,"activeCount":103},[],{"trials":10853,"activeCount":103},[],{"trials":10855,"activeCount":103},[],{"trials":10857,"activeCount":103},[],{"trials":10859,"activeCount":103},[10860],{"nctId":10839,"briefTitle":10840,"status":1053,"phases":10861,"primaryCompletion":1982,"completion":1982,"start":10842,"enrollment":2099,"conditions":10862,"interventions":10863},[95],[15],[10824,10845],{"intervention":10865,"totalTrials":323,"cells":10866},"CYP2C19 genotyping",{"EARLY_PHASE1":10867,"PHASE1":10869,"PHASE2":10871,"PHASE3":10873,"PHASE4":10875,"NA":10877},{"trials":10868,"activeCount":103},[],{"trials":10870,"activeCount":103},[],{"trials":10872,"activeCount":103},[],{"trials":10874,"activeCount":103},[],{"trials":10876,"activeCount":103},[],{"trials":10878,"activeCount":103},[10879],{"nctId":10880,"briefTitle":10881,"status":115,"phases":10882,"primaryCompletion":6837,"completion":6837,"start":3079,"enrollment":10883,"conditions":10884,"interventions":10886},"NCT02930824","Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing",[95],185,[10885],"Gastroesophageal Reflux Disease",[10865],{"intervention":10888,"totalTrials":323,"cells":10889},"Glycogen Storage Disease markers",{"EARLY_PHASE1":10890,"PHASE1":10892,"PHASE2":10894,"PHASE3":10896,"PHASE4":10898,"NA":10900},{"trials":10891,"activeCount":103},[],{"trials":10893,"activeCount":103},[],{"trials":10895,"activeCount":103},[],{"trials":10897,"activeCount":103},[],{"trials":10899,"activeCount":103},[],{"trials":10901,"activeCount":103},[10902],{"nctId":10903,"briefTitle":10904,"status":115,"phases":10905,"primaryCompletion":9782,"completion":9782,"start":6815,"enrollment":10906,"conditions":10907,"interventions":10909},"NCT02057731","Study of Glycogen Storage Disease Expression in Carriers",[],114,[10908],"Glycogen Storage Disease",[10888],{"intervention":10911,"totalTrials":323,"cells":10912},"Pre-meal bolus",{"EARLY_PHASE1":10913,"PHASE1":10915,"PHASE2":10917,"PHASE3":10919,"PHASE4":10921,"NA":10923},{"trials":10914,"activeCount":103},[],{"trials":10916,"activeCount":103},[],{"trials":10918,"activeCount":103},[],{"trials":10920,"activeCount":103},[],{"trials":10922,"activeCount":103},[],{"trials":10924,"activeCount":103},[10925],{"nctId":10926,"briefTitle":10927,"status":115,"phases":10928,"primaryCompletion":733,"completion":733,"start":734,"enrollment":1260,"conditions":10929,"interventions":10931},"NCT02218268","Arterial Stiffness in Type I Diabetes Mellitus",[],[10930],"Arterial Stiffness in Youth With Type 1 Diabetes",[10911,10932],"No meal bolus",{"intervention":10932,"totalTrials":323,"cells":10934},{"EARLY_PHASE1":10935,"PHASE1":10937,"PHASE2":10939,"PHASE3":10941,"PHASE4":10943,"NA":10945},{"trials":10936,"activeCount":103},[],{"trials":10938,"activeCount":103},[],{"trials":10940,"activeCount":103},[],{"trials":10942,"activeCount":103},[],{"trials":10944,"activeCount":103},[],{"trials":10946,"activeCount":103},[10947],{"nctId":10926,"briefTitle":10927,"status":115,"phases":10948,"primaryCompletion":733,"completion":733,"start":734,"enrollment":1260,"conditions":10949,"interventions":10950},[],[10930],[10911,10932],{"intervention":10952,"totalTrials":323,"cells":10953},"Blood collected specifically for this study",{"EARLY_PHASE1":10954,"PHASE1":10956,"PHASE2":10958,"PHASE3":10960,"PHASE4":10962,"NA":10964},{"trials":10955,"activeCount":103},[],{"trials":10957,"activeCount":103},[],{"trials":10959,"activeCount":103},[],{"trials":10961,"activeCount":103},[],{"trials":10963,"activeCount":103},[],{"trials":10965,"activeCount":103},[10966],{"nctId":10967,"briefTitle":10968,"status":257,"phases":10969,"primaryCompletion":10970,"completion":10970,"start":10971,"enrollment":103,"conditions":10972,"interventions":10973},"NCT04028752","A 3D Hydrogel Model to Assess Endothelial Cell-macrophage Interactions in Simulated Microgravity (OR-DRPD-SRI2019)",[],"2021-06-01","2021-06",[2866],[10952],{"intervention":10975,"totalTrials":323,"cells":10976},"rAAV9-CB6-AspA",{"EARLY_PHASE1":10977,"PHASE1":10979,"PHASE2":10981,"PHASE3":10983,"PHASE4":10985,"NA":10987},{"trials":10978,"activeCount":103},[],{"trials":10980,"activeCount":103},[],{"trials":10982,"activeCount":103},[],{"trials":10984,"activeCount":103},[],{"trials":10986,"activeCount":103},[],{"trials":10988,"activeCount":103},[10989],{"nctId":10990,"briefTitle":10991,"status":1972,"phases":10992,"conditions":10993,"interventions":10995},"NCT05317780","Canavan-Single Patient IND",[],[10994],"Canavan Disease",[10975],{"intervention":10997,"totalTrials":323,"cells":10998},"Anesthestic",{"EARLY_PHASE1":10999,"PHASE1":11001,"PHASE2":11003,"PHASE3":11005,"PHASE4":11007,"NA":11009},{"trials":11000,"activeCount":103},[],{"trials":11002,"activeCount":103},[],{"trials":11004,"activeCount":103},[],{"trials":11006,"activeCount":103},[],{"trials":11008,"activeCount":103},[],{"trials":11010,"activeCount":103},[11011],{"nctId":11012,"briefTitle":11013,"status":115,"phases":11014,"primaryCompletion":6122,"completion":6122,"start":773,"enrollment":31,"conditions":11015,"interventions":11017},"NCT01720797","Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment",[95],[11016],"Malocclusion",[10997],{"intervention":11019,"totalTrials":323,"cells":11020},"Laboratory biomarker analysis",{"EARLY_PHASE1":11021,"PHASE1":11023,"PHASE2":11025,"PHASE3":11027,"PHASE4":11029,"NA":11031},{"trials":11022,"activeCount":103},[],{"trials":11024,"activeCount":103},[],{"trials":11026,"activeCount":103},[],{"trials":11028,"activeCount":103},[],{"trials":11030,"activeCount":103},[],{"trials":11032,"activeCount":103},[11033],{"nctId":11034,"briefTitle":11035,"status":1053,"phases":11036,"primaryCompletion":11037,"completion":11037,"start":11038,"enrollment":31,"conditions":11039,"interventions":11040},"NCT01954576","NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme",[95],"2021-05-14","2013-10-10",[964,3265],[11019],{"intervention":11042,"totalTrials":323,"cells":11043},"CD34+ cell enriched stem cell graft",{"EARLY_PHASE1":11044,"PHASE1":11046,"PHASE2":11048,"PHASE3":11050,"PHASE4":11052,"NA":11054},{"trials":11045,"activeCount":103},[],{"trials":11047,"activeCount":103},[],{"trials":11049,"activeCount":103},[],{"trials":11051,"activeCount":103},[],{"trials":11053,"activeCount":103},[],{"trials":11055,"activeCount":103},[11056],{"nctId":11057,"briefTitle":11058,"status":11059,"phases":11060,"conditions":11061,"interventions":11064},"NCT06731036","Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts","AVAILABLE",[],[6618,11062,11063,6608],"Fanconi Anemia","Dyskeratosis Congenita",[11042],{"intervention":1997,"totalTrials":323,"cells":11066},{"EARLY_PHASE1":11067,"PHASE1":11069,"PHASE2":11071,"PHASE3":11073,"PHASE4":11075,"NA":11077},{"trials":11068,"activeCount":103},[],{"trials":11070,"activeCount":103},[],{"trials":11072,"activeCount":103},[],{"trials":11074,"activeCount":103},[],{"trials":11076,"activeCount":103},[],{"trials":11078,"activeCount":103},[11079],{"nctId":1988,"briefTitle":1989,"status":115,"phases":11080,"completion":1991,"start":1992,"enrollment":1272,"conditions":11081,"interventions":11082},[95],[1994,1995],[1997,1814],{"intervention":2004,"totalTrials":323,"cells":11084},{"EARLY_PHASE1":11085,"PHASE1":11087,"PHASE2":11089,"PHASE3":11091,"PHASE4":11093,"NA":11095},{"trials":11086,"activeCount":103},[],{"trials":11088,"activeCount":103},[],{"trials":11090,"activeCount":103},[],{"trials":11092,"activeCount":103},[],{"trials":11094,"activeCount":103},[],{"trials":11096,"activeCount":103},[11097],{"nctId":1999,"briefTitle":1979,"status":1053,"phases":11098,"primaryCompletion":782,"completion":782,"start":2001,"enrollment":210,"conditions":11099,"interventions":11100},[95],[15],[1814,2004],{"intervention":11102,"totalTrials":323,"cells":11103},"Atorvastatin 20 mg daily for 3 months",{"EARLY_PHASE1":11104,"PHASE1":11106,"PHASE2":11108,"PHASE3":11110,"PHASE4":11112,"NA":11114},{"trials":11105,"activeCount":103},[],{"trials":11107,"activeCount":103},[],{"trials":11109,"activeCount":103},[],{"trials":11111,"activeCount":103},[],{"trials":11113,"activeCount":103},[],{"trials":11115,"activeCount":103},[11116],{"nctId":11117,"briefTitle":11118,"status":115,"phases":11119,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":687,"conditions":11120,"interventions":11121},"NCT00130481","Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)",[95],[6078,2633],[11102],{"intervention":9797,"totalTrials":323,"cells":11123},{"EARLY_PHASE1":11124,"PHASE1":11126,"PHASE2":11128,"PHASE3":11130,"PHASE4":11132,"NA":11134},{"trials":11125,"activeCount":103},[],{"trials":11127,"activeCount":103},[],{"trials":11129,"activeCount":103},[],{"trials":11131,"activeCount":103},[],{"trials":11133,"activeCount":103},[],{"trials":11135,"activeCount":103},[11136],{"nctId":9787,"briefTitle":9788,"status":115,"phases":11137,"primaryCompletion":9790,"completion":9790,"start":9791,"enrollment":9792,"conditions":11138,"interventions":11139},[],[9794,2601,2602,2603],[9796,9797,5518,5517,9798,9799,9800],{"intervention":9798,"totalTrials":323,"cells":11141},{"EARLY_PHASE1":11142,"PHASE1":11144,"PHASE2":11146,"PHASE3":11148,"PHASE4":11150,"NA":11152},{"trials":11143,"activeCount":103},[],{"trials":11145,"activeCount":103},[],{"trials":11147,"activeCount":103},[],{"trials":11149,"activeCount":103},[],{"trials":11151,"activeCount":103},[],{"trials":11153,"activeCount":103},[11154],{"nctId":9787,"briefTitle":9788,"status":115,"phases":11155,"primaryCompletion":9790,"completion":9790,"start":9791,"enrollment":9792,"conditions":11156,"interventions":11157},[],[9794,2601,2602,2603],[9796,9797,5518,5517,9798,9799,9800],{"intervention":9799,"totalTrials":323,"cells":11159},{"EARLY_PHASE1":11160,"PHASE1":11162,"PHASE2":11164,"PHASE3":11166,"PHASE4":11168,"NA":11170},{"trials":11161,"activeCount":103},[],{"trials":11163,"activeCount":103},[],{"trials":11165,"activeCount":103},[],{"trials":11167,"activeCount":103},[],{"trials":11169,"activeCount":103},[],{"trials":11171,"activeCount":103},[11172],{"nctId":9787,"briefTitle":9788,"status":115,"phases":11173,"primaryCompletion":9790,"completion":9790,"start":9791,"enrollment":9792,"conditions":11174,"interventions":11175},[],[9794,2601,2602,2603],[9796,9797,5518,5517,9798,9799,9800],{"intervention":9800,"totalTrials":323,"cells":11177},{"EARLY_PHASE1":11178,"PHASE1":11180,"PHASE2":11182,"PHASE3":11184,"PHASE4":11186,"NA":11188},{"trials":11179,"activeCount":103},[],{"trials":11181,"activeCount":103},[],{"trials":11183,"activeCount":103},[],{"trials":11185,"activeCount":103},[],{"trials":11187,"activeCount":103},[],{"trials":11189,"activeCount":103},[11190],{"nctId":9787,"briefTitle":9788,"status":115,"phases":11191,"primaryCompletion":9790,"completion":9790,"start":9791,"enrollment":9792,"conditions":11192,"interventions":11193},[],[9794,2601,2602,2603],[9796,9797,5518,5517,9798,9799,9800],{"intervention":11195,"totalTrials":323,"cells":11196},"Dabigatran",{"EARLY_PHASE1":11197,"PHASE1":11199,"PHASE2":11201,"PHASE3":11203,"PHASE4":11205,"NA":11207},{"trials":11198,"activeCount":103},[],{"trials":11200,"activeCount":103},[],{"trials":11202,"activeCount":103},[],{"trials":11204,"activeCount":103},[],{"trials":11206,"activeCount":103},[],{"trials":11208,"activeCount":103},[11209],{"nctId":11210,"briefTitle":11211,"status":115,"phases":11212,"primaryCompletion":2654,"completion":6815,"start":11213,"enrollment":3856,"conditions":11214,"interventions":11215},"NCT01852162","Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy",[95],"2012-02",[18],[11195],{"intervention":11217,"totalTrials":323,"cells":11218},"Anesthesia",{"EARLY_PHASE1":11219,"PHASE1":11221,"PHASE2":11223,"PHASE3":11225,"PHASE4":11227,"NA":11229},{"trials":11220,"activeCount":103},[],{"trials":11222,"activeCount":103},[],{"trials":11224,"activeCount":103},[],{"trials":11226,"activeCount":103},[],{"trials":11228,"activeCount":103},[],{"trials":11230,"activeCount":103},[11231],{"nctId":11232,"briefTitle":11233,"status":257,"phases":11234,"primaryCompletion":7277,"completion":7277,"start":7084,"enrollment":103,"conditions":11235,"interventions":11237},"NCT02372760","For A More Comfortable Bronchoscopy: Is Spray Catheter The Answer?",[95],[11236],"Airway Complication of Anaesthesia",[11217],{"intervention":11239,"totalTrials":323,"cells":11240},"methacholine",{"EARLY_PHASE1":11241,"PHASE1":11243,"PHASE2":11245,"PHASE3":11247,"PHASE4":11249,"NA":11251},{"trials":11242,"activeCount":103},[],{"trials":11244,"activeCount":103},[],{"trials":11246,"activeCount":103},[],{"trials":11248,"activeCount":103},[],{"trials":11250,"activeCount":103},[],{"trials":11252,"activeCount":103},[11253],{"nctId":11254,"briefTitle":11255,"status":115,"phases":11256,"primaryCompletion":11257,"completion":11257,"start":1991,"enrollment":926,"conditions":11258,"interventions":11259},"NCT00145990","The Impact of Dosimeter on Measurement of Airway Responsiveness to Methacholine",[95],"2005-12",[2716],[11239],{"intervention":11261,"totalTrials":323,"cells":11262},"Muscle Biopsy Medication: Lidocaine",{"EARLY_PHASE1":11263,"PHASE1":11265,"PHASE2":11267,"PHASE3":11269,"PHASE4":11271,"NA":11273},{"trials":11264,"activeCount":103},[],{"trials":11266,"activeCount":103},[],{"trials":11268,"activeCount":103},[],{"trials":11270,"activeCount":103},[],{"trials":11272,"activeCount":103},[],{"trials":11274,"activeCount":103},[11275],{"nctId":11276,"briefTitle":11277,"status":115,"phases":11278,"primaryCompletion":11279,"completion":11280,"start":4624,"enrollment":250,"conditions":11281,"interventions":11282},"NCT02467023","Project 4B: Lower Extremity Strength Training in ICU Patients",[95],"2016-07-07","2016-07-15",[10169],[11261,11283,11284],"Muscle Biopsy Medication: Versed","Muscle Biopsy Medication: Fentanyl",{"intervention":11283,"totalTrials":323,"cells":11286},{"EARLY_PHASE1":11287,"PHASE1":11289,"PHASE2":11291,"PHASE3":11293,"PHASE4":11295,"NA":11297},{"trials":11288,"activeCount":103},[],{"trials":11290,"activeCount":103},[],{"trials":11292,"activeCount":103},[],{"trials":11294,"activeCount":103},[],{"trials":11296,"activeCount":103},[],{"trials":11298,"activeCount":103},[11299],{"nctId":11276,"briefTitle":11277,"status":115,"phases":11300,"primaryCompletion":11279,"completion":11280,"start":4624,"enrollment":250,"conditions":11301,"interventions":11302},[95],[10169],[11261,11283,11284],{"intervention":11284,"totalTrials":323,"cells":11304},{"EARLY_PHASE1":11305,"PHASE1":11307,"PHASE2":11309,"PHASE3":11311,"PHASE4":11313,"NA":11315},{"trials":11306,"activeCount":103},[],{"trials":11308,"activeCount":103},[],{"trials":11310,"activeCount":103},[],{"trials":11312,"activeCount":103},[],{"trials":11314,"activeCount":103},[],{"trials":11316,"activeCount":103},[11317],{"nctId":11276,"briefTitle":11277,"status":115,"phases":11318,"primaryCompletion":11279,"completion":11280,"start":4624,"enrollment":250,"conditions":11319,"interventions":11320},[95],[10169],[11261,11283,11284],{"intervention":11322,"totalTrials":323,"cells":11323},"formoterol",{"EARLY_PHASE1":11324,"PHASE1":11326,"PHASE2":11328,"PHASE3":11330,"PHASE4":11332,"NA":11334},{"trials":11325,"activeCount":103},[],{"trials":11327,"activeCount":103},[],{"trials":11329,"activeCount":103},[],{"trials":11331,"activeCount":103},[],{"trials":11333,"activeCount":103},[],{"trials":11335,"activeCount":103},[11336],{"nctId":11337,"briefTitle":11338,"status":115,"phases":11339,"primaryCompletion":2631,"completion":2631,"start":10842,"enrollment":6747,"conditions":11340,"interventions":11341},"NCT00643578","Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay",[95],[2716],[11322,11322],{"intervention":11343,"totalTrials":323,"cells":11344},"Genetic markers",{"EARLY_PHASE1":11345,"PHASE1":11347,"PHASE2":11349,"PHASE3":11351,"PHASE4":11353,"NA":11355},{"trials":11346,"activeCount":103},[],{"trials":11348,"activeCount":103},[],{"trials":11350,"activeCount":103},[],{"trials":11352,"activeCount":103},[],{"trials":11354,"activeCount":103},[],{"trials":11356,"activeCount":103},[11357],{"nctId":11358,"briefTitle":11359,"status":115,"phases":11360,"primaryCompletion":11361,"completion":11361,"start":733,"enrollment":11362,"conditions":11363,"interventions":11364},"NCT02407743","TEMporal PostOperative Pain Signatures",[],"2020-08",428,[265],[11343],{"intervention":11366,"totalTrials":323,"cells":11367},"Rituximab",{"EARLY_PHASE1":11368,"PHASE1":11370,"PHASE2":11372,"PHASE3":11374,"PHASE4":11376,"NA":11378},{"trials":11369,"activeCount":103},[],{"trials":11371,"activeCount":103},[],{"trials":11373,"activeCount":103},[],{"trials":11375,"activeCount":103},[],{"trials":11377,"activeCount":103},[],{"trials":11379,"activeCount":103},[11380],{"nctId":11381,"briefTitle":11382,"status":115,"phases":11383,"primaryCompletion":167,"completion":167,"start":7876,"enrollment":2099,"conditions":11384,"interventions":11385},"NCT01451879","Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies",[],[5512],[11366,11386],"Miglustat",{"intervention":11386,"totalTrials":323,"cells":11388},{"EARLY_PHASE1":11389,"PHASE1":11391,"PHASE2":11393,"PHASE3":11395,"PHASE4":11397,"NA":11399},{"trials":11390,"activeCount":103},[],{"trials":11392,"activeCount":103},[],{"trials":11394,"activeCount":103},[],{"trials":11396,"activeCount":103},[],{"trials":11398,"activeCount":103},[],{"trials":11400,"activeCount":103},[11401],{"nctId":11381,"briefTitle":11382,"status":115,"phases":11402,"primaryCompletion":167,"completion":167,"start":7876,"enrollment":2099,"conditions":11403,"interventions":11404},[],[5512],[11366,11386],{"intervention":11406,"totalTrials":323,"cells":11407},"ACE inhibitor + exercise",{"EARLY_PHASE1":11408,"PHASE1":11410,"PHASE2":11412,"PHASE3":11414,"PHASE4":11416,"NA":11418},{"trials":11409,"activeCount":103},[],{"trials":11411,"activeCount":103},[],{"trials":11413,"activeCount":103},[],{"trials":11415,"activeCount":103},[],{"trials":11417,"activeCount":103},[],{"trials":11419,"activeCount":103},[11420],{"nctId":11421,"briefTitle":11422,"status":115,"phases":11423,"primaryCompletion":8368,"completion":8368,"start":2654,"enrollment":11424,"conditions":11425,"interventions":11426},"NCT01891513","ACE Inhibitors Combined With Exercise for Seniors - Pilot Study",[],104,[27,21],[11406,11427,11428],"Thiazide diuretic + exercise","Angiotensin receptor blocker + exercise",{"intervention":11427,"totalTrials":323,"cells":11430},{"EARLY_PHASE1":11431,"PHASE1":11433,"PHASE2":11435,"PHASE3":11437,"PHASE4":11439,"NA":11441},{"trials":11432,"activeCount":103},[],{"trials":11434,"activeCount":103},[],{"trials":11436,"activeCount":103},[],{"trials":11438,"activeCount":103},[],{"trials":11440,"activeCount":103},[],{"trials":11442,"activeCount":103},[11443],{"nctId":11421,"briefTitle":11422,"status":115,"phases":11444,"primaryCompletion":8368,"completion":8368,"start":2654,"enrollment":11424,"conditions":11445,"interventions":11446},[],[27,21],[11406,11427,11428],{"intervention":11428,"totalTrials":323,"cells":11448},{"EARLY_PHASE1":11449,"PHASE1":11451,"PHASE2":11453,"PHASE3":11455,"PHASE4":11457,"NA":11459},{"trials":11450,"activeCount":103},[],{"trials":11452,"activeCount":103},[],{"trials":11454,"activeCount":103},[],{"trials":11456,"activeCount":103},[],{"trials":11458,"activeCount":103},[],{"trials":11460,"activeCount":103},[11461],{"nctId":11421,"briefTitle":11422,"status":115,"phases":11462,"primaryCompletion":8368,"completion":8368,"start":2654,"enrollment":11424,"conditions":11463,"interventions":11464},[],[27,21],[11406,11427,11428],{"intervention":11466,"totalTrials":323,"cells":11467},"Amoxicillin",{"EARLY_PHASE1":11468,"PHASE1":11470,"PHASE2":11472,"PHASE3":11474,"PHASE4":11476,"NA":11478},{"trials":11469,"activeCount":103},[],{"trials":11471,"activeCount":103},[],{"trials":11473,"activeCount":103},[],{"trials":11475,"activeCount":103},[],{"trials":11477,"activeCount":103},[],{"trials":11479,"activeCount":103},[11480],{"nctId":11481,"briefTitle":11482,"status":257,"phases":11483,"primaryCompletion":168,"completion":168,"start":9806,"enrollment":103,"conditions":11484,"interventions":11485},"NCT02688634","The Role of Antibiotic Prophylaxis in Cleft Palate and Velopharyngeal Insufficiency Repair",[],[320],[11466],{"intervention":11487,"totalTrials":323,"cells":11488},"CYP2D6 genotyping",{"EARLY_PHASE1":11489,"PHASE1":11491,"PHASE2":11493,"PHASE3":11495,"PHASE4":11497,"NA":11499},{"trials":11490,"activeCount":103},[],{"trials":11492,"activeCount":103},[],{"trials":11494,"activeCount":103},[],{"trials":11496,"activeCount":103},[],{"trials":11498,"activeCount":103},[],{"trials":11500,"activeCount":103},[11501],{"nctId":11502,"briefTitle":11503,"status":115,"phases":11504,"primaryCompletion":8943,"completion":11505,"start":9492,"enrollment":11506,"conditions":11507,"interventions":11508},"NCT02335307","Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics",[],"2017-10-25",505,[33],[11487],{"intervention":11510,"totalTrials":323,"cells":11511},"Dalfampridine",{"EARLY_PHASE1":11512,"PHASE1":11514,"PHASE2":11516,"PHASE3":11518,"PHASE4":11520,"NA":11522},{"trials":11513,"activeCount":103},[],{"trials":11515,"activeCount":103},[],{"trials":11517,"activeCount":103},[],{"trials":11519,"activeCount":103},[],{"trials":11521,"activeCount":103},[],{"trials":11523,"activeCount":103},[11524],{"nctId":11525,"briefTitle":11526,"status":115,"phases":11527,"primaryCompletion":5813,"completion":5813,"start":773,"enrollment":34,"conditions":11528,"interventions":11533},"NCT01811706","Dalfampridine and Gait in Spinocerebellar Ataxias",[95],[11529,11530,11531,11532],"Spinocerebellar Ataxias Type 1","Spinocerebellar Ataxias Type 2","Spinocerebellar Ataxias Type 3","Spinocerebellar Ataxias Type 6",[11510]]